U.S. patent application number 16/980318 was filed with the patent office on 2021-08-26 for anti-her2 biparatopic antibody-drug conjugates and methods of use.
This patent application is currently assigned to Zymeworks Inc.. The applicant listed for this patent is ZYMEWORKS INC.. Invention is credited to Stuart D. BARNSCHER, Rupert H. DAVIES, Vincent K.C. FUNG, Kevin HAMBLETT, James R. RICH, Gerald J. ROWSE.
Application Number | 20210260210 16/980318 |
Document ID | / |
Family ID | 1000005596517 |
Filed Date | 2021-08-26 |
United States Patent
Application |
20210260210 |
Kind Code |
A1 |
HAMBLETT; Kevin ; et
al. |
August 26, 2021 |
ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF
USE
Abstract
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which
the drug is an auristatin analogue and is conjugated to the
antibody at a low average drug-to-antibody ratio (DAR), and methods
of using the ADCs in the treatment of a HER2-expressing cancer. The
low average DAR (<3.9) ADCs as described herein have improved
tolerability and decreased toxicity as compared to a corresponding
ADC having a DAR .gtoreq.3.9 when administered at the same toxin
dose.
Inventors: |
HAMBLETT; Kevin; (Seattle,
WA) ; DAVIES; Rupert H.; (Seattle, WA) ; RICH;
James R.; (Vancouver, CA) ; ROWSE; Gerald J.;
(Vancouver, CA) ; FUNG; Vincent K.C.; (Vancouver,
CA) ; BARNSCHER; Stuart D.; (Vancouver, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ZYMEWORKS INC. |
Vancouver |
|
CA |
|
|
Assignee: |
; Zymeworks Inc.
Vancouver
BC
|
Family ID: |
1000005596517 |
Appl. No.: |
16/980318 |
Filed: |
March 12, 2019 |
PCT Filed: |
March 12, 2019 |
PCT NO: |
PCT/CA2019/050303 |
371 Date: |
September 11, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62743884 |
Oct 10, 2018 |
|
|
|
62658477 |
Apr 16, 2018 |
|
|
|
62642483 |
Mar 13, 2018 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 47/6817 20170801;
A61P 35/00 20180101; C07K 2317/565 20130101; A61K 47/6869 20170801;
A61K 38/00 20130101; C07K 2317/55 20130101; C07K 2317/526 20130101;
C07K 16/32 20130101; C07K 2317/622 20130101; A61K 47/6855 20170801;
C07K 2317/31 20130101; A61K 2039/505 20130101; C07K 2317/73
20130101 |
International
Class: |
A61K 47/68 20060101
A61K047/68; C07K 16/32 20060101 C07K016/32; A61P 35/00 20060101
A61P035/00 |
Claims
1. An antibody-drug conjugate comprising an anti-HER2 biparatopic
antibody conjugated to an auristatin analogue via a linker (L) at a
low average drug-to-antibody ratio (DAR), wherein the anti-HER2
biparatopic antibody comprises a first antigen-binding polypeptide
construct which binds a first HER2 epitope and a second
antigen-binding polypeptide construct which binds a second HER2
epitope, wherein the first and second HER2 epitopes are on
different domains of HER2, wherein the auristatin analogue and
linker have general Formula (X) ##STR00063## wherein: R.sup.1 is
selected from: ##STR00064## L is the linker, and represents the
point of attachment of the linker to the anti-HER2 biparatopic
antibody, and wherein the low average DAR is an average DAR of
between 1.5 and 2.5.
2. (canceled)
3. The antibody-drug conjugate according to claim 1, wherein
R.sup.1 is: ##STR00065##
4. (canceled)
5. The antibody-drug conjugate according to claim 1, wherein
R.sup.1 is: ##STR00066##
6-8. (canceled)
9. The antibody-drug conjugate according to claim 1, wherein the
average DAR is between 1.8 and 2.5.
10-11. (canceled)
12. The antibody-drug conjugate according to claim 1, wherein the
conjugate comprises between about 5% and about 50% DAR0
species.
13. The antibody-drug conjugate according to claim 1, wherein the
conjugate comprises between about 10% and about 30% DAR0
species.
14. The antibody-drug conjugate according to claim 1, wherein the
conjugate comprises between about 10% and about 25% DAR0
species.
15. The antibody-drug conjugate according to claim 1, wherein the
conjugate comprises between about 15% and about 25% DAR0
species.
16-17. (canceled)
18. The antibody-drug conjugate according to claim 1, wherein the
conjugate comprises between 0% and about 15% DAR6 or greater
species.
19. The antibody-drug conjugate according to claim 1, wherein the
conjugate comprises between about 0% and about 10% DAR6 or greater
species.
20. The antibody-drug conjugate according to claim 1, wherein L is
a cleavable linker.
21. The antibody-drug conjugate according to claim 20, wherein L is
a protease-cleavable linker.
22. The antibody-drug conjugate according to claim 1, wherein L has
general Formula (VI): ##STR00067## wherein: Z is a functional group
capable of reacting with the target group on the anti-HER2
biparatopic antibody; Str is a stretcher; AA.sub.1 and AA.sub.2 are
each independently an amino acid, wherein AA.sub.1-[AA.sub.2].sub.m
forms a protease cleavage site; X is a self-immolative group; D is
the point of attachment to the auristatin analogue; s is 0 or 1; m
is an integer between 1 and 4, and o is 0, 1 or 2.
23. The antibody-drug conjugate according to claim 1, wherein L has
general Formula (VIII): ##STR00068## wherein: A-S-- is the point of
attachment to the anti-HER2 biparatopic antibody; Y is one or more
additional linker components, or is absent, and D is the point of
attachment to the auristatin analogue.
24. The antibody-drug conjugate according to claim 1, wherein L has
general Formula (X): ##STR00069## wherein: A-S-- is the point of
attachment to the anti-HER2 biparatopic antibody; Y is one or more
additional linker components, or is absent, and D is the point of
attachment to the auristatin analogue.
25. The antibody-drug conjugate according to claim 1, wherein the
auristatin analogue-linker has the structure: ##STR00070## wherein
A-S-- is the point of attachment to the anti-HER2 biparatopic
antibody.
26-27. (canceled)
28. The antibody-drug conjugate according to claim 25, wherein the
conjugate comprises between about 10% and about 30% DAR0
species.
29. (canceled)
30. The antibody-drug conjugate according to claim 25, wherein the
conjugate comprises between 0% and about 15% DAR6 or greater
species.
31-33. (canceled)
34. The antibody-drug conjugate according to claim 1, wherein the
first and second antigen-binding polypeptide constructs are
independently an scFv or a Fab.
35. The antibody-drug conjugate according to claim 34, wherein the
first antigen-binding polypeptide construct is an scFv, and the
second antigen-binding polypeptide construct is a Fab.
36-37. (canceled)
38. The antibody-drug conjugate according to claim 1, wherein the
first HER2 epitope is on ECD4 of HER2 and the second HER2 epitope
is on ECD2 of HER2.
39. The antibody-drug conjugate according to claim 38, wherein the
first antigen-binding polypeptide construct competes with
trastuzumab for binding to HER2.
40. The antibody-drug conjugate according to claim 38, wherein the
second antigen-binding polypeptide construct competes with
pertuzumab for binding to HER2.
41. The antibody-drug conjugate according to claim 38, wherein the
first antigen-binding polypeptide construct comprises the CDR
sequences from the ECD4-binding arm of any one of v5019, v5020,
v7091, v10000, v6902, v6903 or v6717, and the second
antigen-binding polypeptide construct comprises the CDR sequences
from the ECD2-binding arm of any one of v5019, v5020, v7091,
v10000, v6902, v6903, v6717, v7133, v15079, v15080, v15081, v15082,
v15083, v15084 or v15085.
42. (canceled)
43. The antibody-drug conjugate according to claim 41, wherein the
second antigen-binding polypeptide construct comprises the CDR
sequences from the ECD2-binding arm of v10000.
44. (canceled)
45. The antibody-drug conjugate according to claim 38, wherein the
first antigen-binding polypeptide construct comprises a set of six
CDRs that have 90% or greater sequence identity to a set of CDRs
from the ECD4-binding arm of v10000, wherein the antigen-binding
polypeptide construct retains the ability to bind ECD4, and the
second antigen-binding polypeptide construct comprises a set of six
CDRs that have 90% or greater sequence identity to a set of CDRs
from the ECD2-binding arm of v10000, wherein the antigen-binding
polypeptide construct retains the ability to bind ECD2.
46. (canceled)
47. The antibody-drug conjugate according to claim 1, wherein the
first antigen-binding polypeptide construct comprises the CDR
sequences set forth in SEQ ID NOs: 27, 28, 29, 39, 40 and 41, and
the second antigen-binding polypeptide construct comprises the CDR
sequences set forth in SEQ ID NOs: 67, 68, 69, 70, 71 and 72.
48-49. (canceled)
50. The antibody-drug conjugate according to claim 491, wherein the
anti-HER2 biparatopic antibody comprises an IgG Fc region that is a
heterodimeric Fc region comprising a modified CH3 domain.
51. (canceled)
52. The antibody-drug conjugate according to claim 50, wherein the
modified CH3 domain comprises a first polypeptide sequence and a
second polypeptide sequence, and wherein: (a) the first polypeptide
sequence of the modified CH3 domain comprises the amino acid
modifications L351Y, F405A and Y407V, and the second polypeptide
sequence of the modified CH3 domain comprises the amino acid
modifications T366L, K392M and T394W; or (b) the first polypeptide
sequence of the modified CH3 domain comprises the amino acid
modifications L351Y, F405A and Y407V, and the second polypeptide
sequence of the modified CH3 domain comprises the amino acid
modifications T366L, K392L and T394W; or (c) the first polypeptide
sequence of the modified CH3 domain comprises the amino acid
modifications T350V, L351Y, F405A and Y407V, and the second
polypeptide sequence of the modified CH3 domain comprises the amino
acid modifications T350V, T366L, K392M and T394W; or (d) the first
polypeptide sequence of the modified CH3 domain comprises the amino
acid modifications T350V, L351Y, F405A and Y407V, and the second
polypeptide sequence of the modified CH3 domain comprises the amino
acid modifications T350V, T366L, K392L and T394W; or (e) the first
polypeptide sequence of the modified CH3 domain comprises the amino
acid modifications T350V, L351Y, S400E, F405A and Y407V, and the
second polypeptide sequence of the modified CH3 domain comprises
the amino acid modifications T350V, T366L, N390R, K392M and
T394W.
53. A pharmaceutical composition comprising the antibody-drug
conjugate according to claim 1 and a pharmaceutically acceptable
carrier or diluent.
54. (canceled)
55. A method of treating a HER2-expressing cancer comprising
administering to a subject having a HER2-expressing cancer an
effective amount of the antibody-drug conjugate according to claim
1.
56. The method according to claim 55, wherein the HER2-expressing
cancer is a breast cancer, ovarian cancer, lung cancer or gastric
cancer.
57. The method according to claim 55, wherein the HER2-expressing
cancer is a breast cancer.
58. The method according to claim 55, wherein the HER2-expressing
cancer is an ovarian cancer.
59. The method according to claim 55, wherein the HER2-expressing
cancer is scored as HER2 negative by immunohistochemistry.
60-71. (canceled)
72. The antibody-drug conjugate according to claim 1, wherein the
average DAR is about 2.0.
73. The antibody-drug conjugate according to claim 22, wherein s is
1, and o is 0.
74. The antibody-drug conjugate according to claim 52, wherein the
first polypeptide sequence of the modified CH3 domain comprises the
amino acid modifications T350V, L351Y, F405A and Y407V, and the
second polypeptide sequence of the modified CH3 domain comprises
the amino acid modifications T350V, T366L, K392L and T394W.
75. The method according to claim 55, wherein the HER2-expressing
cancer is a HER2 high cancer.
76. The method according to claim 55, wherein the HER2-expressing
cancer is a HER2 low cancer.
77. The method according to claim 55, wherein the subject has
relapsed from prior therapy.
Description
FIELD
[0001] The present disclosure relates to the field of cancer
therapeutics and, in particular, to antibody-drug conjugates
comprising a biparatopic anti-HER2 antibody and an auristatin
analogue.
BACKGROUND
[0002] HER2 (ErbB2) is a transmembrane surface-bound receptor
tyrosine kinase that is a member of the ErbB family of receptor
tyrosine kinases and is normally involved in the signal
transduction pathways leading to cell growth and differentiation.
HER2 is a promising target for treatment of breast cancer as it was
found to be overexpressed in about one-quarter of breast cancer
patients (Bange et al, Nature Medicine 7:548 (2001)).
[0003] Herceptin.RTM. (trastuzumab, U.S. Pat. No. 5,821,337) was
the first monoclonal antibody developed for the treatment of
HER2-positive breast cancer and has increased survival times for
patients so that they are now the same as for patients with
HER2-negative breast cancer. Pertuzumab (Perjeta.RTM., U.S. Pat.
No. 7,862,817) is a humanized monoclonal antibody, which is
designed specifically to prevent the HER2 receptor from pairing
(dimerizing) with other HER receptors (EGFR/HER1, HER3 and HER4) on
the surface of cells, a process that is believed to play a role in
tumour growth and survival. The combination of Perjeta, Herceptin
and chemotherapy is thought to provide a more comprehensive
blockade of HER signaling pathways. Pertuzumab binds to domain II
of HER2, essential for dimerization, while trastuzumab binds to
extracellular domain IV of HER2.
[0004] Li et al (Cancer Res., 73:6471-6483 (2013)) describe
bispecific, bivalent antibodies to HER2 that are based on the
native trastuzumab and pertuzumab sequences and which overcome
trastuzumab resistance. Other bispecific anti-HER2 antibodies have
been described (International Patent Application Publication Nos.
WO 2015/077891 and WO 2016/179707; U.S. Patent Application
Publication Nos. 2014/0170148, 2015/0284463, 2017/0029529 and
2017/0291955; U.S. Pat. No. 9,745,382). An antibody-drug conjugate
comprising a HER2-targeting biparatopic antibody site-specifically
conjugated to a tubulysin derivative has also been described (Li et
al., Cancer Cell, 29:117-129 (2016)).
[0005] Auristatins are synthetic analogues of dolastatin 10, which
is a potent microtubule inhibitor with anti-cancer activity.
Antibody-drug conjugates comprising auristatin payloads, such as
monomethyl auristatin E (MMAE) or monomethyl auristatin F (MMAF),
have been described (U.S. Pat. Nos. 7,498,298 and 7,659,241;
International Patent Application Publication Nos. WO 2002/088172
and WO 2016/041082). International Patent Application Publication
No. WO 2106/041082 describes N-acyl sulfonamide modified
auristatins and their use as antibody-drug conjugate payloads.
[0006] This background information is provided for the purpose of
making known information believed by the applicant to be of
possible relevance to the present disclosure. No admission is
necessarily intended, nor should be construed, that any of the
preceding information constitutes prior art against the claimed
invention.
SUMMARY
[0007] Described herein are anti-HER2 biparatopic antibody-drug
conjugates and methods of use. In one aspect, the present
disclosure relates to an antibody-drug conjugate comprising an
anti-HER2 biparatopic antibody conjugated to an auristatin analogue
via a linker (L) at a low average drug-to-antibody ratio (DAR),
wherein the anti-HER2 biparatopic antibody comprises a first
antigen-binding polypeptide construct which binds a first HER2
epitope and a second antigen-binding polypeptide construct which
binds a second HER2 epitope, the first and second HER2 epitopes
being different epitopes, and wherein the low average DAR is an
average DAR of less than 3.9.
[0008] In certain embodiments of the antibody-drug conjugate the
auristatin analogue-linker has general Formula (II):
##STR00001## [0009] wherein: [0010] X is
--C(O)NHCH(CH.sub.2R.sup.2)--, or X is absent; [0011] R.sup.1 is
selected from:
[0011] ##STR00002## [0012] L is the linker, and [0013] represents
the point of attachment of the linker-toxin to the anti-HER2
biparatopic antibody; [0014] wherein the anti-HER2 biparatopic
antibody comprises a first antigen-binding polypeptide construct
which binds a first HER2 epitope and a second antigen-binding
polypeptide construct which binds a second HER2 epitope, the first
and second HER2 epitopes being different epitopes, and [0015]
wherein the low average DAR is an average DAR of less than 3.9.
[0016] In certain embodiments, the low average DAR of the
antibody-drug conjugate is between 0.5 and 3.5, or between 0.5 and
2.5.
[0017] In certain embodiments, the antibody-drug conjugate
comprises 5% or more DAR0 species or 15% or more DAR0 species. In
some embodiments, the antibody-drug conjugate comprises between
about 5% and about 50% DAR0 species, or between about 10% and about
30% DAR0 species, or between about 10% and about 25% DAR0 species,
or between about 15% and about 25% DAR0 species.
[0018] In certain embodiments, the antibody-drug conjugate
comprises 25% or less DAR6 or greater species, or 15% or less DAR6
or greater species. In some embodiments, the antibody-drug
conjugate comprises between 0% and about 15% DAR6 or greater
species, or between about 0% and about 10% DAR6 or greater
species.
[0019] Another aspect of the present disclosure relates to a
pharmaceutical composition comprising an anti-HER2 biparatopic
antibody-drug conjugate as described herein and a pharmaceutically
acceptable carrier or diluent.
[0020] Another aspect relates to a method of inhibiting the growth
of a HER2-expressing cancer cell, the method comprising contacting
the cancer cell with an effective amount of an anti-HER2
biparatopic antibody-drug conjugate as described herein.
[0021] Another aspect relates to a method of treating a
HER2-expressing cancer comprising administering to a subject having
a HER2-expressing cancer an effective amount of an anti-HER2
biparatopic antibody-drug conjugate as described herein.
[0022] Another aspect relates to an antibody-drug conjugate as
described herein for use in therapy.
[0023] Another aspect relates to an antibody-drug conjugate as
described herein for use to treat a HER2-expressing cancer in a
subject in need thereof.
[0024] Another aspect relates to a use of an antibody-drug
conjugate as described herein in the manufacture of a medicament
for the treatment of a HER2-expressing cancer.
[0025] Another aspect relates to an antibody-drug conjugate
composition comprising an anti-HER2 biparatopic antibody conjugated
to an auristatin analogue via a linker (L), the auristatin
analogue-linker having general Formula (II):
##STR00003## [0026] wherein: [0027] X is absent; [0028] R.sup.1 is
selected from:
[0028] ##STR00004## [0029] L is the linker, and [0030] represents
the point of attachment of the auristatin analogue-linker to the
anti-HER2 biparatopic antibody; [0031] wherein the anti-HER2
biparatopic antibody comprises a first antigen-binding polypeptide
construct which binds a first HER2 epitope on ECD4 of HER2 and a
second antigen-binding polypeptide construct which binds a second
HER2 epitope on ECD2 of HER2, and [0032] wherein the antibody-drug
conjugate composition has an average DAR of between 0.5 and 2.5 and
comprises between about 10% and about 30% DAR0 species and between
0% and about 15% DAR6 or greater species.
BRIEF DESCRIPTION OF THE DRAWINGS
[0033] FIG. 1 shows non-reducing and reducing SDS-PAGE of (A)
v17597 (anti-HER2 biparatopic antibody conjugated to Linker-Toxin
001 at DAR4), and (B) v21252 (anti-HER2 biparatopic antibody
conjugated to Linker-Toxin 001 at DAR2), each compared to parent
anti-HER2 biparatopic antibody (v10000).
[0034] FIG. 2 shows hydrophobic interaction chromatography (HIC)
traces for (A) parent anti-HER2 biparatopic antibody v0000, (B)
v17597 (anti-HER2 biparatopic antibody conjugated to Linker-Toxin
001 showing an average DAR of 3.92), and (C) v21252 (anti-HER2
biparatopic antibody conjugated to Linker-Toxin 001 showing an
average DAR of 2.07). The individual contributions of the DAR0,
DAR2, DAR4 and DAR6 species to the average DAR of the purified ADCs
is shown in (D) and (E).
[0035] FIG. 3 shows size-exclusion chromatography (SEC) traces for
(A) parent anti-HER2 biparatopic antibody v10000, (B) v17597
(anti-HER2 biparatopic antibody conjugated to Linker-Toxin 001 at
DAR4), and (C) v21252 (anti-HER2 biparatopic antibody conjugated to
Linker-Toxin 001 at DAR2).
[0036] FIG. 4 shows the results of flow cytometry binding assays on
antigen-positive cells, comparison of v17597 (anti-HER2 biparatopic
antibody conjugated to Linker-Toxin 001 at DAR4) and v10000 (parent
biparatopic anti-HER2 antibody) binding to (A) JIMT-1 breast
carcinoma cells, and (B) RT-112 bladder carcinoma cells, and (C)
comparison of v21252 (anti-HER2 biparatopic antibody conjugated to
Linker-Toxin 001 at DAR2) and v0000 (parent anti-HER2 biparatopic
antibody) binding to JIMT-1 breast carcinoma cells.
[0037] FIG. 5 shows the results of treating the HER2-expressing
breast carcinoma cell lines BT-474 (A), SK-BR-3 (B), HCC1954 (C),
JIMT-1 (D) and ZR-75-1 (E), and the HER2 negative cell line
MDA-MB-468 (F) with v17597 (anti-HER2 biparatopic antibody
conjugated to Linker-Toxin 001 at DAR4) and v21252 (anti-HER2
biparatopic antibody conjugated to Linker-Toxin 001 at DAR2).
[0038] FIG. 6 shows the results of treating the HER2-expressing
ovarian carcinoma cell line SK-OV-3 (A), and the breast carcinoma
cell lines ZR-75-1 (B) and JIMT-1 (C) with antibody-drug conjugates
comprising v10000 conjugated to Linker-Toxin 001 at various average
DAR. The individual contributions of the DAR0, DAR2, DAR4 and DAR6
species to the average DAR of the ADCs having an average DAR of
0.7, 2.2 and 3.9 is shown in (D).
[0039] FIG. 7 shows the results of treating HBCx-13b breast cancer
patient derived xenograft mice g14d x2 with the noted doses of (A)
v17597 (anti-HER2 biparatopic antibody conjugated to Linker-Toxin
001 at DAR4) and (B) v21252 (anti-HER2 biparatopic antibody
conjugated to Linker-Toxin 001 at DAR2). v15496=vehicle.
[0040] FIG. 8 shows the results of treating ST-910 breast cancer
patient derived xenograft mice qdx1 with the noted doses of (A)
v17597 (anti-HER2 biparatopic antibody conjugated to Linker-Toxin
001 at DAR4) and (B) v21252 (anti-HER2 biparatopic antibody
conjugated to Linker-Toxin 001 at DAR2). v15496=vehicle.
[0041] FIG. 9 shows (A) the mean (.+-.SD) v21252 serum
concentration-time profiles, and (B) the mean (.+-.SD) total
antibody serum concentration-time profiles, following
administration of a single dose of v21252 to female cynomolgus
monkeys (n=3) at 9 mg/kg or 12 mg/kg.
[0042] FIG. 10 shows the mean (.+-.SD) v21252 serum
concentration-time profiles on Day 1 (A) and Day 29 (B) following a
bi-weekly infusion of v21252 to cynomolgus monkeys (n=6) at either
12 mg/kg or 9 mg/kg.
[0043] FIG. 11 shows the mean (.+-.SD) total antibody serum
concentration-time profiles on Day 1 (A) and Day 29 (B) following a
bi-weekly infusion of v21252 to cynomolgus monkeys (n=6) at either
12 mg/kg or 9 mg/kg.
[0044] FIG. 12 shows the mean (.+-.SD) serum concentration-time
profiles for both v21252 and total antibody (conjugated and
unconjugated) following a bi-weekly infusion of v21252 to
cynomolgus monkeys (n=6) at either 12 mg/kg or 9 mg/kg.
[0045] FIG. 13 shows internalization of pHAb-conjugated v21252
compared to pHAb-conjugated Trastuzumab-Linker-Toxin 001 and
negative control into (A) SKBR3 cells, and (B) JIMT-1 cells.
[0046] FIG. 14 shows internalization of pHAb-conjugated v21252 (A)
compared to pHAb-conjugated Trastuzumab-Linker-Toxin 001 (B) into
SKBR3 cells at various time points as indicated. Nuclei are shown
in grey, and pHAb is shown in white.
[0047] FIG. 15 shows comparative exposure in cynomolgus monkeys and
mice treated with v21252 at the indicated doses: (A) exposure in
cynomolgus monkeys and mice subcutaneously implanted with high HER2
patient derived tumour (HBCx-13b), (B) exposure in cynomolgus
monkeys and mice subcutaneously implanted with low HER2 patient
derived tumour (ST-910).
[0048] FIG. 16 shows the results of treating LTL-654 ovarian cancer
patient derived xenograft mice qwk x4 with 3 mg/kg of vehicle or
v21252.
[0049] FIG. 17 provides the survival results for mice
intracranially implanted with BT-474 breast tumour cells after
weekly i.v. administration of vehicle, control conjugate (humanized
antibody against respiratory syncytial virus conjugated to
Linker-Toxin 001), v21252, v7155 (T-DM1, DAR3.5) and v24029
(trastuzumab conjugated at DAR8 to an exatecan-derivative
topoisomerase I inhibitor (DXd)), each at 6 mg/kg weekly for 12
total injections.
[0050] FIG. 18 provides the survival results for mice
intracranially implanted with BT-474 breast tumour cells after i.v.
administration of vehicle, control conjugate (humanized antibody
against respiratory syncytial virus conjugated to Linker-Toxin
001), or v7155 (T-DM1, DAR3.5) at 6 mg/kg weekly for 12 total
injections or v21252 or v24029 (trastuzumab conjugated at DAR8 to
an exatecan-derivative topoisomerase I inhibitor (DXd)), each at 6
mg/kg every two weeks for 6 total injections.
DETAILED DESCRIPTION
[0051] The present disclosure relates to anti-HER2 biparatopic
antibody-drug conjugates (ADCs) in which the drug is an auristatin
analogue and is conjugated to the antibody at a low average
drug-to-antibody ratio (DAR). The low average DAR (<3.9) ADCs as
described herein have improved tolerability and decreased toxicity
as compared to a corresponding ADC having a DAR .gtoreq.3.9 when
administered at the same toxin (auristatin analogue) dose. Of
particular interest are ADCs having an average DAR of about 2.5 or
less, such as between about 1.8 and 2.5.
[0052] The present disclosure also relates to methods of using the
ADCs described herein in the treatment of a HER2-expressing
cancer.
Definitions
[0053] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art.
[0054] The term "subject," as used herein, refers to an animal, in
some embodiments a mammal, which is the object of treatment,
observation or experiment. The animal may be a human, a non-human
primate, a companion animal (for example, dog, cat, or the like),
farm animal (for example, cow, sheep, pig, horse, or the like) or a
laboratory animal (for example, rat, mouse, guinea pig, non-human
primate, or the like). In certain embodiments, the subject is a
human.
[0055] The term "mammal," as used herein, includes but is not
limited to humans, non-human primates, canines, felines, murines,
bovines, equines and porcines. In certain embodiments, the mammal
is a human.
[0056] As used herein, the term "about" refers to an approximately
+/-10% variation from a given value. It is to be understood that
such a variation is always included in any given value provided
herein, whether or not it is specifically referred to.
[0057] The use of the word "a" or "an" when used herein in
conjunction with the term "comprising" may mean "one," but it is
also consistent in certain embodiments with the meaning of "one or
more," "at least one" or "one or more than one."
[0058] As used herein, the terms "comprising," "having,"
"including" and "containing," and grammatical variations thereof,
are inclusive or open-ended and do not exclude additional,
unrecited elements and/or method steps. The term "consisting
essentially of" when used herein in connection with a composition,
use or method, denotes that additional elements and/or method steps
may be present, but that these additions do not materially affect
the manner in which the recited composition, method or use
functions. The term "consisting of" when used herein in connection
with a composition, use or method, excludes the presence of
additional elements and/or method steps. A composition, use or
method described herein as comprising certain elements and/or steps
may also, in certain embodiments consist essentially of those
elements and/or steps, and in other embodiments consist of those
elements and/or steps, whether or not these embodiments are
specifically referred to.
[0059] It is contemplated that any embodiment discussed herein can
be implemented with respect to any method, use or composition
disclosed herein.
[0060] Particular features, structures and/or characteristics
described in connection with an embodiment disclosed herein may be
combined with features, structures and/or characteristics described
in connection with another embodiment disclosed herein in any
suitable manner to provide one or more further embodiments.
[0061] It is also to be understood that the positive recitation of
a feature in one embodiment, serves as a basis for excluding the
feature in an alternative embodiment. For example, where a list of
options is presented for a given embodiment or claim, it is to be
understood that one or more option may be deleted from the list and
the shortened list may form an alternative embodiment, whether or
not such an alternative embodiment is specifically referred to.
Anti-HER2 Biparatopic Antibody-Drug Conjugates
[0062] The antibody-drug conjugates (ADCs) of the present
disclosure comprise an anti-HER2 biparatopic antibody conjugated to
a toxin via a linker at a low average drug-to-antibody ratio (DAR),
the toxin being an auristatin-based toxin (or "auristatin
analogue"). Examples of auristatin-based toxins are known in the
art.
[0063] In certain embodiments, the auristatin analogue is a
compound of general Formula (I):
##STR00005## [0064] wherein: [0065] X is
--C(O)NHCH(CH.sub.2R.sup.2)--, or X is absent; [0066] R.sup.1 is
selected from:
[0066] ##STR00006## [0067] and [0068] R.sup.2 is phenyl.
[0069] "Low DAR" as used herein, is defined as an average DAR of
less than 3.9, but more than 0.5. In some embodiments, the average
DAR of the ADCs is less than 3.5. In some embodiments, the average
DAR of the ADCs is less than 3.4, for example, less than 3.3, less
than 3.2 or less than 3.1. In some embodiments, the average DAR of
the ADCs is 3.0 or less. In some embodiments, the average DAR of
the ADCs is 2.9 or less, for example, 2.8 or less, 2.7 or less, or
2.6 or less. In some embodiments, the average DAR of the ADCs is
2.5 or less, for example, 2.4 or less, 2.3 or less, or 2.2 or less.
In some embodiments, the average DAR of the ADCs is about 2.0.
[0070] In some embodiments, the average DAR of the ADCs is between
0.5 and 3.8, for example, between 0.5 and 3.5, or between 0.5 and
2.5. In some embodiments, the average DAR of the ADCs is between
0.7 and 3.8, for example, between 0.7 and 3.5, between 0.7 and 3.0,
or between 0.7 and 2.5. In some embodiments, the average DAR of the
ADCs is between 1.0 and 3.8, for example, between 1.0 and 3.5,
between 1.0 and 3.0, or between 1.0 and 2.5. In some embodiments,
the average DAR of the ADCs is between 1.5 and 3.8, for example,
between 1.5 and 3.5, between 1.5 and 3.0, or between 1.5 and 2.5.
In some embodiments, the average DAR of the ADCs is between 1.6 and
3.8, for example, between 1.6 and 3.5, between 1.6 and 3.0, or
between 1.6 and 2.5. In some embodiments, the average DAR of the
ADCs is between 1.8 and 2.8, for example, between 1.8 and 2.5.
[0071] As noted above, the low average DAR (<3.9) ADCs as
described herein have improved tolerability and decreased toxicity
as compared to a corresponding ADC having a DAR .gtoreq.3.9 when
administered at the same toxin dose. As is known in the art, the
majority of conjugation methods yield an ADC composition that
includes various DAR species, with the reported DAR being the
average of the individual DAR species. Without being limited by any
particular theory, the higher tolerability and decreased toxicity
of the low DAR ADC may be due to one or both of a decrease in high
DAR (6 or greater) species in the ADC composition and/or an
increase in the DAR0 species in the ADC composition.
[0072] In certain embodiments, ADC compositions that include a
proportion of DAR0 species above a certain threshold may be
advantageous. Accordingly, in some embodiments, the low DAR ADC
composition may include 5% or more DAR0 species. In some
embodiments, the low DAR ADC composition may include 10% or more
DAR0 species. In some embodiments, the low DAR ADC composition may
include 15% or more DAR0 species, for example, 20% or more DAR0
species. In some embodiments, the low DAR ADC composition may
include between about 5% and about 50% DAR0 species. In some
embodiments, the low DAR ADC composition may include between about
10% and about 50% DAR0 species, for example, between about 10% and
about 40%, between about 10% and about 30% DAR0 species, or between
about 10% and about 25% DAR0 species. In some embodiments, the low
DAR ADC composition may include between about 12% and about 28%
DAR0 species, for example, between about 12% and about 28% DAR0
species, or between about 15% and about 25% DAR0 species.
[0073] In certain embodiments, ADC compositions that include a
proportion of DAR6 or greater species below a certain threshold may
be advantageous. Accordingly, in some embodiments, the low DAR ADC
composition may include less than about 35% DAR6 or greater
species. In some embodiments, the low DAR ADC composition may
include 30% or less DAR6 or greater species. In some embodiments,
the low DAR ADC composition may include 25% or less DAR6 or greater
species, for example, 20% or less, 15% or less, or 10% or less DAR6
or greater species. In some embodiments, the low DAR ADC
composition may include 9% or less DAR6 or greater species, for
example, 8% or less, 7% or less, 6% or less, or 5% or less DAR6 or
greater species. In some embodiments, the low DAR ADC composition
may include between 0% and about 35% DAR6 or greater species. In
some embodiments, the low DAR ADC composition may include between
0% and about 30% DAR6 or greater species, for example, between 0%
and about 25%, or between 0% and about 20% DAR6 or greater species.
In some embodiments, the low DAR ADC composition may include
between 0% and about 15% DAR6 or greater species, for example,
between about 0% and about 10%, between about 0% and about 8%, or
between 0% and about 5% DAR6 or greater species.
[0074] Certain embodiments relate to ADCs that comprise an
anti-HER2 biparatopic antibody conjugated to an auristatin analogue
via a linker (L) at a low average drug-to-antibody ratio (DAR), the
auristatin analogue-linker having general Formula (II):
##STR00007## [0075] wherein X and R.sup.1 are as defined for
general Formula (I); [0076] L is the linker, and [0077] represents
the point of attachment of the auristatin analogue-linker to the
anti-HER2 biparatopic antibody.
[0078] Certain embodiments relate to an ADC having general Formula
(III):
##STR00008## [0079] wherein X and R.sup.1 are as defined for
general Formula (I); [0080] L is a linker; [0081] n is the average
drug-to-antibody ratio (DAR) and is less than 3.9, and [0082] Ab is
an anti-HER2 biparatopic antibody.
Anti-HER2 Biparatopic Antibodies
[0083] The ADCs described herein comprise an anti-HER2 biparatopic
antibody that binds to two different epitopes of HER2.
[0084] The term "antibody," as used herein, generally refers to a
proteinaceous binding molecule with immunoglobulin-like functions.
Typical examples of an antibody are immunoglobulins, as well as
derivatives or functional fragments thereof which still retain
binding specificity. Techniques for the production of antibodies
are well known in the art. The term "antibody" may also include
immunoglobulins of different classes (i.e. IgA, IgG, IgM, IgD and
IgE) and subclasses (such as IgG.sub.1, IgG.sub.2, IgG.sub.3,
IgG.sub.4, IgA.sub.1 and IgA.sub.2). Illustrative examples of an
antibody are whole antibodies and antigen-binding fragments
thereof, such as Fab fragments, F(ab').sub.2, Fv fragments,
single-chain Fv fragments (scFv), diabodies, domain antibodies, and
combinations thereof. Domain antibodies may be single domain
antibodies, single variable domain antibodies or immunoglobulin
single variable domain having only one variable domain, which may
be a heavy chain variable domain or a light chain variable domain,
that specifically bind an antigen or epitope independently of other
variable regions or domains. The term "antibody" also includes
embodiments such as chimeric, single chain and humanized
antibodies.
[0085] A typical whole antibody comprises at least two heavy (H)
chains and two light (L) chains interconnected by disulfide bonds.
Each heavy chain is comprised of a heavy chain variable region (VH)
and a heavy chain constant region (CH). The heavy chain constant
region comprises three domains: CH1, CH2 and CH3. The heavy chain
constant domains that correspond to the different classes of
immunoglobulins are known as .alpha. (IgA), .delta. (IgD),
.epsilon. (IgE), .gamma. (IgG) and .mu. (IgM). Each light chain is
comprised of a light chain variable region (VL) and a light chain
constant region. The light chain constant region comprises just one
domain: CL. Light chains are classified as either kappa or lambda.
The VH and VL regions can be further subdivided into regions of
hypervariability, termed Complementarity Determining Regions (CDR),
interspersed with regions that are more conserved, termed framework
regions (FW). Each VH and VL is composed of three CDRs and four
FWs, arranged from amino-terminus to carboxy-terminus in the
following order: FW1, CDR1, FW2, CDR2, FW3, CDR3, FW4. The variable
regions of the heavy and light chains contain a binding domain (a
paratope) that interacts with an antigen. The constant regions of
the antibodies can mediate the binding of the immunoglobulin to
host tissues or factors, including various cells of the immune
system (such as effector cells) and C1q, which is a component of
the complement system.
[0086] In certain embodiments, the anti-HER2 biparatopic antibodies
for inclusion in the ADCs described herein comprise two
antigen-binding polypeptide constructs, each of which binds to a
different epitope of HER2. An "antigen-binding polypeptide
construct," as used herein, may be an immunoglobulin-based
construct, for example, an antibody fragment, or it may be a
non-immunoglobulin-based antibody mimetic format, such as an
anticalin, a fynomer, an affimer, an alphabody, a DARPin or an
avimer. In some embodiments, the antigen-binding polypeptide
constructs comprised by the anti-HER2 biparatopic antibody may be
immunoglobulin-based constructs. In some embodiments, the
antigen-binding polypeptide constructs comprised by the anti-HER2
biparatopic antibody may be antibody fragments.
[0087] In certain embodiments, the antigen-binding polypeptide
constructs comprised by the anti-HER2 biparatopic antibody may each
independently be a Fab fragment, a Fab' fragment, an scFv or an
sdAb. In some embodiments, the antigen-binding polypeptide
constructs comprised by the anti-HER2 biparatopic antibody may each
independently be a Fab fragment or an scFv. In some embodiments,
one antigen-binding polypeptide construct comprised by the
anti-HER2 biparatopic antibody may be a Fab fragment and the other
antigen-binding polypeptide construct may be an scFv.
[0088] In certain embodiments, at least one of the antigen-binding
polypeptide constructs comprised by the anti-HER2 biparatopic
antibody may be a Fab fragment or a Fab' fragment. A "Fab fragment"
contains the constant domain of the light chain (CL) and the first
constant domain of the heavy chain (CH1) along with the variable
domains of the light and heavy chains (VL and VH, respectively).
Fab' fragments differ from Fab fragments by the addition of a few
amino acid residues at the C-terminus of the heavy chain CH1
domain, including one or more cysteines from the antibody hinge
region. A Fab fragment may also be a single-chain Fab molecule,
i.e. a Fab molecule in which the Fab light chain and the Fab heavy
chain are connected by a peptide linker to form a single peptide
chain. For example, the C-terminus of the Fab light chain may be
connected to the N-terminus of the Fab heavy chain in the
single-chain Fab molecule.
[0089] In certain embodiments, at least one of the antigen-binding
polypeptide constructs comprised by the anti-HER2 biparatopic
antibody may be a single-chain Fv (scFv). An "scFv" includes a
heavy chain variable domain (VH) and a light chain variable domain
(VL) of an antibody in a single polypeptide chain. The scFv may
optionally further comprise a polypeptide linker between the VH and
VL domains which enables the scFv to form a desired structure for
antigen binding. For example, an scFv may include a VL connected
from its C-terminus to the N-terminus of a VH by a polypeptide
linker. Alternately, an scFv may comprise a VH connected through
its C-terminus to the N-terminus of a VL by a polypeptide chain or
linker (see review in Pluckthun in The Pharmacology of Monoclonal
Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag,
New York, pp. 269-315 (1994)).
[0090] In certain embodiments, at least one of the antigen-binding
polypeptide constructs comprised by the anti-HER2 biparatopic
antibody may be in a single domain antibody (sdAb) format. An sdAb
format refers to a single immunoglobulin domain. The sdAb may be,
for example, of camelid origin. Camelid antibodies lack light
chains and their antigen-binding sites consist of a single domain,
termed a "VHH." An sdAb comprises three CDR/hypervariable loops
that form the antigen-binding site: CDR1, CDR2 and CDR3. sdAbs are
fairly stable and easy to express, for example, as a fusion with
the Fc chain of an antibody (see, for example, Harmsen & De
Haard, Appl. Microbiol Biotechnol. 77(1): 13-22 (2007)).
Antibody Formats
[0091] The anti-HER2 biparatopic antibodies for inclusion in the
ADCs described herein may have various formats. The minimal
components of the anti-HER2 biparatopic antibody are a first
antigen-binding polypeptide construct that binds to a first HER2
epitope and a second antigen-binding polypeptide construct that
binds to a second HER2 epitope, with the first and second HER2
epitopes being different. An antibody that comprises two
antigen-binding polypeptide constructs that bind to different HER2
epitopes may be considered to be a bivalent, biparatopic antibody.
Certain embodiments relate to bivalent, anti-HER2 biparatopic
antibodies. In some embodiments, the anti-HER2 biparatopic antibody
may comprise one or more additional antigen-binding polypeptide
constructs, each of which bind to either the first or second HER2
epitope. For example, in some embodiments, the anti-HER2
biparatopic antibody may be trivalent or tetravalent.
[0092] In some embodiments, the anti-HER2 biparatopic antibody
further comprises a linker that links the first and second
antigen-binding polypeptide constructs. In some embodiments, the
anti-HER2 biparatopic antibody further comprises a scaffold and the
first and second antigen-binding polypeptide constructs are
operably linked to the scaffold. The term "operably linked," as
used herein, means that the components described are in a
relationship permitting them to function in their intended
manner.
[0093] The anti-HER2 biparatopic antibodies may thus be considered
to have a modular architecture that includes two antigen-binding
polypeptide construct modules and optionally one or both of a
linker module and a scaffold module. One skilled in the art will
understand that these modules may be combined in various ways to
provide anti-HER2 biparatopic antibodies having different formats.
These formats are based generally on antibody formats known in the
art (see, for example, review by Brinkmann & Kontermann, MABS,
9(2):182-212 (2017), and Muller & Kontermann, "Bispecific
Antibodies" in Handbook of Therapeutic Antibodies, Wiley-VCH Verlag
GmbH & Co. (2014)).
[0094] In certain embodiments, the anti-HER2 biparatopic antibody
comprises two antigen-binding polypeptide constructs operably
linked to a scaffold. Suitable scaffolds are described below. In
some embodiments, the anti-HER2 biparatopic antibody comprises two
antigen-binding polypeptide constructs operably linked to a
scaffold, and at least one of the antigen-binding polypeptide
constructs is an scFv. In some embodiments, the anti-HER2
biparatopic antibody comprises two antigen-binding polypeptide
constructs operably linked to a scaffold, and at least one of the
antigen-binding polypeptide constructs is a Fab.
[0095] In some embodiments, the anti-HER2 biparatopic antibody may
comprise three or four antigen-binding polypeptide constructs and a
scaffold. In this format, at least the first and second
antigen-binding constructs are operably linked to the scaffold. The
third and optional fourth antigen-binding polypeptide constructs
may each independently be operably linked to the scaffold or to the
first antigen-binding polypeptide construct or to the second
antigen-binding polypeptide construct.
[0096] Anti-HER2 biparatopic antibodies that lack a scaffold
typically comprise two antigen-binding polypeptide constructs
operably linked by one or more linkers. The antigen-binding
polypeptide constructs may be in the form of scFvs, Fabs, sdAbs, or
a combination thereof. For example, using scFvs as the
antigen-binding polypeptide constructs, formats such as a tandem
scFv ((scFv).sub.2 or taFv) may be constructed, in which the scFvs
are connected together by a flexible linker. scFvs may also be used
to construct diabody formats, which comprise two scFvs connected by
a short linker (usually about 5 amino acids in length). The
restricted length of the linker results in dimerization of the
scFvs in a head-to-tail manner. In any of the preceding formats,
the scFvs may be further stabilized by inclusion of an interdomain
disulfide bond. For example, a disulfide bond may be introduced
between VL and VH through introduction of an additional cysteine
residue in each chain (for example, at position 44 in VH and 100 in
VL) (see, for example, Fitzgerald et al., Protein Engineering,
10:1221-1225 (1997)), or a disulfide bond may be introduced between
two VHs to provide construct having a DART format (see, for
example, Johnson et al., J Mol. Biol., 399:436-449 (2010)).
[0097] Similarly, formats comprising two sdAbs, such as VHs or
VHHs, connected together through a suitable linker may be employed
in some embodiments.
[0098] Other examples of anti-HER2 biparatopic antibody formats
that lack a scaffold include those based on Fab fragments, for
example, Fab.sub.2 and F(ab').sub.2 formats, in which the Fab
fragments are connected through a linker or an IgG hinge
region.
[0099] Combinations of antigen-binding polypeptide constructs in
different forms may also be employed to generate alternative
scaffold-less formats. For example, an scFv or a sdAb may be fused
to the C-terminus of either or both of the light and heavy chain of
a Fab fragment resulting in a bivalent (Fab-scFv/sdAb)
construct.
[0100] In certain embodiments, the anti-HER2 biparatopic antibody
may comprise two antigen-binding polypeptide constructs and one or
more linkers, and does not include a scaffold. In some embodiments,
the anti-HER2 biparatopic antibody comprises two antigen-binding
polypeptide constructs which are scFvs, Fabs, sdAbs, or a
combination thereof, and one or more linkers, and does not include
a scaffold.
Scaffolds
[0101] Anti-HER2 biparatopic antibodies comprising a scaffold may
be constructed by linking the two antigen-binding polypeptide
constructs to a suitable scaffold. The antigen-binding polypeptide
constructs may be in one or a combination of the forms described
above (for example, scFvs, Fabs and/or sdAbs). Examples of suitable
scaffolds are described in more detail below and include, but are
not limited to, immunoglobulin Fc regions, albumin, albumin analogs
and derivatives, heterodimerizing peptides (such as leucine
zippers, heterodimer-forming "zipper" peptides derived from Jun and
Fos, IgG CH1 and CL domains or bamase-barstar toxins), cytokines,
chemokines or growth factors. Other examples include antibodies
based on the DOCK-AND-LOCK.TM. (DNL.TM.) technology developed by
IBC Pharmaceuticals, Inc. and Immunomedics, Inc. (see, for example,
Chang, et al., Clin Cancer Res 13:5586s-5591s (2007)).
[0102] In some embodiments, the anti-HER2 biparatopic antibodies
comprise two or more antigen-binding polypeptide constructs and a
scaffold. In some embodiments, the anti-HER2 biparatopic antibodies
comprise two antigen-binding polypeptide constructs operably linked
to a scaffold.
[0103] A scaffold may be a peptide, polypeptide, polymer,
nanoparticle or other chemical entity. Where the scaffold is a
polypeptide, each antigen-binding polypeptide construct of the
anti-HER2 biparatopic antibody may be linked to either the N- or
C-terminus of the polypeptide scaffold. Anti-HER2 biparatopic
antibodies comprising a polypeptide scaffold in which one or more
of the antigen-binding polypeptide constructs are linked to a
region other than the N- or C-terminus, for example, via the side
chain of an amino acid with or without a linker, are also
contemplated in certain embodiments.
[0104] In embodiments where the scaffold is a peptide or
polypeptide, the antigen-binding polypeptide constructs may be
linked to the scaffold by genetic fusion or chemical conjugation.
Typically, when the scaffold is a peptide or polypeptide, the
antigen-binding polypeptide constructs are linked to the scaffold
by genetic fusion. In some embodiments, where the scaffold is a
polymer or nanoparticle, the antigen-binding polypeptide constructs
may be linked to the scaffold by chemical conjugation.
[0105] A number of protein domains are known in the art that
comprise selective pairs of two different polypeptides and may be
used to form a scaffold. An example is leucine zipper domains such
as Fos and Jun that selectively pair together (Kostelny, et al., J
Immunol, 148:1547-53 (1992); Wranik, et al., J. Biol. Chem., 287:
43331-43339 (2012)). Other selectively pairing molecular pairs
include, for example, the barnase barstar pair (Deyev, et al., Nat
Biotechnol, 21:1486-1492 (2003)), DNA strand pairs (Chaudri, et
al., FEBS Letters, 450(1-2):23-26 (1999)) and split fluorescent
protein pairs (International Patent Application Publication No. WO
2011/135040).
[0106] Other examples of protein scaffolds include immunoglobulin
Fc regions, albumin, albumin analogues and derivatives, toxins,
cytokines, chemokines and growth factors. The use of protein
scaffolds in combination with antigen-binding moieties has been
described (see, for example, Muller et al., J Biol Chem,
282:12650-12660 (2007); McDonaugh et al., Mol Cancer Ther,
11:582-593 (2012); Vallera et al., Clin Cancer Res, 11:3879-3888
(2005); Song et al., Biotech Appl Biochem, 45:147-154 (2006), and
U.S. Patent Application Publication No. 2009/0285816).
[0107] For example, fusing antigen-binding moieties such as scFvs,
diabodies or single chain diabodies to albumin has been shown to
improve the serum half-life of the antigen-binding moieties (Muller
et al., ibid.). Antigen-binding moieties may be fused at the N-
and/or C-termini of albumin, optionally via a linker.
[0108] Derivatives of albumin in the form of heteromultimers that
comprise two transporter polypeptides obtained by segmentation of
an albumin protein such that the transporter polypeptides
self-assemble to form quasi-native albumin have been described (see
International Patent Application Publication Nos. WO 2012/116453
and WO 2014/012082). As a result of the segmentation of albumin,
the heteromultimer includes four termini and thus can be fused to
up to four different antigen-binding moieties, optionally via
linkers.
[0109] In certain embodiments, the anti-HER2 biparatopic antibody
may comprise a protein scaffold. In some embodiments, the anti-HER2
biparatopic antibody may comprise a protein scaffold that is based
on an immunoglobulin Fc region, an albumin or an albumin analogue
or derivative. In some embodiments, the anti-HER2 biparatopic
antibody may comprise a protein scaffold that is based on an
immunoglobulin Fc region, for example, an IgG Fc region.
[0110] In some embodiments, the anti-HER2 biparatopic antibody may
comprise a protein scaffold that is based on an albumin, for
example human serum albumin (HSA), or an albumin analogue or
derivative. In some embodiments, the anti-HER2 biparatopic antibody
may comprise a protein scaffold that is based on an albumin
derivative as described in International Patent Application
Publication No. WO 2012/116453 or WO 2014/012082.
Fc Regions
[0111] The terms "Fc region," "Fc" or "Fc domain" as used herein
refer to a C-terminal region of an immunoglobulin heavy chain that
contains at least a portion of the constant region. The term
includes native sequence Fe regions and variant Fe regions. Unless
otherwise specified herein, numbering of amino acid residues in the
Fc region or constant region is according to the EU numbering
system, also called the EU index, as described in Kabat et al,
Sequences of Proteins of Immunological Interest, 5th Ed. Public
Health Service, National Institutes of Health, Bethesda, Md.
(1991).
[0112] In certain embodiments, the anti-HER2 biparatopic antibodies
may comprise a scaffold that is based on an immunoglobulin Fc
region. In some embodiments, the Fc region may be dimeric and
composed of two Fc polypeptides. In some embodiments, the Fc region
may be composed of a single polypeptide.
[0113] An "Fc polypeptide" of a dimeric Fc refers to one of the two
polypeptides forming the dimeric Fc domain, i.e. a polypeptide
comprising one or more C-terminal constant regions of an
immunoglobulin heavy chain that is capable of stable
self-association. The terms "first Fc polypeptide" and "second Fc
polypeptide" may be used interchangeably provided that the Fc
region comprises one first Fc polypeptide and one second Fc
polypeptide.
[0114] An Fc region comprises a CH3 domain or both a CH3 and a CH2
domain. For example, an Fc polypeptide of a dimeric IgG Fc region
comprises an IgG CH2 and an IgG CH3 constant domain sequence. The
CH3 domain comprises two CH3 sequences, one from each of the two Fc
polypeptides of the dimeric Fc region. The CH2 domain comprises two
CH2 sequences, one from each of the two Fc polypeptides of the
dimeric Fc region.
[0115] In some embodiments, the anti-HER2 biparatopic antibody may
comprise a scaffold that is based on an IgG Fc region. In some
embodiments, the anti-HER2 biparatopic antibody may comprise a
scaffold that is based on a human Fc region. In some embodiments,
the anti-HER2 biparatopic antibody may comprise a scaffold based on
a human IgG Fc region, for example a human IgG1 Fc region.
[0116] In certain embodiments, the anti-HER2 biparatopic antibody
may comprise a scaffold based on an IgG Fc region, which is a
heterodimeric Fc region, comprising a first Fc polypeptide and a
second Fc polypeptide, each comprising a CH3 sequence, and
optionally a CH2 sequence.
[0117] In some embodiments, the anti-HER2 biparatopic antibody may
comprise a scaffold based on an Fc region which comprises first and
second Fc polypeptides, and the first antigen-binding polypeptide
construct is operably linked to the first Fc polypeptide and the
second antigen-binding polypeptide construct is operably linked to
the second Fc polypeptide.
[0118] In some embodiments, the anti-HER2 biparatopic antibody may
comprise a scaffold based on an Fc region which comprises first and
second Fc polypeptides, in which the first antigen-binding
polypeptide construct is operably linked to the first Fc
polypeptide and the second antigen-binding polypeptide construct is
operably linked to the second Fc polypeptide, and in which the
first and second antigen-binding polypeptide constructs are
independently a Fab fragment or an scFv.
[0119] In some embodiments, the anti-HER2 biparatopic antibody may
comprise a scaffold based on an Fc region which comprises two CH3
sequences, at least one of which comprises one or more amino acid
modifications. In some embodiments, the anti-HER2 biparatopic
antibody may comprise a scaffold based on an Fc region which
comprises two CH3 sequences and two CH2 sequences, at least one of
the CH2 sequences comprising one or more amino acid
modifications.
[0120] In some embodiments, the anti-HER2 biparatopic antibody
comprises a heterodimeric Fc region comprising a modified CH3
domain, wherein the modified CH3 domain is an asymmetrically
modified CH3 domain. Generally, the first Fc polypeptide of the
heterodimeric Fc comprises a first CH3 sequence and the second Fc
polypeptide comprises a second CH3 sequence.
[0121] As used herein, "asymmetric amino acid modification" refers
to a modification where an amino acid at a specific position on a
first CH3 sequence is different to the amino acid on a second CH3
sequence at the same position. For CH3 sequences comprising
asymmetric amino acid modifications, the first and second CH3
sequence will typically preferentially pair to form a heterodimer,
rather than a homodimer. These asymmetric amino acid modifications
can be a result of modification of only one of the two amino acids
at the same respective amino acid position on each sequence, or
different modifications of both amino acids on each sequence at the
same respective position on each of the first and second CH3
sequences. Each of the first and second CH3 sequence of a
heterodimeric Fc may comprise one or more than one asymmetric amino
acid modification.
[0122] In some embodiments, the anti-HER2 biparatopic antibody may
comprise a scaffold based on a modified Fc region as described in
International Patent Application Publication No. WO 2012/058768 or
WO 2013/063702.
[0123] Table 1 provides the amino acid sequence of the human IgG1
Fc sequence (SEQ ID NO:1), corresponding to amino acids 231 to 447
of the full-length human IgG1 heavy chain. The CH3 sequence
comprises amino acids 341-447 of the full-length human IgG1 heavy
chain.
[0124] In certain embodiments, the anti-HER2 biparatopic antibody
may comprise a heterodimeric Fc scaffold comprising a modified CH3
domain that comprises asymmetric amino acid modifications that
promote formation of a heterodimeric Fc rather than a homodimeric
Fc. In some embodiments, the anti-HER2 biparatopic antibody may
comprise a heterodimeric Fc scaffold which includes modifications
at one or more of the following positions: L351, F405, Y407, T366,
K392, T394, T350, S400 and/or N390, using EU numbering.
[0125] In certain embodiments, the anti-HER2 biparatopic antibody
may comprise a heterodimeric Fc comprising a modified CH3 domain
having a first polypeptide sequence that comprises amino acid
modifications at positions F405 and Y407, and optionally further
comprises an amino acid modification at position L351, and a second
polypeptide sequence that comprises amino acid modifications at
positions T366 and T394, and optionally further comprises an amino
acid modification at position K392. In some embodiments, a first
polypeptide sequence of the modified CH3 domain may comprise amino
acid modifications at positions F405 and Y407, and optionally
further comprises an amino acid modification at position L351, and
a second polypeptide sequence of the modified CH3 domain comprises
amino acid modifications at positions T366 and T394, and optionally
further comprises an amino acid modification at position K392, and
the amino acid modification at position F405 is F405A, F405I,
F405M, F405S, F405T or F405V; the amino acid modification at
position Y407 is Y407I or Y407V; the amino acid modification at
position T366 is T366I, T366L or T366M; the amino acid modification
at position T394 is T394W; the amino acid modification at position
L351 is L351Y, and the amino acid modification at position K392 is
K392F, K392L or K392M. In some embodiments, the amino acid
modification at position F405 is F405A, F405S, F405T or F405V.
[0126] In some embodiments, the anti-HER2 biparatopic antibody may
comprise a heterodimeric Fc comprising a modified CH3 domain having
a first Fc polypeptide sequence comprising amino acid modifications
at positions F405 and Y407, and optionally further comprises an
amino acid modification at position L351, and a second Fc
polypeptide sequence comprising amino acid modifications at
positions T366 and T394, and optionally further comprises an amino
acid modification at position K392, and the amino acid modification
at position F405 is F405A, F405I, F405M, F405S, F405T or F405V; the
amino acid modification at position Y407 is Y407I or Y407V; the
amino acid modification at position T366 is T366I, T366L or T366M;
the amino acid modification at position T394 is T394W; the amino
acid modification at position L351 is L351Y, and the amino acid
modification at position K392 is K392F, K392L or K392M, and one or
both of the first and second Fc polypeptide sequences further
comprises the amino acid modification T350V. In some embodiments,
the amino acid modification at position F405 is F405A, F405S, F405T
or F405V.
[0127] In certain embodiments, the anti-HER2 biparatopic antibody
may comprise a heterodimeric Fc comprising a modified CH3 domain as
described above, in which the first Fe polypeptide sequence
comprises amino acid modifications at positions F405 and Y407, and
optionally further comprises an amino acid modification at position
L351, and the second Fc polypeptide sequence comprises amino acid
modifications at positions T366 and T394, and optionally further
comprises an amino acid modification at position K392, and in which
the first Fc polypeptide sequence further comprises an amino acid
modification at one or both of positions S400 or Q347 and/or the
second Fe polypeptide sequence further comprises an amino acid
modification at one or both of positions K360 or N390, where the
amino acid modification at position 5400 is S400E, S400D, S400R or
S400K; the amino acid modification at position Q347 is Q347R, Q347E
or Q347K; the amino acid modification at position K360 is K360D or
K360E, and the amino acid modification at position N390 is N390R,
N390K or N390D. In some embodiments, the amino acid modification at
position F405 is F405A, F405S, F405T or F405V.
[0128] In some embodiments, the anti-HER2 biparatopic antibody may
comprise a heterodimeric Fc scaffold having a modified CH3 domain
comprising the modifications of any one of Variant 1, Variant 2,
Variant 3, Variant 4 or Variant 5, as shown in Table 1.
TABLE-US-00001 TABLE 1 IgG1 Fc sequences Human IgG1
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS Fc sequence
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS 231-447 (EU-
VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG numbering)
QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQID NO: 1) Variant IgG1 Fc
sequence Chain Mutations 1 A L351Y_F405A_Y407V B T366L_K392M_T394W
2 A L351Y_F405A_Y407V B T366L_K392L_T394W 3 A
T350V_L351Y_F405A_Y407V B T350V_T366L_K392L_T394W 4 A
T350V_L351Y_F405A_Y407V B T350V_T366L_K392M_T394W 5 A
T350V_L351Y_S400E_F405A_Y407V B T350V_T366L_N390R_K392M_T394W
[0129] In certain embodiments, the anti-HER2 biparatopic antibody
may comprise a heterodimeric Fc scaffold having a modified CH3
domain with a first CH3 sequence comprising one or more amino acid
modifications selected from L351Y, F405A, and Y407V, and the second
CH3 sequence comprising the amino acid modifications T366L or
T366I; K392L or K392M, and T394W, and one or both of the first and
second CH3 sequences may optionally further comprise the amino acid
modification T350V.
[0130] In certain embodiments, the anti-HER2 biparatopic antibody
may comprise a heterodimeric Fc scaffold having a modified CH3
domain comprising asymmetric amino acid modifications as described
above that promote the formation of a heterodimeric Fc in which the
heterodimeric CH3 domain has a stability that is comparable to a
wild-type homodimeric CH3 domain. The stability of the CH3 domain
may be assessed by measuring the melting temperature (Tm) of the
CH3 domain, for example by differential scanning calorimetry (DSC).
In some embodiments, the one or more asymmetric amino acid
modifications promote the formation of a heterodimeric Fc domain in
which the CH3 domain has a stability as observed via the melting
temperature (Tm) in a differential scanning calorimetry study that
is within about 8.degree. C., for example, within about 7.degree.
C., about 6.degree. C., about 5.degree. C., or about 4.degree. C.,
of that observed for the corresponding symmetric wild-type
homodimeric CH3 domain.
[0131] A heterodimeric Fc comprising modified CH3 sequences may be
formed with a purity of at least about 75% as compared to
homodimeric Fc in the expressed product. In some embodiments, the
anti-HER2 biparatopic antibody may comprise a heterodimeric Fc
scaffold having a modified CH3 domain comprising asymmetric amino
acid modifications that promote the formation of a heterodimeric Fc
with a purity greater than about 80%, greater than about 85%,
greater than about 90%, greater than about 95% or greater than
about 97%.
[0132] Additional methods for modifying monomeric Fc polypeptides
to promote heterodimeric Fc formation are known in the art and
include, for example, those described in International Patent
Application Publication No. WO 96/027011 (knobs into holes);
Gunasekaran et al. J Biol Chem, 285, 19637-46 (2010) (electrostatic
design to achieve selective heterodimerization); Davis et al., Prot
Eng Des Sel, 23(4):195-202 (2010) (strand exchange engineered
domain (SEED) technology), and Labrijn et al., Proc Natl Acad Sci
USA, 110(13):5145-50 (2013) (Fab-arm exchange).
[0133] In some embodiments, in which the anti-HER2 biparatopic
antibody comprises a heterodimeric Fc scaffold, the heterodimeric
Fc also comprises a CH2 domain. In some embodiments, the CH2 domain
is a modified CH2 domain. One example of a CH2 domain of an Fc is
amino acids 231-340 of the sequence shown in Table 1. Several
effector functions are mediated by Fc receptors (FcRs), which bind
to the Fc of an antibody.
[0134] Fe receptors (FcRs) include receptors of the Fc.gamma.RI,
Fc.gamma.RII, and Fc.gamma.RIII subclasses, including allelic
variants and alternatively spliced forms of these receptors. The
term FcR may also include in certain embodiments the neonatal
receptor, FcRn.
[0135] Modifications in the CH2 domain can affect the binding of
FcRs to the Fc. A number of amino acid modifications in the Fc
region are known in the art for selectively altering the affinity
of the Fc for different Fc.gamma. receptors. In some embodiments,
in which the anti-HER2 biparatopic antibody comprises a
heterodimeric Fc scaffold having a modified CH2 domain, the
modified CH2 domain may comprise one or more modifications to
promote selective binding of Fc.gamma. receptors.
[0136] Non-limiting examples of modifications that alter the
binding of the Fe by FcRs include S298A/E333A/K334A and
S298A/E333A/K334A/K326A (Lu, et al., J Immunol Methods,
365(1-2):132-41 (2011)); F243L/R292P/Y300L/V305I/P396L and
F243L/R292P/Y300L/L235V/P396L (Stavenhagen, et al., Cancer Res,
67(18):8882-90 (2007) and Nordstrom J L, et al., Breast Cancer Res,
13(6):R123 (2011)); F243L (Stewart, et al., Protein Eng Des Sel.
24(9):671-8 (2011)); S298A/E333A/K334A (Shields, et al., J Biol
Chem, 276(9):6591-604 (2001)); S239D/1332E/A330L and S239D/I332E
(Lazar, et al., Proc Natl Acad Sci USA, 103(11):4005-10 (2006));
S239D/S267E and S267E/L328F (Chu, et al., Mol Immunol,
45(15):3926-33 (2008)). Additional modifications that affect Fc
binding by FcRs are described in Therapeutic Antibody Engineering
(Strohl & Strohl, Woodhead Publishing series in Biomedicine No
11, ISBN 1907568 37 9, October 2012, page 283). Fc regions that
comprise asymmetric modifications that affect binding by FcRs are
described in International Patent Publication No. WO
2014/190441.
[0137] Additional modifications may be made to Fc regions to
improve their ability to mediate effector function. Such
modifications are known in the art and include afucosylation, or
engineering of the affinity of the Fc towards an activating
receptor, mainly Fc.gamma.RIIIa for ADCC, and towards C1q for CDC.
In certain embodiments, the anti-HER2 biparatopic antibody may
comprise an Fc region modified to improve its ability to mediate
effector function.
[0138] Methods of producing antibodies with little or no fucose on
the Fc glycosylation site (Asn 297, EU numbering) without altering
the amino acid sequence are well known in the art. For example, the
GlymaX.RTM. technology (ProBioGen AG) (see von Horsten et al.,
Glycobiology, 20(12):1607-18 (2010) and U.S. Pat. No. 8,409,572).
In certain embodiments, the anti-HER2 biparatopic antibody may
comprise an Fc region that is aglycosylated. In this context, the
anti-HER2 biparatopic antibody may be fully afucosylated (i.e.
containing no detectable fucose) or partially afucosylated, such
that the anti-HER2 biparatopic antibody contains less than 95%,
less than 85%, less than 75%, less than 65%, less than 55%, less
than 45%, less than 35%, less than 25%, less than 15% or less than
5%, or any amount therebetween, of the amount of fucose normally
detected for a similar construct produced by a mammalian expression
system.
[0139] Fc modifications reducing Fc.gamma.R and/or complement
binding and/or effector function are known in the art and include
those described above. Various publications describe strategies
that have been used to engineer antibodies with reduced or silenced
effector activity (see, for example, Strohl, Curr Opin Biotech
20:685-691 (2009), and Strohl & Strohl, "Antibody Fc
engineeringfor optimal antibody performance" In Therapeutic
Antibody Engineering, Cambridge: Woodhead Publishing (2012), pp
225-249). These strategies include reduction of effector function
through modification of glycosylation, use of IgG2/IgG4 scaffolds,
or the introduction of mutations in the hinge or CH2 regions of the
Fc (see also, U.S. Patent Publication No. 2011/0212087,
International Patent Publication No. WO 2006/105338, U.S. Patent
Publication No. 2012/0225058, U.S. Patent Publication No.
2012/0251531 and Strop et al., J. Mol. Biol. 420: 204-219
(2012)).
[0140] Specific, non-limiting examples of known amino acid
modifications to reduce Fc.gamma.R or complement binding to the Fc
include those identified in Table 2.
TABLE-US-00002 TABLE 2 Modifications to reduce Fc.gamma.R or
complement binding to the Fc Company Mutations GSK N297A Ortho
Biotech L234A/L235A Protein Design labs IgG2 V234A/G237A Wellcome
Labs IgG4 L235A/G237A/E318A GSK IgG4 S228P/L236E Alexion
IgG2/IgG4combo Merck IgG2 H268Q/V309L/A330S/A331S Bristol-Myers
C220S/C226S/C229S/P238S Seattle Genetics
C226S/C229S/E3233P/L235V/L235A Amgen E. coli production,
non-glycosylated Medimmune L234F/L235E/P331S Trubion Hinge mutant,
possibly C226S/P230S
[0141] In some embodiments, the anti-HER2 biparatopic antibody may
comprise an Fc region that comprises a modified CH2 domain having
one or more mutations identified in Table 2. In some embodiments,
the anti-HER2 biparatopic antibody may comprise an Fc region
comprising a modified CH2 domain having amino acid modifications at
positions L234, L235 and/or D265. In some embodiments, the
anti-HER2 biparatopic antibody may comprise an Fc region comprising
a modified CH2 domain having the amino acid modifications L234A,
L235A and D265S.
HER2 Epitopes
[0142] The two antigen-binding polypeptide constructs comprised by
the anti-HER2 biparatopic antibody each bind to a different epitope
of HER2, that is, a first antigen-binding polypeptide construct
binds to a first HER2 epitope and a second antigen-binding
polypeptide construct binds to a second HER2 epitope. In the
context of the present disclosure, each of the antigen-binding
polypeptide constructs specifically binds to its target
epitope.
[0143] "Specifically binds" or "specific binding" mean that the
binding is selective for the antigen and can be discriminated from
unwanted or non-specific interactions. The ability of an
antigen-binding polypeptide construct to bind to a specific epitope
can be measured, for example, through an enzyme-linked
immunosorbent assay (ELISA), surface plasmon resonance (SPR)
techniques (analyzed on a BIAcore instrument) (Liljeblad et al,
Glyco J 17, 323-329 (2000)) or traditional binding assays (Heeley,
Endocr Res 28, 217-229 (2002)). In some embodiments, the
antigen-binding polypeptide construct is considered to specifically
bind to its target epitope when the extent of binding of the
antigen-binding polypeptide construct to an unrelated protein is
less than about 10% of the binding of the antigen-binding
polypeptide construct to its target epitope as measured, for
example, by SPR.
[0144] "HER2" (also known as ErbB2) refers to human HER2 protein
described, for example, in Semba et al., PNAS (USA), 82:6497-6501
(1985) and Yamamoto et al., Nature, 319:230-234 (1986) (GenBank
accession number X03363). The terms "erbB2" and "neu" refer to the
gene encoding human HER2 protein. The terms p185 or p185neu may
also be used to refer to the protein product of the neu gene.
[0145] HER2 comprises an extracellular domain, which typically
binds a HER ligand, a lipophilic transmembrane domain, a conserved
intracellular tyrosine kinase domain and a carboxyl-terminal
signaling domain harboring several tyrosine residues which can be
phosphorylated. The extracellular (ecto) domain of HER2 comprises
four domains, Domains I-IV. The sequence of HER2 is provided in
Table 3 (SEQ ID NO:2). The Extracellular Domain (ECD) boundaries
are: Domain I--approximately amino acids 1-165; Domain
II--approximately amino acids 166-322; Domain III--approximately
amino acids 323-488, and Domain IV--approximately amino acids
489-607.
TABLE-US-00003 TABLE 3 Amino Acid Sequence of Human HER2 (SEQ ID
NO: 2) 1 TQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYL
PTNASLSFLQDIQEVQG 61 YVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNN
TTPVTGASPGGLRELQL 121 RSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLID
TNRSRACHPCSPMCKGS 181 RCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCT
GPKHSDCLACLHFNHSG 241 ICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLS
TDVGSCTLVCPLHNQEV 301 TAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFA
GCKKIFGSLAFLPESFD 361 GDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVF
QNLQVIRGRILHNGAYS 421 LTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQL
FRNPHQALLHTANRPED 481 ECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECR
VLQGLPREYVNARHCLP 541 CHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVK
PDLSYMPIWKFPDEEGA 601 CQPCPIN
[0146] "Epitope 2C4" is the region in the extracellular domain of
HER2 to which the antibody 2C4 binds and comprises residues from
Domain II in the extracellular domain of HER2 (also referred to as
ECD2). 2C4 and Pertuzumab bind to the extracellular domain of HER2
at the junction of Domains I, II and III (Franklin et al. Cancer
Cell 5:317-328 (2004)).
[0147] "Epitope 4D5" is the region in the extracellular domain of
HER2 to which the antibody 4D5 (ATCC CRL 10463) and trastuzumab
bind. This epitope is close to the transmembrane domain of HER2,
and within Domain IV of HER2 (also referred to as ECD4).
[0148] In general, the anti-HER2 biparatopic antibody of the
present disclosure will bind to epitopes within the extracellular
domains of HER2. In some embodiments, the first and second HER2
epitopes bound by the first and second antigen-binding polypeptide
constructs of the anti-HER2 biparatopic antibody are
non-overlapping epitopes. In some embodiments, the first and second
HER2 epitopes bound by the first and second antigen-binding
polypeptide constructs of the anti-HER2 biparatopic antibody are on
different extracellular domains of HER2. In some embodiments, the
first antigen-binding polypeptide construct of the anti-HER2
biparatopic antibody binds to a first HER2 epitope on a first
domain of HER2, and the second antigen-binding polypeptide
construct binds to a second HER2 epitope on a second domain of
HER2. In some embodiments, the first domain of HER2 is ECD2 and the
second domain of HER2 is ECD4.
[0149] In some embodiments, one of the antigen-binding polypeptide
constructs comprised by the anti-HER2 biparatopic antibody competes
with trastuzumab for binding to HER2. In some embodiments, one of
the antigen-binding polypeptide constructs comprised by the
anti-HER2 biparatopic antibody competes with Pertuzumab for binding
to HER2. In some embodiments, one of the antigen-binding
polypeptide constructs comprised by the anti-HER2 biparatopic
antibody competes with trastuzumab for binding to HER2, and the
other antigen-binding polypeptide construct competes with
Pertuzumab for binding to HER2.
[0150] In some embodiments, one of the antigen-binding polypeptide
constructs comprised by the anti-HER2 biparatopic antibody is in a
Fab or scFv format and competes with trastuzumab for binding to
HER2, and the other antigen-binding polypeptide construct is in a
Fab or scFv format and competes with Pertuzumab for binding to
HER2. In some embodiments, one of the antigen-binding polypeptide
constructs comprised by the anti-HER2 biparatopic antibody is in a
Fab format and competes with trastuzumab for binding to HER2, and
the other antigen-binding polypeptide construct is in an scFv
format and competes with Pertuzumab for binding to HER2.
[0151] In some embodiments, one of the antigen-binding polypeptide
constructs comprised by the anti-HER2 biparatopic antibody binds to
the same epitope on HER2 as trastuzumab. In some embodiments, one
of the antigen-binding polypeptide constructs comprised by the
anti-HER2 biparatopic antibody binds to the same epitope on HER2 as
Pertuzumab. In some embodiments, one of the antigen-binding
polypeptide constructs comprised by the anti-HER2 biparatopic
antibody binds to the same epitope on HER2 as trastuzumab, and the
other antigen-binding polypeptide construct binds to the same
epitope on HER2 as Pertuzumab.
[0152] In some embodiments, one of the antigen-binding polypeptide
constructs comprised by the anti-HER2 biparatopic antibody
comprises the CDR sequences of trastuzumab or a variant thereof
comprising one or more mutations known to increase HER2 binding,
and the other antigen-binding polypeptide construct comprises the
CDRs of pertuzumab or a variant thereof comprising one or more
mutations known to increase HER2 binding. Literature mutations
known to enhance HER2 binding by trastuzumab or pertuzumab include
those listed in Tables 4 and 5 below (HC=heavy chain; LC=light
chain). Combinations of these mutations are also contemplated.
TABLE-US-00004 TABLE 4 Trastuzumab Mutations that Increase Binding
to HER2 Mutation Reported Improvement HC: D102W (HC: D98W) 3.2X HC:
D102Y 3.1X HC: D102K 2.3X HC: D102T 2.2X HC: N55K 2.0X HC: N55T
1.9X LC: H91F 2.1X LC: D28R 1.9X
TABLE-US-00005 TABLE 5 Pertuzumab Mutations that Increase Binding
to HER2 Mutation Reported Improvement LC: I31A 1.9X LC: Y96A 2.1X
LC: Y96F 2.5X HC: T30A 2.1X HC: G56A 8.3X HC: F63V 1.9X
[0153] Various anti-HER2 biparatopic antibodies are known in the
art and may be suitable candidate antibodies for inclusion in the
ADCs described herein. Examples include antibodies described in
U.S. Patent Application Publication Nos. 2014/0170148;
2015/0284463; 2016/0289335; 2017/0029529; 2017/0291955 and
2018/0022820, and International Patent Application Publication No.
WO 2016/179707.
[0154] In certain embodiments, the anti-HER2 biparatopic antibody
is one of the biparatopic antibodies described in U.S. Patent
Application Publication No. 2016/0289335. In some embodiments, the
anti-HER2 biparatopic antibody is one of v5019, v5020, v7091,
v10000, v6902, v6903 or v6717 (see Tables 6, 6A and 6B, and
Sequence Tables). In some embodiments, one of the antigen-binding
polypeptide constructs of the anti-HER2 biparatopic antibody
comprises a VH sequence and a VL sequence from the ECD2-binding arm
of one of v5019, v5020, v7091, v10000, v6902, v6903 or v6717. In
some embodiments, one of the antigen-binding polypeptide constructs
of the anti-HER2 biparatopic antibody comprises a VH sequence and a
VL sequence from the ECD2-binding arm of one of v5019, v5020,
v7091, v10000, v6902, v6903 or v6717, and the other antigen-binding
polypeptide construct comprises a VH sequence and a VL sequence
from the ECD4-binding arm of one of v5019, v5020, v7091, v10000,
v6902, v6903 or v6717.
[0155] In some embodiments, one of the antigen-binding polypeptide
constructs of the anti-HER2 biparatopic antibody comprises the CDR
sequences from the ECD2-binding arm of one of v5019, v5020, v7091,
v0000, v6902, v6903 or v6717. In some embodiments, one of the
antigen-binding polypeptide constructs of the anti-HER2 biparatopic
antibody comprises the CDR sequences from the ECD2-binding arm of
one of v5019, v5020, v7091, v10000, v6902, v6903 or v6717, and the
other antigen-binding polypeptide construct comprises the CDR
sequences from the ECD4-binding arm of one of v5019, v5020, v7091,
v10000, v6902, v6903 or v6717.
[0156] One skilled in the art will appreciate that a limited number
of amino acid substitutions may be introduced into the CDR
sequences or to the VH or VL sequences of known antibodies without
the antibody losing its ability to bind its target. Candidate amino
acid substitutions may be identified by computer modeling or by
art-known techniques such as alanine scanning, with the resulting
variants being tested for binding activity by standard techniques.
Accordingly, in certain embodiments, one of the antigen-binding
polypeptide constructs of the anti-HER2 biparatopic antibody
comprises a set of CDRs (i.e. heavy chain CDR1, CDR2 and CDR3, and
light chain CDR1, CDR2 and CDR3) that have 90% or greater, 95% or
greater, 98% or greater, 99% or greater, or 100% sequence identity
to a set of CDRs from the ECD2-binding arm of one of v5019, v5020,
v7091, v10000, v6902, v6903 or v6717, wherein the antigen-binding
polypeptide construct retains the ability to bind ECD2. In certain
embodiments, one of the antigen-binding polypeptide constructs of
the anti-HER2 biparatopic antibody comprises a variant of these CDR
sequences comprising between 1 and 10 amino acid substitutions
across the six CDRs (that is, the CDRs may be modified by including
up to 10 amino acid substitutions with any combination of CDRs
being modified), for example, between 1 and 7 amino acid
substitutions, between 1 and 5 amino acid substitutions, between 1
and 4 amino acid substitutions, between 1 and 3 amino acid
substitutions, between 1 and 2 amino acid substitutions, or 1 amino
acid substitution, across the CDRs, wherein the variant retains the
ability to bind ECD2. Typically, such amino acid substitutions will
be conservative amino acid substitutions. In certain embodiments,
one of the antigen-binding polypeptide constructs of the anti-HER2
biparatopic antibody comprises a set of CDRs (i.e. heavy chain
CDR1, CDR2 and CDR3, and light chain CDR1, CDR2 and CDR3) that have
90% or greater, 95% or greater, 98% or greater, 99% or greater, or
100% sequence identity to a set of CDRs from the ECD2-binding arm
of v10000, wherein the antigen-binding polypeptide construct
retains the ability to bind ECD2.
[0157] In certain embodiments, one of the antigen-binding
polypeptide constructs of the anti-HER2 biparatopic antibody
comprises a VH sequence that is at least 80%, at least 85%, at
least 90%, at least 91%, at least 92%, at least 93%, at least 94%,
at least 95%, at least 96%, at least 97%, at least 98%, at least
99%, or 100% identical to the VH sequence from the ECD2-binding arm
of one of v5019, v5020, v7091, v10000, v6902, v6903 or v6717,
wherein the antigen-binding polypeptide construct retains the
ability to bind ECD2. In some embodiments, one of the
antigen-binding polypeptide constructs of the anti-HER2 biparatopic
antibody comprises a VL sequence that is at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99%, or 100% identical to the VL sequence from the
ECD2-binding arm of one of v5019, v5020, v7091, v10000, v6902,
v6903 or v6717, wherein the antigen-binding polypeptide construct
retains the ability to bind ECD2.
[0158] In certain embodiments, one of the antigen-binding
polypeptide constructs of the anti-HER2 biparatopic antibody
comprises a VH sequence that is at least 80%, at least 85%, at
least 90%, at least 91%, at least 92%, at least 93%, at least 94%,
at least 95%, at least 96%, at least 97%, at least 98%, at least
99%, or 100% identical to the VH sequence from the ECD2-binding arm
of v10000, wherein the antigen-binding polypeptide construct
retains the ability to bind ECD2. In some embodiments, one of the
antigen-binding polypeptide constructs of the anti-HER2 biparatopic
antibody comprises a VL sequence that is at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99%, or 100% identical to the VL sequence from the
ECD2-binding arm of v10000, wherein the antigen-binding polypeptide
construct retains the ability to bind ECD2.
[0159] In certain embodiments, one of the antigen-binding
polypeptide constructs of the anti-HER2 biparatopic antibody
comprises a set of CDRs (i.e. heavy chain CDR1, CDR2 and CDR3, and
light chain CDR1, CDR2 and CDR3) that have 90% or greater, 95% or
greater, 98% or greater, 99% or greater, or 100% sequence identity
to a set of CDRs from the ECD4-binding arm of one of v5019, v5020,
v7091, v10000, v6902, v6903 or v6717, wherein the antigen-binding
polypeptide construct retains the ability to bind ECD4. In certain
embodiments, one of the antigen-binding polypeptide constructs of
the anti-HER2 biparatopic antibody comprises a variant of these CDR
sequences comprising between 1 and 10 amino acid substitutions
across the six CDRs (that is, the CDRs may be modified by including
up to 10 amino acid substitutions with any combination of CDRs
being modified), for example, between 1 and 7 amino acid
substitutions, between 1 and 5 amino acid substitutions, between 1
and 4 amino acid substitutions, between 1 and 3 amino acid
substitutions, between 1 and 2 amino acid substitutions, or 1 amino
acid substitution, across the CDRs, wherein the variant retains the
ability to bind ECD4. Typically, such amino acid substitutions will
be conservative amino acid substitutions. In certain embodiments,
one of the antigen-binding polypeptide constructs of the anti-HER2
biparatopic antibody comprises a set of CDRs (i.e. heavy chain
CDR1, CDR2 and CDR3, and light chain CDR1, CDR2 and CDR3) that have
90% or greater, 95% or greater, 98% or greater, 99% or greater, or
100% sequence identity to a set of CDRs from the ECD4-binding arm
of v10000, wherein the antigen-binding polypeptide construct
retains the ability to bind ECD4.
[0160] In certain embodiments, one of the antigen-binding
polypeptide constructs of the anti-HER2 biparatopic antibody
comprises a VH sequence that is at least 80%, at least 85%, at
least 90%, at least 91%, at least 92%, at least 93%, at least 94%,
at least 95%, at least 96%, at least 97%, at least 98%, at least
99%, or 100% identical to the VH sequence from the ECD4-binding arm
of one of v5019, v5020, v7091, v10000, v6902, v6903 or v6717,
wherein the antigen-binding polypeptide construct retains the
ability to bind ECD4. In some embodiments, one of the
antigen-binding polypeptide constructs of the anti-HER2 biparatopic
antibody comprises a VL sequence that is at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99%, or 100% identical to the VL sequence from the
ECD4-binding arm of one of v5019, v5020, v7091, v10000, v6902,
v6903 or v6717, wherein the antigen-binding polypeptide construct
retains the ability to bind ECD4.
[0161] In certain embodiments, one of the antigen-binding
polypeptide constructs of the anti-HER2 biparatopic antibody
comprises a VH sequence that is at least 80%, at least 85%, at
least 90%, at least 91%, at least 92%, at least 93%, at least 94%,
at least 95%, at least 96%, at least 97%, at least 98%, at least
99%, or 100% identical to the VH sequence from the ECD4-binding arm
of v10000, wherein the antigen-binding polypeptide construct
retains the ability to bind ECD4. In some embodiments, one of the
antigen-binding polypeptide constructs of the anti-HER2 biparatopic
antibody comprises a VL sequence that is at least 80%, at least
85%, at least 90%, at least 91%, at least 92%, at least 93%, at
least 94%, at least 95%, at least 96%, at least 97%, at least 98%,
at least 99%, or 100% identical to the VL sequence from the
ECD4-binding arm of v10000, wherein the antigen-binding polypeptide
construct retains the ability to bind ECD4.
TABLE-US-00006 TABLE 6 Exemplary Anti-HER2 Biparatopic Antibodies
Variant Chain A Chain B 5019 Domain ECD2 ECD4 containing target
epitope Format Fab scFv Antibody name Pertuzumab Trastuzumab CH3
sequence T350V_L351Y_F405A_Y407V T366I_N390R_K392M_T394W
substitutions.sup..sctn. 5020 Domain ECD4 ECD2 containing target
epitope Format scFv Fab Antibody name Trastuzumab Pertuzumab CH3
sequence L351Y_S400E_F405A_Y407V T350V_T366L_K392L_T394W
substitutions 7091 Domain ECD2 ECD4 containing target epitope
Format Fab scFv Antibody name Pertuzumab Trastuzumab CH3 sequence
T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W substitutions 10000
Domain ECD2 ECD4 containing target epitope Format Fab scFv Antibody
name Pertuzumab Trastuzumab Fab sequence HC: T30A_A49G_L69F
substitutions* LC: Y96A CH3 sequence T350V_L351Y_F405A_Y407V
T350V_T366L_K392L_T394W substitutions 6902 Domain ECD4 ECD2
containing target epitope Format Fab Fab Antibody name Trastuzumab
Pertuzumab Fab sequence HC: L143E_K145T HC: D146G_Q179K
substitutions LC: Q124R LC: Q124E_Q160E_T180E CH3 sequence
T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W substitutions 6903
Domain ECD4 ECD2 containing target epitope Format Fab Fab Fab
sequence HC: L143E_K145T HC: D146G_Q179K substitutions LC:
Q124R_Q1160K_T178R LC: Q124E_Q160E_T180E Antibody name Trastuzumab
Pertuzumab CH3 sequence T350V_L351Y_F405A_Y407V
T350V_T366L_K392L_T394W substitutions 6717 Domain ECD2 ECD4
containing target epitope Format scFv scFv Antibody name Pertuzumab
Trastuzumab CH3 sequence T350V_L351Y_F405A_Y407V
T366I_N390R_K392M_T394W substitutions *Fab or variable domain
numbering according to Kabat (Kabat et al., Sequences of proteins
of immunological interest, 5.sup.th Edition, US Department of
Health and Human Services, NIH Publication No. 91-3242, p.647,
1991) .sup..sctn.CH3 numbering according to EU index as in Kabat
(Edelman et al., 1969, PNAS USA, 63: 78-85)
TABLE-US-00007 TABLE 6A CDR Sequences of the ECD2-Binding Arm of
Variants v5019, v5020, v7091, v10000, v6902, v6903 and v6717 SEQ
SEQ ID ID Variant HC CDRs NO LC CDRs NO 5019, 5020, H1: GFTFTDYT 6
L1: QDVSIG 12 7091, 6902, H2: VNPNSGGS 8 L2: SAS 14 6903 & 6717
H3: ARNLGPSFYFDY 7 L3: QQYYIYPYT 13 10000 H1: GFTFADYT 39 L1:
QDVSIG 27 H2: VNPNSGGS 41 L2: SAS 29 H3: ARNLGPSFYFDY 40 L3:
QQYYIYPAT 28
TABLE-US-00008 TABLE 6B CDR Sequences of the ECD4-Binding Arm of
Variants v5019, v5020, v7091, v10000, v6902, v6903 and v6717 SEQ ID
SEQ ID HC CDRs NO LC CDRs NO H1: GFNIKDTY 33 L1: QDVNTA 67 H2:
IYPTNGYT 35 L2: SAS 68 H3: SRWGGDGFYAMDY 34 L3: QQHYTTPPT 69
[0162] In certain embodiments, the anti-HER2 biparatopic antibody
is one of the biparatopic antibodies described in International
Patent Application Publication No. WO 2016/179707. This application
describes high-affinity variants of the anti-HER2 antibody
pertuzumab, including biparatopic antibodies comprising sequences
from a high-affinity variant as one antigen-binding domain. In some
embodiments, the anti-HER2 biparatopic antibody is one of v7133,
v15079, v15080, v15081, v15082, v15083, v15084 or v15085 (see
Tables 7 and 7A, and Sequence Tables). In some embodiments, one of
the antigen-binding polypeptide constructs of the anti-HER2
biparatopic antibody comprises a VH sequence and a VL sequence from
the ECD2-binding arm of one of v7133, v15079, v15080, v15081,
v15082, v15083, v15084 or v15085. In some embodiments, one of the
antigen-binding polypeptide constructs of the anti-HER2 biparatopic
antibody comprises the CDR sequences from the ECD2-binding arm of
one of v7133, v15079, v15080, v15081, v15082, v15083, v15084 or
v15085. In some embodiments, one of the antigen-binding polypeptide
constructs of the anti-HER2 biparatopic antibody comprises a VH
sequence and a VL sequence from the ECD2-binding arm of one of
v7133, v15079, v15080, v15081, v15082, v15083, v15084 or v15085,
and the other antigen-binding polypeptide construct comprises the
VH sequence and VL sequence from trastuzumab. In some embodiments,
one of the antigen-binding polypeptide constructs of the anti-HER2
biparatopic antibody comprises the CDR sequences from the
ECD2-binding arm of one of v7133, v15079, v15080, v15081, v15082,
v15083, v15084 or v15085, and the other antigen-binding polypeptide
construct comprises the CDR sequences from trastuzumab.
TABLE-US-00009 TABLE 7 Additional Exemplary Anti-HER2 Biparatopic
Antibodies Variant Chain A Chain B 7133 Domain ECD2 ECD4 containing
target epitope Format Fab scFv Antibody name Pertuzumab Trastuzumab
Fab sequence HC: T30A substitutions* LC: Y96A CH3 sequence
T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W
substitutions.sup..sctn. 15082 Domain ECD2 ECD4 containing target
epitope Format Fab scFv Antibody name Pertuzumab Trastuzumab Fab
sequence HC: G56Y_K75W substitutions CH3 sequence
T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W substitutions 15085
Domain ECD2 ECD4 containing target epitope Format Fab scFv Antibody
name Pertuzumab Trastuzumab Fab sequence HC: T30Q_S99W
substitutions CH3 sequence T350V_L351Y_F405A_Y407V
T350V_T366L_K392L_T394W substitutions 15083 Domain ECD2 ECD4
containing target epitope Format Fab scFv Antibody name Pertuzumab
Trastuzumab Fab sequence HC: T30Q substitutions LC: Y49W_Y96G CH3
sequence T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W
substitutions 15080 Domain ECD2 ECD4 containing target epitope
Format Fab scFv Antibody name Pertuzumab Trastuzumab Fab sequence
HC: T30Q_K75W substitutions LC: Y49W_Y96G CH3 sequence
T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W substitutions 15079
Domain ECD2 ECD4 containing target epitope Format Fab scFv Antibody
name Pertuzumab Trastuzumab Fab sequence HC: T30Y_K75W
substitutions LC: Y49W_Y96G CH3 sequence T350V_L351Y_F405A_Y407V
T350V_T366L_K392L_T394W substitutions 15084 Domain ECD2 ECD4
containing target epitope Format Fab scFv Antibody name Pertuzumab
Trastuzumab Fab sequence HC: T30Q_G56Y_S99W substitutions LC: Y49W
CH3 sequence T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W
substitutions 15081 Domain ECD2 ECD4 containing target epitope
Format Fab scFv Antibody name Pertuzumab Trastuzumab Fab sequence
HC: T30Q_G56Y substitutions LC: Y49W_Y96G CH3 sequence
T350V_L351Y_F405A_Y407V T350V_T366L_K392L_T394W substitutions *Fab
or variable domain numbering according to Kabat (Kabat et al.,
Sequences of proteins of immunological interest, 5.sup.th Edition,
US Department of Health and Human Services, NIH Publication No.
91-3242, p.647, 1991) .sup..sctn.CH3 numbering according to EU
index as in Kabat (Edelman et al., 1969, PNAS USA, 63: 78-85)
TABLE-US-00010 TABLE 7A CDR Sequences of the ECD2-Binding Arm of
Variants v7133, v15079, v15080, v15081, v15082, v15083, v15084 and
v15085 SEQ SEQ ID ID Variant HC CDRs NO LC CDRs NO 7133 H1:
GFTFADYT 39 L1: QDVSIG 12 H2: VNPNSGGS 8 L2: SAS 14 H3:
ARNLGPSFYFDY 7 L3: QQYYIYPAT 28 15082 H1: GFTFTDYT 6 L1: QDVSIG 12
H2: VNPNSGYS 73 L2: SAS 14 H3: ARNLGPSFYFDY 7 L3: QQYYIYPYT 13
15085 H1: GFTFQDYT 74 L1: QDVSIG 12 H2: VNPNSGGS 8 L2: SAS 14 H3:
ARNLGPWFYFDY 75 L3: QQYYIYPYT 13 15083 & H1: GFTFQDYT 74 L1:
QDVSIG 12 15080 H2: VNPNSGGS 8 L2: SAS 14 H3: ARNLGPSFYFDY 7 L3:
QQYYIYPGT 76 15079 H1: GFTFYDYT 77 L1: QDVSIG 12 H2: VNPNSGGS 8 L2:
SAS 14 H3: ARNLGPSFYFDY 7 L3: QQYYIYPGT 76 15084 H1: GFTFQDYT 74
L1: QDVSIG 12 H2: VNPNSGYS 73 L2: SAS 14 H3: ARNLGPWFYFDY 75 L3:
QQYYIYPYT 13 15081 H1: GFTFQDYT 74 L1: QDVSIG 12 H2: VNPNSGYS 73
L2: SAS 14 H3: ARNLGPSFYFDY 7 L3: QQYYIYPGT 76
Properties of Anti-HER2 Biparatopic Antibodies
[0163] Conjugation of toxin at low DAR is of particular benefit to
anti-HER2 biparatopic antibodies that show an increased binding to
HER2 and/or a higher internalization into HER2-expressing cells
compared to a corresponding bivalent monospecific antibody. A
corresponding bivalent monospecific antibody may comprise two of
the first antigen-binding polypeptide constructs, or two of the
second antigen-binding polypeptide constructs that are comprised by
the biparatopic antibody.
[0164] In certain embodiments, the anti-HER2 biparatopic antibodies
show an increased binding (i.e. bind with a higher affinity) to
HER2 compared to a corresponding bivalent monospecific antibody.
Increased binding may be shown, for example, by a decrease in
dissociation constant and/or an increase in maximal binding.
[0165] A dissociation constant or (K.sub.D) refers to the
equilibrium dissociation constant of a particular ligand-protein
interaction, such as antibody-antigen interactions. The K.sub.D
measures the propensity of two proteins (e.g. AB) to dissociate
reversibly into smaller components (A+B), and is defined as the
ratio of the rate of dissociation (also called the "off-rate" or
k.sub.off) to the association rate (also called the "on-rate" or
k.sub.on). Thus, K.sub.D equals k.sub.off/k.sub.on and is expressed
as a molar concentration (M). It follows that the smaller the
K.sub.D, the stronger the affinity of binding. K.sub.D values for
antibodies can be determined using methods well established in the
art. Examples of such methods include surface plasmon resonance
(SPR), typically using a biosensor system such as a Biacore.RTM.
system, and isothermal titration calorimetry (ITC).
[0166] Apparent K.sub.D, or apparent equilibrium dissociation
constant, represents the antibody concentration at which half
maximal cell binding is observed. The apparent K.sub.D is dependent
on the conditions of the cell binding experiment, such as different
receptor levels expressed on the cells and incubation conditions,
and thus the apparent K.sub.D is generally different from the
K.sub.D values determined from cell-free molecular experiments such
as SPR and ITC. However, there is generally good agreement between
the different methods.
[0167] Maximal binding (or "Bmax") refers to the maximum antibody
binding level on the cells at saturating concentrations of
antibody. This parameter can be reported in the arbitrary unit MFI
for relative comparisons, or converted into an absolute value
corresponding to the number of antibodies bound to the cell with
the use of a standard curve.
[0168] Bmax and apparent K.sub.D can be determined by various
techniques. One example is the measurement of binding to target
antigen-expressing cells by flow cytometry. Typically, in such an
experiment, the target antigen-expressing cells are incubated with
antibodies at different concentrations, washed, incubated with a
secondary agent for detecting the antibody, washed, and analyzed in
the flow cytometer to measure the median fluorescent intensity
(MFI) representing the strength of detection signal on the cells,
which in turn is related to the number of antibodies bound to the
cells. The antibody concentration vs. MFI data is then fitted into
a saturation binding equation to yield Bmax and apparent
K.sub.D.
[0169] In certain embodiments, the anti-HER2 biparatopic antibody
displays an increase in Bmax to a target cell displaying HER2 as
compared to a corresponding reference antibody. For an anti-HER2
biparatopic antibody comprising a first antigen-binding polypeptide
construct and a second antigen-binding polypeptide construct as
described herein, a corresponding reference antibody would be a
bivalent monospecific antibody that comprises two of the first
antigen-binding polypeptide constructs, or two of the second
antigen-binding polypeptide constructs. In certain embodiments, the
Bmax determined for the anti-HER2 biparatopic antibody is at least
about 110% of the Bmax of a corresponding reference antibody. In
some embodiments, the Bmax determined for the anti-HER2 biparatopic
antibody is at least about 125% of the Bmax for a corresponding
reference antibody, for example, about 150% of the Bmax of the
corresponding reference antibody, or at least about 200% of the
Bmax of the corresponding reference antibody.
[0170] In some embodiments, the Bmax determined for the anti-HER2
biparatopic antibody is 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9
or 2.0 times the Bmax of a reference antibody.
[0171] In certain embodiments, the anti-HER2 biparatopic antibodies
show a higher internalization into HER2-expressing cells than a
corresponding reference bivalent monospecific antibody. The
anti-HER2 biparatopic antibodies are internalized in HER2+ cells
through binding to the receptor HER2. The anti-HER2 biparatopic
antibodies thus can be considered as being able to induce receptor
internalization in HER2+ cells.
[0172] Antibody internalization may be measured using art-known
methods, for example, by a direct internalization method according
to the protocol detailed in Schmidt, M. et al., Cancer Immunol
Immunother, 57:1879-1890 (2008). As is known in the art, cancer
cells may express HER2 at various levels. One method of classifying
HER2 expressing cells is as HER2 1+, 2+ or 3+(low, medium and high,
respectively). In certain embodiments, the anti-HER2 biparatopic
antibody shows a higher internalization than a corresponding
reference bivalent monospecific antibody in cells expressing HER2
at the 3+ level. In some embodiments, the anti-HER2 biparatopic
antibody shows a higher internalization than a corresponding
reference bivalent monospecific antibody in cells expressing HER2
at the 2+ level. In some embodiments, the anti-HER2 biparatopic
antibody shows a higher internalization than a corresponding
reference bivalent monospecific antibody in cells expressing HER2
at the 1+ level. Examples of cell lines expressing different levels
of HER2 are described in more detail below.
[0173] In the context of the present disclosure, an anti-HER2
biparatopic antibody is considered to demonstrate a higher
internalization into HER2-expressing cells than a corresponding
reference bivalent monospecific antibody when the amount of
anti-HER2 biparatopic antibody internalized into the
HER2-expressing cells is at least 1.2 times greater than the amount
of reference bivalent monospecific antibody internalized into the
same HER2-expressing cells. In certain embodiments, the amount of
internalized antibody is determined by the direct internalization
method according to the protocol detailed in Schmidt, M. et al.,
Cancer Immunol Immunother, 57:1879-1890 (2008). In some
embodiments, the amount of internalized antibody is determined in
HER2-expressing cells that express HER2 at the 2+ level.
[0174] In some embodiments, an anti-HER2 biparatopic antibody is
considered to demonstrate a higher internalization into
HER2-expressing cells than a corresponding reference bivalent
monospecific antibody when the amount of anti-HER2 biparatopic
antibody internalized into the HER2-expressing cells is at least
1.3 times greater than the amount of reference bivalent
monospecific antibody internalized into the same HER2-expressing
cells. In some embodiments, an anti-HER2 biparatopic antibody is
considered to demonstrate a higher internalization into
HER2-expressing cells than a corresponding reference bivalent
monospecific antibody when the amount of anti-HER2 biparatopic
antibody internalized into the HER2-expressing cells is at least
1.4 times greater, for example, at least 1.5 times greater, 1.6
times greater, 1.7 times greater, 1.8 times greater, 1.9 times
greater, or 2.0 times greater, than the amount of reference
bivalent monospecific antibody internalized into the same
HER2-expressing cells. In certain embodiments, the amount of
internalized antibody is determined by the direct internalization
method according to the protocol detailed in Schmidt, M. et al.,
Cancer Immunol Immunother, 57:1879-1890 (2008). In some
embodiments, the amount of internalized antibody is determined in
HER2-expressing cells that express HER2 at the 2+ level.
Auristatin Analogues
[0175] The ADCs described herein comprise an auristatin-based toxin
(or "auristatin analogue"). Various auristatin analogues are known
in the art. Examples include, but are not limited to,
monomethylauristatin F (MMAF), monomethylauristatin E (MMAE),
auristatin EB (AEB), auristatin EVB (AEVB) and auristatin F
phenylenediamine (AFP). The synthesis and structure of various
auristatin analogues are described in U.S. Pat. Nos. 6,884,869;
7,098,308; 7,256,257 and 7,498,298.
[0176] In certain embodiments, the auristatin analogue included in
the ADCs described herein may be an auristatin analogue as
described in International Patent Application Publication No. WO
2016/041082. In certain embodiments, the auristatin analogue
included the ADCs described herein is a compound of general Formula
(I):
##STR00009## [0177] wherein: [0178] X is
--C(O)NHCH(CH.sub.2R.sup.2)--, or X is absent; [0179] R.sup.1 is
selected from:
[0179] ##STR00010## [0180] and [0181] R.sup.2 is phenyl.
[0182] In certain embodiments, in compounds of general Formula (I),
R.sup.1 is selected from:
##STR00011##
[0183] In certain embodiments, in compounds of general Formula (I),
X is absent.
[0184] In certain embodiments, the compound of general Formula (I)
has general Formula (IV):
##STR00012## [0185] wherein R.sup.1 is as defined for general
Formula (I).
[0186] In certain embodiments, in compounds of Formula (IV),
R.sup.1 is selected from:
##STR00013##
[0187] In certain embodiments, in compounds of Formula (IV),
R.sup.1 is:
##STR00014##
[0188] In certain embodiments, in compounds of Formula (IV),
R.sup.1 is:
##STR00015##
[0189] In certain embodiments, the compound of general Formula (I)
has general Formula (V):
##STR00016## [0190] wherein R.sup.1 is as defined for general
Formula (I).
[0191] In certain embodiments, in compounds of Formula (V), R.sup.1
is selected from:
##STR00017##
[0192] In certain embodiments, in compounds of Formula (V), R.sup.1
is:
##STR00018##
[0193] In certain embodiments, in compounds of Formula (V), R.sup.1
is:
##STR00019##
[0194] Compounds of general Formula (I) may be prepared by standard
synthetic organic chemistry protocols from commercially available
starting materials. Exemplary methods are provided in International
Patent Application Publication No. WO 2016/041082 and in the
Examples section below.
[0195] It is to be understood that reference to compounds of
general Formula (I) throughout the remainder of this disclosure
includes, in various embodiments, compounds of general Formula (IV)
and (V), to the same extent as if embodiments reciting each of
these formulae individually were specifically recited.
[0196] In certain embodiments, the ADC of the present disclosure
comprises an anti-HER2 biparatopic antibody conjugated to an
auristatin analogue (toxin) via a linker (L), in which the
linker-toxin has general Formula (II):
##STR00020## [0197] wherein: [0198] X is
--C(O)NHCH(CH.sub.2R.sup.2)--, or X is absent; [0199] R.sup.1 is
selected from:
[0199] ##STR00021## [0200] R.sup.2 is phenyl; [0201] L is a linker,
and [0202] represents the point of attachment of the linker-toxin
to the anti-HER2 biparatopic antibody.
[0203] In some embodiments, in the linker-toxin of general Formula
(II), R.sup.1 is selected from:
##STR00022##
[0204] In some embodiments, in the linker-toxin of general Formula
(II), X is absent.
[0205] In some embodiments, in the linker-toxin of general Formula
(II), L is a cleavable linker.
[0206] In some embodiments, in the linker-toxin of general Formula
(II), L is a peptide-containing linker.
[0207] In certain embodiments, the linker-toxin of general Formula
(II) has general Formula (X):
##STR00023## [0208] wherein R, L and are as defined above for
general Formula (II).
[0209] In some embodiments, in the linker-toxin of general Formula
(X), R.sup.1 is selected from:
##STR00024##
[0210] In some embodiments, in the linker-toxin of general Formula
(X), R.sup.1 is:
##STR00025##
[0211] In some embodiments, in compounds of Formula (X), R.sup.1
is:
##STR00026##
[0212] In some embodiments, in the linker-toxin of general Formula
(X), L is a cleavable linker.
[0213] In some embodiments, in the linker-toxin of general Formula
(X), L is a peptide-containing linker.
[0214] In some embodiments, in the linker-toxin of general Formula
(X), L is a protease-cleavable linker.
[0215] In certain embodiments, the linker-toxin of general Formula
(II) has general Formula (XI):
##STR00027## [0216] wherein R.sup.1, L and are as defined above for
general Formula (II).
[0217] In some embodiments, in the linker-toxin of general Formula
(XI), R.sup.1 is selected from:
##STR00028##
[0218] In some embodiments, in the linker-toxin of general Formula
(XI), R.sup.1 is:
##STR00029##
[0219] In some embodiments, in the linker-toxin of general Formula
(XI), R.sup.1 is:
##STR00030##
[0220] In some embodiments, in the linker-toxin of general Formula
(XI), L is a cleavable linker.
[0221] In some embodiments, in the linker-toxin of general Formula
(XI), L is a peptide-containing linker.
[0222] In some embodiments, in the linker-toxin of general Formula
(XI), L is a protease-cleavable linker.
[0223] Also contemplated herein, are ADCs comprising an anti-HER2
biparatopic antibody conjugated to a linker-toxin of general
Formula (II), Formula (X) or Formula (XI), in which the linker has
general Formula (VIII) or (IX) as shown below.
[0224] In certain embodiments, the ADC comprises a linker-toxin
having the structure:
##STR00031## [0225] wherein A-S-- is the point of attachment to the
anti-HER2 biparatopic antibody.
[0226] In certain embodiments, the ADC of the present disclosure
comprising an anti-HER2 biparatopic antibody conjugated to an
auristatin analogue (toxin) via a linker (L) has general Formula
(III):
##STR00032## [0227] wherein X and R.sup.1 are as defined for
general Formula (II); [0228] L is a linker; [0229] n is the average
drug-to-antibody ratio (DAR) and is less than 3.9, and [0230] Ab is
an anti-HER2 biparatopic antibody.
[0231] In some embodiments, in the ADC of general Formula (III),
R.sup.1 is selected from:
##STR00033##
[0232] In some embodiments, in the ADC of general Formula (III), X
is absent.
[0233] In some embodiments, in the ADC of general Formula (III),
R.sup.1 is:
##STR00034##
and [0234] X is absent.
[0235] In some embodiments, in the ADC of general Formula (III),
R.sup.1 is:
##STR00035##
and [0236] X is absent.
[0237] In some embodiments, in the ADC of general Formula (III), X
is --C(O)NHCH(CH.sub.2R.sup.2)--
[0238] In some embodiments, in the ADC of general Formula (III),
R.sup.1 is:
##STR00036##
and [0239] X is --C(O)NHCH(CH.sub.2R.sup.2)--.
[0240] In some embodiments, in the ADC of general Formula (III),
R.sup.1 is:
##STR00037##
and [0241] X is --C(O)NHCH(CH.sub.2R.sup.2)--.
[0242] In some embodiments, in the ADC of general Formula (III), L
is a cleavable linker.
[0243] In some embodiments, in the ADC of general Formula (III), L
is a peptide-containing linker.
[0244] In some embodiments, in the ADC of general Formula (III), L
is a protease-cleavable linker.
[0245] In some embodiments, in the ADC of general Formula (III), n
is between 0.5 and 3.8.
[0246] In some embodiments, in the ADC of general Formula (III), n
is between 0.7 and 3.8, between 0.7 and 3.5, between 0.7 and 3.0,
or between 0.7 and 2.5.
[0247] In some embodiments, in the ADC of general Formula (III), n
is between 1.0 and 3.8, between 1.0 and 3.5, between 1.0 and 3.0,
or between 1.0 and 2.5.
[0248] In some embodiments, in the ADC of general Formula (III), n
is between 1.5 and 3.8, between 1.5 and 3.5, between 1.5 and 3.0,
or between 1.5 and 2.5.
[0249] In some embodiments, in the ADC of general Formula (III), n
is between 1.6 and 3.8, between 1.6 and 3.5, between 1.6 and 3.0,
or between 1.6 and 2.5.
[0250] In some embodiments, in the ADC of general Formula (III), n
is between 1.8 and 2.8, or between 1.8 and 2.5.
[0251] Combinations of any of the foregoing embodiments for
compounds of general Formula (III) are also contemplated and each
combination forms a separate embodiment for the purposes of the
present disclosure.
Linkers
[0252] In the ADCs described herein, the anti-HER2 biparatopic
antibody is linked to the auristatin analogue (toxin) by a linker.
Linkers are bifunctional or multifunctional moieties capable of
linking one or more toxin molecules to an antibody. A linker may be
bifunctional (or monovalent) such that it links a single drug to a
single site on the antibody, or it may be multifunctional (or
polyvalent) such that it links more than one toxin molecule to a
single site on the antibody. Linkers capable of linking one toxin
molecule to more than one site on the antibody may also be
considered to be multifunctional.
[0253] Attachment of a linker to an antibody can be accomplished in
a variety of ways, such as through surface lysines on the antibody,
reductive-coupling to oxidized carbohydrates on the antibody, or
through cysteine residues on the antibody liberated by reducing
interchain disulfide linkages. Alternatively, attachment of a
linker to an antibody may be achieved by modification of the
antibody to include additional cysteine residues (see, for example,
U.S. Pat. Nos. 7,521,541; 8,455,622 and 9,000,130) or non-natural
amino acids that provide reactive handles, such as
selenomethionine, p-acetylphenylalanine, formylglycine or
p-azidomethyl-L-phenylalanine (see, for example, Hofer et al.,
Biochemistry, 48:12047-12057 (2009); Axup et al., PNAS,
109:16101-16106 (2012); Wu et al., PNAS, 106:3000-3005 (2009);
Zimmerman et al., Bioconj. Chem., 25:351-361 (2014)), to allow for
site-specific conjugation.
[0254] Linkers include a functional group capable of reacting with
the target group or groups on the antibody, and one or more
functional groups capable of reacting with a target group on the
toxin. Suitable functional groups are known in the art and include
those described, for example, in Bioconjugate Techniques (G. T.
Hermanson, 2013, Academic Press).
[0255] Non-limiting examples of functional groups for reacting with
free cysteines or thiols include maleimide, haloacetamide,
haloacetyl, activated esters such as succinimide esters,
4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl
esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates
and isothiocyanates. Also useful in this context are
"self-stabilizing" maleimides as described in Lyon et al., Nat.
Biotechnol., 32:1059-1062 (2014).
[0256] Non-limiting examples of functional groups for reacting with
surface lysines on an antibody and free amines on a toxin include
activated esters such as N-hydroxysuccinamide (NHS) esters,
sulfo-NHS esters, imido esters such as Traut's reagent,
isothiocyanates, aldehydes and acid anhydrides such as
diethylenetriaminepentaacetic anhydride (DTPA). Other examples
include succinimido-1,1,3,3-tetra-methyluronium tetrafluoroborate
(TSTU) and benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexafluorophosphate (PyBOP).
[0257] Non-limiting examples of functional groups capable of
reacting with an electrophilic group on the antibody or toxin (such
as an aldehyde or ketone carbonyl group) include hydrazide, oxime,
amino, hydrazine, thiosemicarbazone, hydrazine carboxylate and
arylhydrazide.
[0258] Other linkers include those having a functional group that
allows for bridging of two interchain cysteines on the antibody,
such as a ThioBridge.TM. linker (Badescu et al., Bioconjug. Chem.,
25:1124-1136 (2014)), a dithiomaleimide (DTM) linker (Behrens et
al., Mol. Pharm., 12:3986-3998 (2015)), a
dithioaryl(TCEP)pyridazinedione based linker (Lee et al., Chem.
Sci., 7:799-802 (2016)), a dibromopyridazinedione based linker
(Maruani et al., Nat. Commun., 6:6645 (2015)) and others known in
the art.
[0259] A linker may comprise one or more linker components.
Typically, a linker will comprise two or more linker components.
Exemplary linker components include functional groups for reaction
with the antibody, functional groups for reaction with the toxin,
stretchers, peptide components, self-immolative groups,
self-elimination groups, hydrophilic moieties, and the like.
Various linker components are known in the art, some of which are
described below.
[0260] Certain useful linker components can be obtained from
various commercial sources, such as Pierce Biotechnology, Inc. (now
Thermo Fisher Scientific, Waltham, Mass.) and Molecular Biosciences
Inc. (Boulder, Colo.), or may be synthesized in accordance with
procedures described in the art (see, for example, Toki et al., J.
Org. Chem., 67:1866-1872 (2002); Dubowchik, et al., Tetrahedron
Letters, 38:5257-60 (1997); Walker, M. A., J. Org. Chem.,
60:5352-5355 (1995); Frisch, et al., Bioconjugate Chem., 7:180-186
(1996); U.S. Pat. Nos. 6,214,345 and 7,553,816, and International
Patent Application Publication No. WO 02/088172).
[0261] Examples of linker components include, but are not limited
to, N-(.beta.-maleimidopropyloxy)-N-hydroxy succinimide ester
(BMPS), N-(s-maleimidocaproyloxy) succinimide ester (EMCS),
N-[.gamma.-maleimidobutyryloxy]succinimide ester (GMBS),
1,6-hexane-bis-vinylsulfone (HBVS), succinimidyl
4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate)
(LC-SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS),
4-(4-N-Maleimidophenyl)butyric acid hydrazide (MPBH), succinimidyl
3-(bromoacetamido)propionate (SBAP), succinimidyl iodoacetate
(SIA), succinimidyl (4-iodoacetyl)aminobenzoate (STAB),
N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP),
N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP), succinimidyl
4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), succinimidyl
4-(p-maleimidophenyl)butyrate (SMPB), succinimidyl
6-[(.beta.-maleimidopropionamido)hexanoate](SMPH), iminothiolane
(IT), sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB,
sulfo-SMCC, sulfo-SMPB and succinimidyl-(4-vinylsulfone)benzoate
(SVSB).
[0262] Additional examples include bis-maleimide reagents such as
dithiobismaleimidoethane (DTME), bis-maleimido-trioxyethylene
glycol (BMPEO), 1,4-bismaleimidobutane (BMB), 1,4
bismaleimidyl-2,3-dihydroxybutane (BMDB), bismaleimidohexane (BMH),
bismaleimidoethane (BMOE), BM(PEG).sub.2 and BM(PEG).sub.3;
bifunctional derivatives of imidoesters (such as dimethyl
adipimidate HCl), active esters (such as disuccinimidyl suberate),
aldehydes (such as glutaraldehyde), bis-azido compounds (such as
bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives
(such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates
(such as toluene 2,6-diisocyanate), and bis-active fluorine
compounds (such as 1,5-difluoro-2,4-dinitrobenzene).
[0263] Suitable linkers typically are more chemically stable to
conditions outside the cell than to conditions inside the cell,
although less stable linkers may be contemplated in certain
situations, such as when the toxin is selective or targeted and has
a low toxicity to normal cells. Linkers may be "cleavable linkers"
or "non-cleavable linkers." A cleavable linker is typically
susceptible to cleavage under intracellular conditions, for
example, through lysosomal processes. Examples include linkers that
are protease-sensitive, acid-sensitive, reduction-sensitive or
photolabile. Non-cleavable linkers by contrast, rely on the
degradation of the antibody in the cell, which typically results in
the release of an amino acid-linker-toxin moiety.
[0264] Suitable cleavable linkers include, for example, linkers
comprising a peptide component that includes two or more amino
acids and is cleavable by an intracellular protease, such as
lysosomal protease or an endosomal protease. A peptide component
may comprise amino acid residues that occur naturally and/or minor
amino acids and/or non-naturally occurring amino acid analogues,
such as citrulline. Peptide components may be designed and
optimized for enzymatic cleavage by a particular enzyme, for
example, a tumour-associated protease, cathepsin B, C or D, or a
plasmin protease.
[0265] In certain embodiments, the linker included in the ADCs may
be a dipeptide-containing linker, such as a linker containing
valine-citrulline (Val-Cit) or phenylalanine-lysine (Phe-Lys).
Other examples of suitable dipeptides for inclusion in linkers
include Val-Lys, Ala-Lys, Me-Val-Cit, Phe-homoLys, Phe-Cit,
Leu-Cit, Ile-Cit, Trp-Cit, Phe-Arg, Ala-Phe, Val-Ala, Met-Lys,
Asn-Lys, Ile-Pro, Ile-Val, Asp-Val, His-Val, Met-(D)Lys,
Asn-(D)Lys, Val-(D)Asp, NorVal-(D)Asp, Ala-(D)Asp, Me.sub.3Lys-Pro,
PhenylGly-(D)Lys, Met-(D)Lys, Asn-(D)Lys, Pro-(D)Lys and
Met-(D)Lys. Cleavable linkers may also include longer peptide
components such as tripeptides, tetrapeptides or pentapeptides.
Examples include, but are not limited to, the tripeptides
Met-Cit-Val, Gly-Cit-Val, (D)Phe-Phe-Lys and (D)Ala-Phe-Lys, and
the tetrapeptides Gly-Phe-Leu-Gly and Ala-Leu-Ala-Leu.
[0266] Additional examples of cleavable linkers include
disulfide-containing linkers, such as, for example,
N-succinimydyl-4-(2-pyridyldithio) butanoate (SPBD) and
N-succinimydyl-4-(2-pyridyldithio)-2-sulfo butanoate (sulfo-SPBD).
Disulfide-containing linkers may optionally include additional
groups to provide steric hindrance adjacent to the disulfide bond
in order to improve the extracellular stability of the linker, for
example, inclusion of a geminal dimethyl group. Other suitable
linkers include linkers hydrolyzable at a specific pH or within a
pH range, such as hydrazone linkers. Linkers comprising
combinations of these functionalities may also be useful, for
example, linkers comprising both a hydrazone and a disulfide are
known in the art.
[0267] A further example of a cleavable linker is a linker
comprising a .beta.-glucuronide, which is cleavable by
.beta.-glucuronidase, an enzyme present in lysosomes and tumour
interstitium (see, for example, De Graaf et al., Curr. Pharm. Des.,
8:1391-1403 (2002)).
[0268] Cleavable linkers may optionally further comprise one or
more additional components such as self-immolative and
self-elimination groups, stretchers or hydrophilic moieties.
[0269] Self-immolative and self-elimination groups that find use in
linkers include, for example, p-aminobenzyloxycarbonyl (PABC) and
p-aminobenzyl ether (PABE) groups, and methylated ethylene diamine
(MED). Other examples of self-immolative groups include, but are
not limited to, aromatic compounds that are electronically similar
to the PABC or PABE group such as heterocyclic derivatives, for
example 2-aminoimidazol-5-methanol derivatives as described in U.S.
Pat. No. 7,375,078. Other examples include groups that undergo
cyclization upon amide bond hydrolysis, such as substituted and
unsubstituted 4-aminobutyric acid amides (Rodrigues et al.,
Chemistry Biology, 2:223-227 (1995)) and 2-aminophenylpropionic
acid amides (Amsberry, et al., J. Org. Chem., 55:5867-5877
(1990)).
[0270] Stretchers that find use in linkers for ADCs include, for
example, alkylene groups and stretchers based on aliphatic acids,
diacids, amines or diamines, such as diglycolate, malonate,
caproate and caproamide. Other stretchers include, for example,
glycine-based stretchers, polyethylene glycol (PEG) stretchers and
monomethoxy polyethylene glycol (mPEG) stretchers. PEG and mPEG
stretchers also function as hydrophilic moieties.
[0271] Examples of components commonly found in cleavable linkers
that may find use in the ADCs of the present disclosure in some
embodiments include, but are not limited to, SPBD, sulfo-SPBD,
hydrazone, Val-Cit, maleidocaproyl (MC or mc), mc-Val-Cit,
mc-Val-Cit-PABC, Phe-Lys, mc-Phe-Lys, mc-Phe-Lys-PABC, maleimido
triethylene glycolate (MT), MT-Val-Cit, MT-Phe-Lys and adipate
(AD).
[0272] In certain embodiments, the linker included in the ADCs of
the present disclosure are peptide-based linkers having general
Formula (VI):
##STR00038## [0273] wherein: [0274] Z is a functional group capable
of reacting with the target group on the antibody; [0275] Str is a
stretcher; [0276] AA.sub.1 and AA.sub.2 are each independently an
amino acid, wherein AA.sub.1-[AA.sub.2].sub.m forms a protease
cleavage site; [0277] X is a self-immolative group; [0278] D is the
point of attachment to the auristatin analogue; [0279] s is 0 or 1;
[0280] m is an integer between 1 and 4, and [0281] o is 0, 1 or
2.
[0282] In some embodiments, in general Formula (VI), Z is:
##STR00039##
[0283] In some embodiments, in general Formula (VI), Str is
selected from:
##STR00040## [0284] wherein: [0285] R.sup.1 is H or C.sub.1-C.sub.6
alkyl; [0286] p is an integer between 2 and 10, and [0287] q is an
integer between 1 and 10.
[0288] In some embodiments, in general Formula (VI), Str is:
##STR00041## [0289] wherein p and q are as defined above.
[0290] In some embodiments, in general Formula (VI), Str is:
##STR00042## [0291] wherein p is an integer between 2 and 6, and
[0292] q is an integer between 2 and 8.
[0293] In some embodiments, in general Formula (VI),
AA.sub.1-[AA.sub.2].sub.m is selected from Val-Lys, Ala-Lys,
Phe-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit, Trp-Cit, Phe-Arg,
Ala-Phe, Val-Ala, Met-Lys, Asn-Lys, Ile-Pro, Ile-Val, Asp-Val,
His-Val, Met-(D)Lys, Asn-(D)Lys, Val-(D)Asp, NorVal-(D)Asp,
Ala-(D)Asp, Me.sub.3Lys-Pro, PhenylGly-(D)Lys, Met-(D)Lys,
Asn-(D)Lys, Pro-(D)Lys, Met-(D)Lys, Met-Cit-Val, Gly-Cit-Val,
(D)Phe-Phe-Lys, (D)Ala-Phe-Lys, Gly-Phe-Leu-Gly and
Ala-Leu-Ala-Leu.
[0294] In some embodiments, in general Formula (VI), m is 1 (i.e.
AA.sub.1-[AA.sub.2].sub.m is a dipeptide).
[0295] In some embodiments, in general Formula (VI),
AA.sub.1-[AA.sub.2].sub.m is a dipeptide selected from Val-Lys,
Ala-Lys, Phe-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit and
Trp-Cit.
[0296] In some embodiments, in general Formula (VI), each X is
independently selected from p-aminobenzyloxycarbonyl (PABC),
p-aminobenzyl ether (PABE) and methylated ethylene diamine
(MED).
[0297] In some embodiments, in general Formula (VI), m is 1, 2 or
3.
[0298] In some embodiments, in general Formula (VI), s is 1.
[0299] In some embodiments, in general Formula (VI), o is 0.
[0300] In some embodiments, in general Formula (VI): [0301] Z
is
[0301] ##STR00043## [0302] Str is
##STR00044##
[0302] wherein p is an integer between 2 and 6, and q is an integer
between 2 and 8; [0303] m is 1 and AA.sub.1-[AA.sub.2].sub.m is a
dipeptide selected from Val-Lys, Ala-Lys, Phe-Lys, Val-Cit,
Phe-Cit, Leu-Cit, Ile-Cit and Trp-Cit; [0304] s is 1, and [0305] o
is 0.
[0306] In some embodiments, the linker is a disulfide-containing
linker and the ADC has general Formula (VII):
##STR00045## [0307] wherein: [0308] A is the antibody; [0309] D is
the auristatin analogue; [0310] Y is --(CH.sub.2).sub.p-- or
--(CH.sub.2CH.sub.2O).sub.q--, wherein p and q are each
independently an integer between 1 and 10; [0311] each R.sup.1 is
independently H or C1-C6 alkyl; [0312] r is 1, 2 or 3, and [0313]
wherein
##STR00046##
[0313] represents an amide bond formed between the linker and the
.epsilon.-amino group of a surface lysine on the antibody.
[0314] In some embodiments in general Formula (VII), p and q are
each independently an integer between 1 and 4.
[0315] In some embodiments in general Formula (VII), Y is
--(CH.sub.2).sub.p-- and p is an integer between 1 and 4.
[0316] In some embodiments in general Formula (VII), each R.sup.1
is independently H or Me.
[0317] In some embodiments in general Formula (VII), r is 1 or
2.
[0318] Various non-cleavable linkers are known in the art for
linking drugs to antibodies and may be useful in the ADCs of the
present disclosure in certain embodiments. Examples of
non-cleavable linkers include linkers having an N-succinimidyl
ester or N-sulfosuccinimidyl ester moiety for reaction with the
antibody, as well as a maleimido- or haloacetyl-based moiety for
reaction with the toxin, or vice versa. An example of such a
non-cleavable linker is based on
sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate
(sulfo-SMCC). Other non-limiting examples of such linkers include
those based on N-succinimidyl
4-(maleimidomethyl)cyclohexanecarboxylate (SMCC),
N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxy-(6-amidocaproa-
te) ("long chain" SMCC or LC-SMCC), x-maleimidoundecanoic acid
N-succinimidyl ester (KMUA), .gamma.-maleimidobutyric acid
N-succinimidyl ester (GMBS), .epsilon.-maleimidocaproic acid
N-hydroxysuccinimide ester (EMCS),
m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS),
N-(.alpha.-maleimidoacetoxy)-succinimide ester (AMAS),
succinimidyl-6-(.beta.-maleimidopropionamido)hexanoate (SMPH),
N-succinimidyl 4-(p-maleimidophenyl)-butyrate (SMPB), and
N-(p-maleimidophenyl)isocyanate (PMPI). Other examples include
those comprising a haloacetyl-based functional group such as
N-succinimidyl-4-(iodoacetyl)-aminobenzoate (SIAB), N-succinimidyl
iodoacetate (SIA), N-succinimidyl bromoacetate (SBA) and
N-succinimidyl 3-(bromoacetamido)propionate (SBAP).
[0319] Other examples of non-cleavable linkers include
maleimidocarboxylic acids, such as maleimidocaproyl (MC).
[0320] Selection of an appropriate linker for a given ADC may be
readily made by the skilled person having knowledge of the art and
taking into account relevant factors, such as the site of
attachment to the antibody, any structural constraints of the toxin
and the hydrophobicity of the toxin (see, for example, review in
Nolting, Chapter 5, Antibody-Drug Conjugates: Methods in Molecular
Biology, 2013, Ducry (Ed.), Springer).
[0321] In certain embodiments, the linker included in the ADCs of
the present disclosure has general Formula (VIII):
##STR00047##
[0322] wherein:
[0323] A-S-- is the point of attachment to anti-HER2 biparatopic
antibody;
[0324] Y is one or more additional linker components, or is absent,
and
[0325] D is the point of attachment to the auristatin analogue.
[0326] In certain embodiments, the linker included in the ADCs of
the present disclosure has general Formula (IX):
##STR00048##
[0327] wherein:
[0328] A-S-- is the point of attachment to anti-HER2 biparatopic
antibody;
[0329] Y is one or more additional linker components, or is absent,
and
[0330] D is the point of attachment to the auristatin analogue.
Preparation of Antibody Drug Conjugates
[0331] The ADCs of the present disclosure may be prepared by one of
several routes known in the art, employing organic chemistry
reactions, conditions, and reagents known to those skilled in the
art (see, for example, Bioconjugate Techniques (G. T. Hermanson,
2013, Academic Press, and the Examples provided herein). For
example, conjugation may be achieved by (1) reaction of a
nucleophilic group or an electrophilic group of an antibody with a
bifunctional linker to form an antibody-linker intermediate Ab-L,
via a covalent bond, followed by reaction with an activated
auristatin analogue (D), or (2) reaction of a nucleophilic group or
an electrophilic group of an auristatin analogue with a linker to
form linker-toxin D-L, via a covalent bond, followed by reaction
with the nucleophilic group or an electrophilic group of an
antibody. Conjugation methods (1) and (2) may be employed with a
variety of antibodies, auristatin analogues, and linkers to prepare
the ADCs described herein.
[0332] As described above, the auristatin analogue may be
conjugated via an appropriate linker to various groups on the
antibody to provide the ADC. For example, conjugation may be
through surface lysines, through oxidized carbohydrates or through
cysteine residues that have been liberated by reducing one or more
interchain disulfide linkages. Alternatively, the antibody may be
modified to include additional cysteine residues or non-natural
amino acids that provide reactive handles, such as
selenomethionine, p-acetylphenylalanine, formylglycine or
p-azidomethyl-L-phenylalanine. Such modifications are well-known in
the art (see, for example, U.S. Pat. Nos. 7,521,541; 8,455,622 and
9,000,130; Hofer et al., Biochemistry, 48:12047-12057 (2009); Axup
et al., PNAS, 109:16101-16106 (2012); Wu et al., PNAS,
106:3000-3005 (2009); Zimmerman et al., Bioconj. Chem., 25:351-361
(2014)).
[0333] In certain embodiments, the ADCs of the present disclosure
comprise an auristatin analogue conjugated via an appropriate
linker to cysteine residues that have been liberated by reducing
one or more interchain disulfide linkages.
[0334] In the ADCs described herein, the anti-HER2 biparatopic
antibody is conjugated to the toxin via a linker at a low average
drug-to-antibody ratio (DAR), specifically an average DAR of less
than 3.9 but more than 0.5, for example, between about 1.5 and
about 2.5 in certain embodiments.
[0335] Various methods are known in the art to prepare ADCs with a
low average DAR (see, for example, review by McCombs and Owen, The
AAPS Journal, 17(2):339-351 (2015) and references therein;
Boutureira & Bernardes, Chem. Rev., 115:2174-2195 (2015)).
[0336] For example, for conjugation to cysteine residues, a partial
reduction of the antibody interchain disulfide bonds may be
conducted followed by conjugation to linker-toxin. Partial
reduction can be achieved by limiting the amount of reducing agent
used in the reduction reaction (see, for example, Lyon et al.,
Methods in Enzymology, 502:123-138 (2012), and examples therein,
and the Examples provided herein). Suitable reducing agents are
known in the art and include, for example, dithiothreitol (DTT),
tris(2-carboxyethyl)phosphine (TCEP), 2-mercaptoethanol, cysteamine
and a number of water soluble phosphines. Alternatively, or in
addition, fewer equivalents of linker-toxin may be employed in
order to obtain a low average DAR.
[0337] Alternatively, an engineered antibody may be employed in
which one or more of the cysteine residues that make up the
interchain disulfide bonds is replaced with a serine residue
resulting in fewer available cysteine residues for conjugation (see
McDonagh et al., Protein Eng. Des. Sel. PEDS, 19(7):299-307). The
engineered antibody can then be treated with reducing agent and
conjugated to linker-toxin.
[0338] Another approach is to employ a bis-thiol linker that
bridges two cysteines that normally make up an interchain disulfide
bond. Use of a bis-thiol linker that carries only one toxin
molecule would produce an ADC with a maximum DAR4 for a full-size
antibody, if all four interchain disulfide bonds are reduced and
replaced with the bis-thiol linker. Partial reduction of the
interchain disulfide bonds and/or fewer equivalents of linker may
be used in conjunction with a bis-thiol linker in order to further
reduce the DAR. Various bis-thiol linkers are known in the art
(see, for example, Badescu et al., Bioconjug. Chem.,
25(6):1124-1136 (2014); Behrens et al., Mol. Pharm., 12:3986-3998
(2015); Lee et al., Chem. Sci., 7:799-802 (2016); Maruani et al.,
Nat. Commun., 6:6645 (2015)).
[0339] Cysteine engineering approaches may also be employed in
order to generate ADCs with a low average DAR. Such approaches
involve engineering solvent-accessible cysteines into the antibody
in order to provide a site-specific handle for conjugation. A
number of appropriate sites for introduction of a cysteine residue
have been identified with the IgG structure, and include those
described in Junutula, et al., J. Immunol Methods, 332(1-2):41-52
(2008); Junutula, et al., Nat. Biotechnol., 26(8), 925-932 (2008),
and U.S. Pat. Nos. 9,315,581; 9,000,130; 8,455,622; 8,507,654 and
7,521,541.
[0340] Low average DAR ADCs may also be prepared by lysine
conjugation employing limiting amounts of activated linker-toxin.
Selective reaction at the antibody N-terminal amino acids may also
be employed. For example, N-terminal serine may be oxidized to an
aldehyde with periodate, then reacted with linker-toxin (see, for
example, Thompson, et al., Bioconjug. Chem., 26(10):2085-2096
(2015)). Similarly, N-terminal cysteine residues can be selectively
reacted with aldehydes to give thiazolidinones (see, for example,
Bernardes, et al., Nature Protocols, 8:2079-2089).
[0341] Additional approaches include engineering the antibody to
include one or more unnatural amino acids, such as
p-acetylphenylalanine (pAcPhe) or selenocysteine (Sec). The keto
group in pAcPhe can be reacted with a linker-toxin comprising a
terminal alkoxyamine or hydrazide to form an oxime or hydrazone
bond (see, for example, Axup, et al., PNAS USA, 109:16101-16106
(2012)). Sec-containing antibodies can be reacted with maleimide-
or iodoacetamide containing linker-toxins to form a selenoether
conjugate (see, for example, Hofer, et al., Biochemistry,
48:12047-12057 (2009)).
[0342] Antibodies may also be engineered to include peptide tags
recognized by certain enzymes to allow for enzyme-catalyzed
conjugation. For example, Sortase-A (SortA) recognizes the sequence
LPXTG. This pentapeptide may be engineered into the N- or
C-terminus of the antibody to allow for SortA-mediated conjugation
(see, for example, U.S. Patent Application Publication No.
2016/0136298; Kornberger and Skerra, mAbs, 6(2):354-366 (2014)).
Transglutaminases have also been employed to generate DAR2 ADCs by
using antibodies that have been deglycosylated at position N297
(which exposes Q295 for enzymatic conjugation) or by engineering
antibodies to include a "glutamine tag" (LLQG) (Jeger, et al.,
Angew. Chem., 49:9995-9997 (2010); Strop, et al., Chem. Biol.,
20(2):161-167 (2013)). In another approach, a formylglycine residue
can be introduced into an antibody by engineering an appropriate
consensus sequence into the antibody and co-expressing the
engineered antibody with formylglycine-generating enzyme (FGE). The
aldehyde functionality of the introduced formylglycine may then be
used as a handle for conjugation of toxin (see, for example, Drake,
et al., Bioconjug. Chem., 25(7):1331-1341 (2014)).
[0343] Another approach used to generate DAR2 ADCs is by
conjugation of linker-toxin to the native sugars found on
glycosylated antibodies. Conjugation to glycosylated antibodies may
be achieved, for example, by periodate oxidation of terminal sugar
residues to yield aldehydes, which may then be conjugated to an
appropriate linker-toxin, or by glycoengineering approaches in
which native sugars are modified with terminal sialic acid
residues, which can then be oxidized to yield aldehydes for
conjugation to linker-toxin (Zhou, et al., Bioconjug. Chem.,
25(3):510-520 (2014)).
[0344] The use of UV cross-linking for conjugation of active
moieties to antibodies has also been reported. This method uses the
nucleotide binding site (NBS) for site-specific covalent
functionalization of antibodies with reactive thiol moieties. An
indole-3-butyric acid (IBA) conjugated version of cysteine was used
to site-specifically photo-cross-link a reactive thiol moiety to
antibodies at the NBS. The thiol moiety may then be used to
conjugate linker-toxin having a thiol reactive group (Alves, et
al., Bioconjug. Chem., 25(7):1198-1202 (2014)).
[0345] Alternatively, ADCs with a low average DAR may be isolated
from an ADC preparation containing a mixture of DAR species using
chromatographic separation techniques, such as hydrophobic
interaction chromatography (see, for example, Hamblett, et al.,
Clin. Cancer Res., 10:7063-7070 (2004); Sun, et al., Bioconj Chem.,
28:1371-81 (2017); U.S. Patent Application Publication No.
2014/0286968).
[0346] ADC preparations with a low average DAR may also be
generated by adding unconjugated (i.e. DAR0) antibody to
preparations of ADC having an average DAR .gtoreq.3.9. As is known
in the art, the majority of conjugation methods yield an ADC
preparation that includes various DAR species, with the reported
DAR being the average of the individual DAR species. In certain
embodiments, ADC preparations that include a proportion of DAR0
species may be advantageous. In some embodiments, the ADC
preparation having an average DAR of less than 3.9 may include at
least 5% DAR0 species. In some embodiments, the ADC preparation may
include at least 10% DAR0 species, for example, at least 15% DAR0
species or at least 20% DAR0 species. In some embodiments, the ADC
preparation may include between about 5% and about 50% DAR0
species. In some embodiments, the ADC preparation may include
between about 10% and about 50% DAR0 species, for example, between
about 10% and about 40%, or between about 10% and abut 30% DAR0
species.
[0347] The average DAR for the ADCs may be determined by standard
techniques such as UV/VIS spectroscopic analysis, ELISA-based
techniques, chromatography techniques such as hydrophobic
interaction chromatography (HIC), UV-MALDI mass spectrometry (MS)
and MALDI-TOF MS. In addition, distribution of drug-linked forms
(for example, the fraction of DAR0, DAR1, DAR2, etc. species) may
also be analyzed by various techniques known in the art, including
MS (with or without an accompanying chromatographic separation
step), hydrophobic interaction chromatography, reverse-phase HPLC
or iso-electric focusing gel electrophoresis (IEF) (see, for
example, Sun et al., Bioconj Chem., 28:1371-81 (2017); Wakankar et
al., mAbs, 3:161-172 (2011)).
[0348] In certain embodiments, the average DAR of the ADCs is
determined by hydrophobic interaction chromatography (HIC)
techniques.
[0349] Following conjugation, the ADCs may be purified and
separated from unconjugated reactants and/or any conjugate
aggregates by purification methods known in the art. Such methods
include, but are not limited to, size exclusion chromatography
(SEC), hydrophobic interaction chromatography (HIC), ion exchange
chromatography, chromatofocusing, ultrafiltration, centrifugal
ultrafiltration, and combinations thereof.
Testing
[0350] The anti-cancer activity of the ADCs in HER2-expressing
cancer cells may be tested in vitro and/or in vivo using standard
techniques.
[0351] For example, the cytotoxic activity of the ADCs may be
measured by exposing HER2-expressing cancer cells to the ADC in a
cell culture medium, culturing the cells for an appropriate period
of time (for example, about 6 hrs to about 7 days), then measuring
cell viability. Non-HER2 expressing cells may be included as a
control.
[0352] A variety of cancer cell lines expressing HER2 at varying
levels, which may be used to test the ADCs are known in the art and
many are commercially available (for example, from the American
Type Culture Collection, Manassas, Va.; Addexbio Technologies, San
Diego, Calif.; DSMZ, Braunschweig, Germany). Examples include the
BT-474 (3+), SK-BR-3 (3+), HCC1954 (3+), JEIMT-1 (2+) and ZR-75-1
(1+) cell lines. These and other examples are summarized in Table
8.
TABLE-US-00011 TABLE 8 Relative Expression Levels of HER2 in Cell
Lines of Interest IHC HER2 Cell Line Description scoring
receptors/cell NCI-N87 Human gastric carcinoma 3+ Not assessed A549
Human lung alveolar carcinoma (non-small 0/1+ Not assessed cell
lung cancer) BxPC-3 Human pancreatic adenocarcinoma 1+ Not assessed
MIA PaCa-2 Human pancreatic ductal adenocarcinoma 2+ Not assessed
FaDu Human pharyngeal squamous cell carcinoma 2+ Not assessed
HCT-116 Human colorectal epithelial carcinoma 1+ Not assessed
MDA-MB-231 Human triple negative breast epithelial 0/1+ 1.7 .times.
10E4-2.3 .times. 10E4 adenocarcinoma MCF-7 Human estrogen receptor
positive breast 1+ 4 .times. 10E4-7 .times. 10E4 epithelial
adenocarcinoma JIMT-1 Trastuzumab-resistant breast epithelial 2+ 2
.times. 10E5-8 .times. 10E5 carcinoma, amplified HER2 oncogene
ZR-75-1 Estrogen receptor positive breast ductal 2+ 3 .times. 10E5
carcinoma SKOV-3 Human ovarian epithelial adenocarcinoma, 2/3+ 5
.times. 10E5-1 .times. 10E6 HER2 gene amplified SK-BR-3 Human
breast epithelial adenocarcinoma 3+ >1 .times. 10E6 BT-474 Human
breast epithelial ductal carcinoma 3+ >1 .times. 10E6 MDA-MB-468
Human breast adenocarcinoma, derived 0 Undetectable from metastatic
site: pleural effusion (.ltoreq.1000)
[0353] The ability of the ADCs to inhibit tumour growth in vivo can
be determined in an appropriate animal model using standard
techniques known in the art (see, for example, Enna, et al.,
Current Protocols in Pharmacology, J. Wiley &Sons, Inc., New
York, N.Y.). In general, current animal models for screening
anti-tumour compounds are xenograft models, in which a human tumour
has been implanted into an animal, typically a rodent.
[0354] For example, the ADCs may be tested in vivo on
HER2-expressing tumours using mice that are subcutaneously grafted
with tumour fragment, or implanted with an appropriate number of
cancer cells, on day 0. The tumours are allowed to develop to the
desired size, with animals having insufficiently developed tumours
being eliminated. ADC treatment generally begins from 3 to 22 days
after grafting, depending on the type of tumour. The ADC may be
administered to the animals, for example, by intravenous (i.v.)
injection. Tumours are measured either after a pre-determined time
period or continuously (for example, 2 or 3 times a week) until a
pre-determined endpoint for the study, for example, when the tumour
reaches a pre-determined size or weight. Tumours expressing HER2 at
various levels may be used in the xenograft models. Patient-derived
xenografts (PDX) are particularly useful.
[0355] In vivo toxic effects of the ADCs may initially be evaluated
in rodents, for example mice or rats, by measuring their effect on
animal body weight during treatment. Hematological profiles and
liver enzyme analysis may also be performed on blood samples taken
from the animals.
[0356] In vivo toxicity and pharmacokinetics may be further
analyzed in appropriate animal models, for example, rats or
non-human primates, following standard protocols. Cynomolgus
monkeys are particularly useful in this regard as human and
cynomolgus monkey HER2 share 98% sequence homology.
[0357] The ADCs described herein have improved tolerability and
lower toxicity as compared to a corresponding ADC having a DAR
.gtoreq.3.9 when administered at the same toxin dose. In certain
embodiments, the ADCs show an improvement in tolerability of
greater than 2.times. that of a corresponding ADC having a DAR
.gtoreq.3.9 when administered at the same toxin dose. In some
embodiments, the ADCs show an improvement in tolerability of
greater than 2.2.times., for example, 2.3.times., 2.4.times. or
2.5.times., that of a corresponding ADC having a DAR .gtoreq.3.9
when administered at the same toxin dose. Improvement in
tolerability may be determined, for example, by comparison of
maximal tolerated dose (MTD), no observed adverse event level
(NOAEL) or highest non-severely toxic dose (HNSTD) for the ADC of
the present disclosure and the corresponding ADC having a DAR
.gtoreq.3.9. MTD, NOAEL and/or HNSTD may be measured by standard
techniques in an appropriate animal model, for example, a rodent or
non-human primate.
Pharmaceutical Compositions
[0358] For therapeutic use, the ADCs may be provided in the form of
compositions comprising the ADC and a pharmaceutically acceptable
carrier or diluent. The compositions may be prepared by known
procedures using well-known and readily available ingredients.
[0359] Pharmaceutical compositions may be formulated for
administration to a subject by, for example, oral (including, for
example, buccal or sublingual), topical, parenteral, rectal or
vaginal routes, or by inhalation or spray. The term "parenteral" as
used herein includes subcutaneous injection, and intradermal,
intra-articular, intravenous, intramuscular, intravascular,
intrasternal, intrathecal injection or infusion. The pharmaceutical
composition will typically be formulated in a format suitable for
administration to the subject, for example, as a syrup, elixir,
tablet, troche, lozenge, hard or soft capsule, pill, suppository,
oily or aqueous suspension, dispersible powder or granule,
emulsion, injectable or solution. Pharmaceutical compositions may
be provided as unit dosage formulations.
[0360] In certain embodiments, the pharmaceutical compositions
comprising the ADCs are formulated for parenteral administration in
a unit dosage injectable form, for example as lyophilized
formulations or aqueous solutions.
[0361] Pharmaceutically acceptable carriers are generally nontoxic
to recipients at the dosages and concentrations employed. Examples
of such carriers include, but are not limited to, buffers such as
phosphate, citrate, and other organic acids; antioxidants such as
ascorbic acid and methionine; preservatives such as
octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride,
benzalkonium chloride, benzethonium chloride, phenol, butyl
alcohol, benzyl alcohol, alkyl parabens (such as methyl or propyl
paraben), catechol, resorcinol, cyclohexanol, 3-pentanol and
m-cresol; low molecular weight (less than about 10 residues)
polypeptides; proteins such as serum albumin or gelatin;
hydrophilic polymers such as polyvinylpyrrolidone; amino acids such
as glycine, glutamine, asparagine, histidine, arginine or lysine;
monosaccharides, disaccharides, and other carbohydrates such as
glucose, mannose or dextrins; chelating agents such as EDTA; sugars
such as sucrose, mannitol, trehalose or sorbitol; salt-forming
counter-ions such as sodium; metal complexes such as Zn-protein
complexes, and non-ionic surfactants such as polyethylene glycol
(PEG).
[0362] In certain embodiments, the compositions comprising the ADCs
may be in the form of a sterile injectable aqueous or oleaginous
solution or suspension. Such suspensions may be formulated using
suitable dispersing or wetting agents and/or suspending agent that
are known in the art. The sterile injectable solution or suspension
may comprise the ADC in a non-toxic parentally acceptable diluent
or carrier. Acceptable diluents and carriers that may be employed
include, for example, 1,3-butanediol, water, Ringer's solution or
isotonic sodium chloride solution. In addition, sterile, fixed oils
may be employed as a carrier. For this purpose, various bland fixed
oils may be employed, including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid find use in the
preparation of injectables. Adjuvants such as local anaesthetics,
preservatives and/or buffering agents may also be included in the
injectable solution or suspension.
[0363] In certain embodiments, the composition comprising the ADC
may be formulated for intravenous administration to humans.
Typically, compositions for intravenous administration are
solutions in sterile isotonic aqueous buffer. Where necessary, the
composition may also include a solubilizing agent and/or a local
anaesthetic such as lignocaine to ease pain at the site of the
injection. Generally, the ingredients are supplied either
separately or mixed together in unit dosage form, for example, as a
dry lyophilized powder or water free concentrate in a hermetically
sealed container such as an ampoule or sachette indicating the
quantity of active agent. Where the composition is to be
administered by infusion, it can be dispensed with an infusion
bottle containing sterile pharmaceutical grade water or saline.
Where the composition is administered by injection, an ampoule of
sterile water for injection or saline can be provided so that the
ingredients may be mixed prior to administration.
[0364] Other pharmaceutical compositions and methods of preparing
pharmaceutical compositions are known in the art and are described,
for example, in "Remington: The Science and Practice of Pharmacy"
(formerly "Remingtons Pharmaceutical Sciences"); Gennaro, A.,
Lippincott, Williams & Wilkins, Philadelphia, Pa. (2000).
METHODS OF USE
[0365] The ADCs described herein may be used in methods of
inhibiting the growth of HER2-expressing tumour cells. The cells
may be in vitro or in vivo. In certain embodiments, the ADCs may be
used in methods of treating a HER2-expressing cancer or tumour in a
subject.
[0366] Treatment of a HER2-expressing cancer may result in one or
more of alleviation of symptoms, shrinking the size of the tumour,
inhibiting growth of the tumour, diminishing one or more direct or
indirect pathological consequences of the disease, preventing
metastasis, decreasing the rate of disease progression,
amelioration or palliation of the disease state, improving
survival, increasing progression-free survival, remission and/or
improving prognosis.
[0367] In certain embodiments, treatment of a HER2-expressing
cancer with an ADC as described herein slows the progression of the
disease. In some embodiments, treatment of a HER2-expressing cancer
with an ADC as described herein results in tumour regression. In
some embodiments, treatment of a HER2-expressing cancer with an ADC
as described herein results in inhibition of tumour growth.
[0368] HER2-expressing cancers are typically solid tumours.
Examples of HER2-expressing solid tumours include, but are not
limited to, breast cancer, ovarian cancer, lung cancer, gastric
cancer, esophageal cancer, colorectal cancer, urothelial cancer,
pancreatic cancer, salivary gland cancer and brain cancer.
HER2-expressing breast cancer include estrogen receptor negative
(ER-) and/or progesterone receptor negative (PR-) breast cancers
and triple negative (ER-, PR-, low HER2) breast cancers.
HER2-expressing lung cancers include non-small cell lung cancer
(NSCLC) and small cell lung cancer.
[0369] In certain embodiments, the ADCs described herein may be
used in the treatment of HER2-expressing breast cancer, ovarian
cancer, lung cancer or gastric cancer. In some embodiments, the
ADCs described herein may be used in the treatment of
HER2-expressing breast cancer. In some embodiments, the ADCs
described herein may be used in the treatment of HER2-expressing
breast cancer that is also estrogen receptor and progesterone
receptor negative. In some embodiments, the ADCs described herein
may be used in the treatment of HER2-expressing triple negative
breast cancer (TNBC). In some embodiments, the ADCs described
herein may be used in the treatment of HER2-expressing breast
cancer that has metastasized to the brain. In some embodiments, the
ADCs described herein may be used in the treatment of
HER2-expressing ovarian cancer.
[0370] As is known in the art, HER2-expressing cancers may be
characterized by the level of HER2 they express (i.e. by "HER2
status"). HER2 status can be assessed, for example, by
immunohistochemistry (IHC), fluorescent in situ hybridization
(FISH) and chromogenic in situ hybridization (CISH).
[0371] IHC identifies HER2 protein expression on the cell membrane.
Paraffin-embedded tissue sections from a tumour biopsy may be
subjected to the IHC assay and accorded a HER2 staining intensity
criteria as follows: [0372] Score 0: no staining observed or
membrane staining is observed in less than 10% of tumour cells;
typically <20,000 receptors/cell. [0373] Score 1+: a
faint/barely perceptible membrane staining is detected in more than
10% of the tumour cells. The cells are only stained in part of
their membrane. Typically about 100,000 receptors/cell. [0374]
Score 2+: a weak to moderate complete membrane staining is observed
in more than 10% of the tumour cells; typically about 500,000
receptors/cell. [0375] Score 3+: a moderate to strong complete
membrane staining is observed in more than 10% of the tumour cells;
typically about 2,000,000 receptors/cell.
[0376] Tumours with 0 or 1+ scores for HER2 expression are
characterized as HER2 negative, whereas those tumours with 2+ or 3+
scores are characterized as HER2 positive.
[0377] Examples of FDA-approved commercial kits available for HER2
detection using IHC include HercepTest.TM. (Dako Denmark A/S);
PATHWAY (Ventana Medical Systems, Inc.); InSite.TM.HER2/NEU kit
(Biogenex Laboratories, Inc.) and Bond Oracle HER2 IHC System
(Leica Biosystems.
[0378] ADCs as described herein may be useful in the treatment of
cancers that express HER2 at various levels. In certain
embodiments, the ADCs may be used in the treatment of cancers that
express high levels of HER2 (IHC 3+). In some embodiments, the ADCs
may be used in the treatment of cancers that express high levels of
HER2 (3+ IHC) or moderate levels of HER2 (2+ IHC or 2+/3+ IHC). In
some embodiments, the ADCs may be used in the treatment of cancers
that express high levels of HER2 (3+ IHC), moderate levels of HER2
(2+ IHC or 2+/3+ IHC), or low levels of HER2 (1+ IHC or 1+/2+ IHC).
In some embodiments, the ADCs described herein may be used in the
treatment of cancers that are scored as HER2 negative by IHC.
[0379] In certain embodiments, HER2 levels of the cancer to be
treated with the ADCs are determined by IHC. In some embodiments,
HER2 levels of the cancer to be treated with the ADCs are
determined by IHC performed using the Herceptest.TM. assay.
[0380] HER2-expressing cancers may be homogeneous in nature (i.e.
the majority of tumour cells express a similar amount of HER2) or
they may be heterogeneous in nature (i.e. comprise different tumour
cell populations expressing different levels of HER2). It is
contemplated that the ADCs may be used to treat HER2-expressing
cancers that are either homogeneous or heterogeneous with respect
to HER2 levels.
[0381] In certain embodiments, the ADCs find use in methods for
treating a subject having a HER2-expressing cancer that is
resistant or becoming resistant to other standard-of-care
therapies. In some embodiments, the ADCs find use in methods for
treating a subject having a HER2-expressing cancer who is
unresponsive to one or more current therapies, such as trastuzumab
(Herceptin.RTM.), pertuzumab (Perjeta.RTM.), T-DM1 (Kadcyla.RTM. or
trastuzumab emtansine) or taxanes (such as such as paclitaxel,
docetaxel, cabazitaxel, and the like). In some embodiments, the
ADCs find use in methods for treating a subject having a
HER2-expressing cancer that is resistant to trastuzumab. In some
embodiments, the ADCs find use in methods for treating a subject
having a HER2-expressing cancer that is resistant to pertuzumab. In
some embodiments, the ADCs find use in methods for treating a
subject having a HER2-expressing cancer that is resistant to T-DM1.
In some embodiments, the ADCs find use in the treatment of
metastatic cancer when the patient has progressed on previous
anti-HER2 therapy.
[0382] When the ADCs are used in the treatment of subjects having a
HER2-expressing cancer that is resistant to, refractory to and/or
relapsed from treatment with another therapeutic agent, the ADCs
may be part of a second-line therapy, or a third- or fourth-line
therapy, depending on the number of prior treatments undergone by
the subject.
[0383] In certain embodiments, the ADCs described herein may be
used in conjunction with an additional anti-tumour agent in the
treatment of subjects having a HER2-expressing cancer. The
additional anti-tumour agent may be a therapeutic antibody such as
those noted above, or a chemotherapeutic agent. Chemotherapeutic
agents commonly used for the treatment of HER2-expressing cancers
include, for example, cisplatin, carboplatin, paclitaxel,
albumin-bound paclitaxel Abraxane.RTM.), docetaxel, gemcitabine,
vinorelbine, irinotecan, etoposide, vinblastine, pemetrexed,
5-fluorouracil (with or without folinic acid), capecitabine,
carboplatin, epirubicin, oxaliplatin, folfirinox, cyclophosphamide,
and various combinations of these agents as is known in the art.
The additional agent(s) may be administered to the subject
concurrently with the ADCs or sequentially.
[0384] In certain embodiments, it is contemplated that the ADCs
described herein may be used to treat a subject having a
HER2-expressing cancer who has not undergone any prior anti-cancer
treatments (i.e. the ADCs may be used as a first line therapy).
[0385] In certain embodiments, the subject being treated with the
ADC in the above methods may be a human, a non-human primate or
other mammal. In some embodiments, the subject being treated with
the ADC in the above methods is a human subject.
[0386] The amount of the ADC to be administered to a subject will
vary in the light of the relevant circumstances, including the
condition to be treated, the chosen route of administration, the
actual compound administered, the age, weight, and response of the
individual subject and the severity of the subject's symptoms, but
is a therapeutically effective amount.
[0387] The term "therapeutically effective amount" as used herein
refers to the amount of ADC required to be administered in order to
accomplish the goal of the recited method, for example,
amelioration of one or more of the symptoms of the disease being
treated. The amount of the ADC described herein that will be
effective in the treatment of a HER2-expressing cancer can be
determined by standard clinical techniques. In addition, in vitro
assays may optionally be employed to help identify optimal dosage
ranges. Effective doses are extrapolated from dose-response curves
derived from in vitro or animal model test systems.
Pharmaceutical Kits
[0388] Certain embodiments provide for pharmaceutical kits
comprising an ADC as described herein.
[0389] The kit typically will comprise a container and a label
and/or package insert on or associated with the container. The
label or package insert contains instructions customarily included
in commercial packages of therapeutic products, providing
information about the indications, usage, dosage, administration,
contraindications and/or warnings concerning the use of such
therapeutic products. The label or package insert may further
include a notice in the form prescribed by a governmental agency
regulating the manufacture, use or sale of pharmaceuticals or
biological products, which notice reflects approval by the agency
of manufacture, for use or sale for human or animal administration.
The label or package insert also indicates that the ADC is for use
to treat a HER2-expressing cancer. The container holds a
composition comprising the ADC and may in some embodiments have a
sterile access port (for example, the container may be an
intravenous solution bag or a vial having a stopper that may be
pierced by a hypodermic injection needle).
[0390] In addition to the container containing the composition
comprising the ADC, the kit may comprise one or more additional
containers comprising other components of the kit. For example, a
pharmaceutically-acceptable buffer, such as bacteriostatic water
for injection (BWFI), phosphate-buffered saline, Ringer's solution
or dextrose solution; other buffers or diluents.
[0391] Suitable containers include, for example, bottles, vials,
syringes, intravenous solution bags, and the like. The containers
may be formed from a variety of materials such as glass or plastic.
If appropriate, one or more components of the kit may be
lyophilized or provided in a dry form, such as a powder or
granules, and the kit can additionally contain a suitable solvent
for reconstitution of the lyophilized or dried component(s).
[0392] The kit may further include other materials desirable from a
commercial or user standpoint, such as filters, needles, and
syringes.
[0393] The following Examples are provided for illustrative
purposes and are not intended to limit the scope of the invention
in any way.
EXAMPLES
Example 1: Synthesis of Linker-Toxin
[0394] The following example describes the preparation of an
exemplary linker-toxin (Linker-Toxin 001) that comprises the
following auristatin analogue (Compound 9):
##STR00049##
[0395] Similar protocols may be employed to prepare linker-toxins
comprising other auristatin analogues including the following
exemplary compounds (see also International Patent Application
Publication No. WO 2016/041082):
##STR00050##
1.1 Ethyl
(2R,3R)-3-methoxy-2-methyl-3-((S)-pyrrolidin-2-yl)propanoate
(Compound 1)
##STR00051##
[0397] To a stirred solution of
(2R,3R)-3-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-3-methoxy-2-methyl-
propanoic acid (Boc-Dap-OH, 4.31 g, 15.0 mmol) in absolute ethanol
(27.0 mL) at 0.degree. C. was added thionyl chloride (3.0 mL) in a
dropwise fashion. The resulting solution was allowed to warm to
room temperature and progress was monitored by HPLC-MS. After 18 h,
no remaining starting material was detected and the solution was
concentrated to dryness under reduced pressure. The resulting oil
was suspended in toluene (10 mL) and concentrated under reduced
pressure two times, then suspended in diethyl ether (5 mL) and
concentrated under reduced pressure two times to afford a white
solid foam (3.78 g, quant yield %). MS m/z obs.=216.5 (M+1).
1.2
(3R,4S,5S)-4-((S)-2-(((benzyloxy)carbonyl)amino)-N,3-dimethylbutanamid-
o)-3-methoxy-5-methylheptanoic Acid (Compound 3)
##STR00052##
[0399] Compound 2 was prepared as described in International Patent
Application Publication No. WO 2016/041082.
[0400] To a stirred solution of Compound 2 (6.965 g, 14.14 mmol) in
dichloromethane (20 mL) was added trifluoroacetic acid (5.0 mL).
The reaction was monitored for completion by HPLC-MS and after 40 h
no starting material remained. The reaction was concentrated under
reduced pressure, co-evaporated with toluene (2.times.10 mL) and
dichloromethane (2.times.10 mL) to obtain a foamy white solid (6.2
g, quant yield with residual TFA). This material was dissolved in
200 mL of hot 1:3 EtOAc:hexanes and allowed to cool to room
temperature. During cooling, a precipitate formed as well as some
small crystals. 5 mL EtOAc was added and the suspension was heated
once again to fully dissolve the precipitate. More crystals formed
on cooling to room temperature and the flask was placed at
-30.degree. C. overnight. The following morning the mother liquor
was decanted and the crystals rinsed with 2.times.50 mL hexanes and
dried under high vacuum. Recovered 5.67 g of crystalline product.
MS m/z obs.=405.7 (M+1).
1.3 Ethyl
(2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-(((benzyloxy)carbonyl)amin-
o)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3--
methoxy-2-methylpropanoate (Compound 4)
##STR00053##
[0402] To a stirred solution of Compound 3 (6.711 g, 15.37 mmol,
1.025 equiv) in a mixture of dichloromethane (5.0 mL) and
N,N-dimethylformamide (5.0 mL) at room temperature was added HATU
(5.732 g, 15.07 mmol, 1.005 equiv) and N,N-diisopropylethylamine
(7.84 mL, 3 equiv). After stirring for 30 minutes at room
temperature, a solution of Compound 1 (3.776 g, 15.00 mmol, 1.0
equiv) in a mixture of dichloromethane (1.0 mL) and
N,N-dimethylformamide (1.0 mL) was added dropwise, rinsed in
residual Compound 1 with an additional 3 mL of 1:1
dichloromethane:N,N-dimethylformamide. The reaction was monitored
by HPLC-MS and no remaining Compound 1 was observed after 15
minutes. The reaction was concentrated under reduced pressure,
diluted with ethyl acetate (125 mL) and the organic phase was
extracted with 1 M HCl (2.times.50 mL), 1.times. dH.sub.2O
(1.times.50 mL), saturated NaHCO.sub.3 (3.times.50 mL), brine (25
mL). Acidic and basic aqueous layers were both washed with 25 mL
EtOAc. All organics were then pooled and dried over MgSO.sub.4,
filtered and concentrated to give a red oil. The residue was
dissolved in a minimal amount of dichloromethane (10 mL), loaded on
to a Biotage.RTM. SNAP Ultra 360 g silica gel column (Isolera.TM.
Flash System; Biotage AB, Sweden) for purification (20-100% EtOAc
in hexanes over 10 column volumes). Fractions containing pure
product were pooled to recover 7.9 g of foamy white solid. Impure
fractions were subjected to a second purification on a Biotage.RTM.
SNAP Ultra 100 g silica gel column and pooled with pure product to
recover a white foam solid (8.390 g, 88.3%). MS m/z obs.=634.7
(M+1).
1.4
(2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-(((benzyloxy)carbonyl)amino)-N,3-
-dimethyl
butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-metho-
xy-2-methylpropanoic Acid (Compound 5)
##STR00054##
[0404] To a stirred solution of Compound 4 (8.390 g, 13.24 mmol) in
1,4-dioxane (158 mL) was added dH.sub.2O (39.7 ml) and lithium
hydroxide monohydrate (1 M in H.sub.2O, 39.7 mL, 3 equiv). The
reaction was stirred at 4.degree. C. and monitored by HPLC-MS for
consumption of starting material, which took 3 days until only
trace Compound 4 remained. During the course of the reaction, a new
product, corresponding to loss of methanol (p-elimination, <2%)
formed in small percentages in addition to the desired material.
The reaction was acidified with the addition of 1 M aqueous HC (50
mL) and concentrated under reduced pressure to remove the dioxane.
The remaining reaction mixture was extracted with ethyl acetate
(4.times.50 mL) and the organic phase was pooled, washed with brine
(15 mL+2 mL 2 M HCl), dried over MgSO.sub.4, filtered and
concentrated under reduced pressure to yield a light coloured oil.
The oil was re-dissolved in diethyl ether (.about.50 mL) and
concentrated under reduced pressure (3.times.) to facilitate the
removal of residual dioxane, affording the title product as a stiff
oil (7.81 g 97% yield with some residual dioxane and Compound 4).
MS m/z obs.=606.7 (M+1).
1.5 Benzyl
((S)-1-(((3R,4S,5S)-3-methoxy-1-((S)-2-((1R,2R)-1-methoxy-2-met-
hyl-3-oxo-3-((4-(2,2,2-trifluoroacetamido)phenyl)sulfonamido)propyl)pyrrol-
idin-1-yl)-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2--
yl)carbamate (Compound 7)
##STR00055##
[0406] Compound 6 was prepared as described in International Patent
Application Publication No. WO 2016/041082).
[0407] To a stirred solution of Compound 5 (7.12 g, 11.754 mmol) in
dichloromethane (20 mL) was added
2,2,2-trifluoro-N-(4-sulfamoylphenyl)acetamide (Compound 6, 4.095
g, 1.3 equiv, dissolved in 3 mL DMF), N,N-dimethylpyridine (1.867
g, 1.3 equiv) and N,N-dimethylformamide (1.5 mL) to generate a
light yellow suspension. Further addition of 5 mL of DMF did not
clarify solution. N-(3-Dimethylaminopropyl)-N,N-ethylcarbodiimide
hydrochloride (EDCI) (2.817 g, 1.25 equiv) was added in a single
portion and the reaction was monitored by HPLC-MS. After 48 hr,
reaction was no longer progressing and an additional 400 mg of EDCI
was added. After 18 hr, no remaining starting material was observed
and the reaction was concentrated under reduced pressure to give a
yellow oil. The oil was dissolved in ethyl acetate (.about.150 mL)
and 1 M HCl (20 mL), and the organic phase was washed with cold 2 M
HCl (2.times.10 mL), saturated NaHCO.sub.3 (1.times.10 mL), brine
(20 mL+5 mL 2 M HCl). Acidic and basic aqueous fractions were
extracted with EtOAc (1.times.20 mL), all organic fractions were
pooled, dried over MgSO.sub.4 and concentrated under reduced
pressure to yield an oily crude solid (13 g). The residue was
dissolved in dichloromethane (.about.10 mL), loaded on to a
Biotage.RTM. SNAP Ultra 360 g silica gel column and purified under
a 10-100% EtOAc (2% AcOH) in hexanes gradient over 12 column
volumes with a 3-column volume plateau at 50% EtOAc. Fractions
containing the pure product were pooled, concentrated under reduced
pressure, dissolved and concentrated from toluene (2.times.10 mL)
and diethyl ether (2.times.10 mL) to afford the desired product,
7.1 g of white foam solid. Impure fractions were subjected to
repeat purification under shallower gradient conditions using a
Biotage.RTM. SNAP Ultra 100 g silica gel column on an Isolera.TM.
instrument. All pure fractions were pooled to recover pure product
as a white foam solid (8.60 g, 86%). MS m/z obs.=856.7 (M+1).
1.6
(S)-2-amino-N-((3R,4S,5S)-3-methoxy-1-((S)-2-((1R,2R)-1-methoxy-2-meth-
yl-3-oxo-3-((4-(2,2,2-trifluoroacetamido)phenyl)sulfonamido)propyl)pyrroli-
din-1-yl)-5-methyl-1-oxoheptan-4-yl)-N,3-dimethylbutanamide
(Compound 7a)
##STR00056##
[0409] Compound 7 (3.71 g, 4.33 mmol) was dissolved in 10%
N,N-dimethylformamide in ethyl acetate (30 mL) in a round bottom
flask containing a magnetic stirrer and fitted with a 3-way gas
line adapter. The vessel was twice evacuated under reduced pressure
and charged with nitrogen gas. 10% palladium on carbon (0.461 g,
0.1 equiv) was added in a single portion, the 3-way adapter was
fitted to the flask, a hydrogen balloon was fitted to the adapter
and the vessel twice evacuated under reduced pressure and charged
with hydrogen. The reaction was allowed to stir for 2 days, over
which time the hydrogen balloon was occasionally recharged. After
approximately 48 h, HPLC-MS analysis indicated that no starting
material remained. The reaction was diluted with methanol (20 mL)
and filtered through a plug of celite. The celite was washed with
methanol (2.times.50 mL). All filtrates were pooled and
concentrated under reduced pressure and the resulting oil dissolved
and concentrated from dichloromethane. After drying under reduced
pressure, the title compound was isolated as a colourless powder
(3.10 g, 99%). MS m/z obs.=722.6 (M+1).
1.7
(S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N-((3R,4S,5S)-3-metho-
xy-1-((S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-((4-(2,2,2-trifluoroacetam-
ido)phenyl)sulfonamido)
propyl)pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl)-N,3-dimethylbutanamide
(Compound 8)
##STR00057##
[0411] To a stirred solution of N,N-(L)-dimethylvaline (1.696 g,
9.35 mmol) in N,N-dimethylformamide (10 mL) was added HATU (3.216
g, 8.46 mmol) and di-isopropylethylamine (3.10 mL, 17.8 mmol). A
clear yellow solution resulted after 5 minutes. Stirring was
continued for an additional 10 minutes, then Compound 7a (3.213 g,
4.45 mmol) was added in a single portion. After an additional 1 h
of stirring, HPLC-MS indicated that trace amounts of Compound 7a
remained and the reaction was for 16 h. The reaction was then
concentrated under reduced pressure, diluted with ethyl acetate
(120 mL) and 40 mL 1:1 NaHCO.sub.3 (sat.): 5% LiCl and transferred
to a separating funnel. The aqueous layer was removed and the
organic phase was washed with LiC (1.times.20 mL), NaHCO.sub.3
(sat., 2.times.20 mL). Aqueous layers were pooled and extracted
with EtOAc (3.times.50 mL). Organic layers were pooled and washed
with brine (1.times.20 mL), dried over sodium sulfate, filtered and
concentrated to give a DMF-laden oil which was concentrated via
rotary evaporator to remove residual DMF, yielding 7 g of crude
straw coloured oil. The oil was dissolved in a minimal amount of
10% methanol in dichloromethane (.about.11 mL) and loaded onto a
Biotage.RTM. SNAP Ultra 360 g silica gel column for purification
(2-20% MeOH in CH.sub.2Cl.sub.2 over 15 column volumes, product
eluting around 10-13%). The fractions containing the desired
product were pooled and concentrated under reduced pressure to
afford the title compound as a colourless foam. Impure fractions
were combined, evaporated and subjected to repeat purification on a
Biotage.RTM. SNAP Ultra 100 g silica gel column on an Isolera.TM.
instrument and combined with the pure product from the first column
to yield a colourless foam solid (3.78 g). MS m/z obs.=850.6
(M+1).
1.8
(S)--N-((3R,4S,5R)-1-((S)-2-((1R,2R)-3-((4-aminophenyl)sulfonamido)-1--
methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxohept-
an-4-yl)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanami-
de (Compound 9)
##STR00058##
[0413] To a stirred solution of Compound 8 (0.980 g, 1.154 mmol) in
1,4-dioxanes (15 mL) was added water (3.5 mL) and 1 M lithium
hydroxide monohydrate (3 equiv., 3.46 mL). The resulting light
suspension was allowed to stir at 4.degree. C. and was monitored by
HPLC-MS for consumption of the starting material. When the
conversion was complete (.about.5 days), the reaction was
neutralized with 3.46 mL of 1 M HCl and concentrated under reduced
pressure to remove dioxane. The resulting aqueous phase was diluted
with 60 mL EtOAc and 5 mL brine, then extracted with ethyl acetate
(2.times.30 mL). The organic fractions were pooled, dried over
Na.sub.2SO.sub.4, filtered and evaporated to yield the title
compound as a tan solid (0.930 g). R.sub.f=0.5 (8% MeOH in
CH.sub.2Cl.sub.2). MS m/z obs.=753.7 (M+1).
1.9 2,3,5,6-tetrafluorophenyl
3-(2-(2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy)ethoxy)ethoxy)pro-
panoate (Compound 15)
##STR00059##
[0415] In a dried 50 mL conical flask,
3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoic acid (Compound 14,
1.000 g, 4.52 mmol) and maleic anhydride (0.443 g, 4.52 mmol) were
dissolved in anhydrous N,N-dimethylformamide (5 mL). The reaction
was stirred at room temperature for 6 hr under N2, at which point
it was cooled to 0.degree. C. and syn-collidine (1.263 mL, 2.1 eq)
was added dropwise. In a separate dried 50 mL conical flask,
tetrafluorophenol (3.002 g, 4 eq) was dissolved in anhydrous
N,N-dimethylformamide (10 mL). The flask was cooled to 0.degree. C.
in an ice bath and trifluoroacetic anhydride (2.548 mL, 4 eq) was
added dropwise. This flask was stirred for 15 minutes, at which
point syn-collidine (2.407 mL, 4 eq) was added dropwise. The flask
was allowed to stir for another 15 minutes, and then the contents
were added to the first flask dropwise, via syringe. The reaction
was allowed to warm to room temperature and stirring was continued
under N2. The reaction was monitored by HPLC-MS for the consumption
of starting materials. After 6 days, the reaction was complete with
the total consumption of Compound 14, leaving only Compound 15 and
a small amount (.about.5%) of the bis-TFP maleic amide
intermediate. The reaction was transferred to a separating funnel,
diluted with diethyl ether (75 ml) and washed with 5% LiCl
(1.times.20 mL), 1 M HCl (2.times.20 mL), sat. NaHCO.sub.3
(5.times.20 mL) and brine (1.times.20 mL). The organic layer was
dried over Na.sub.2SO.sub.4, filtered and evaporated to give brown
crude oil with residual DMF. Crude oil was dissolved in 8 mL of 1:1
DMF:H.sub.2O+0.1% TFA, loaded onto a 60 g Biotage.RTM. SNAP Ultra
C18 column (Biotage AB, Uppsala, Sweden) and purified under a
linear 30-100% gradient of ACN/H.sub.2O+0.1% TFA over 8 column
volumes. Pure fractions were pooled and diluted with brine (20 mL),
then extracted 3.times.50 mL Et.sub.2O. Pooled organics were dried
over MgSO.sub.4, filtered and evaporated to recover a light-yellow
oil (1.34 g, 66% yield).
1.10 Tert-butyl
((S)-1-(((S)-1-((4-(N-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dime-
thylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylh-
eptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)sulfamoyl)phenyl)ami-
no)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate
(Compound 12)
##STR00060##
[0417] Compound 11 was prepared as described in International
Patent Application Publication No. WO 2016/041082.
[0418] To an empty 25 mL pear shaped flask, was added Compound 11
(1.342 g, 3.58 mmol, 3.0 equiv),
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.664
g, 3.46 mmol, 2.9 equiv) and 7-hydroxy-azabenzotriazole (HOAT)
(0.472 g, 3.46 mmol, 2.9 equiv). These solids were dissolved in a
mixture of N,N-dimethylformamide (0.5 mL) and dichloromethane (4.5
mL) with stirring at room temperature over 30 minutes. Separately,
Compound 9 (0.900 g, 1.20 mmol) was dissolved in a mixture of
N,N-dimethylformamide (0.2 mL) and dichloromethane (1.8 mL) and
added to the pear shaped flask, rinsing with dichloromethane (1.0
mL). Stirring rate was increased to 1000 rpm, producing a vortex.
Within 2 minutes of adding Compound 9, copper (II) chloride (0.514
g, 3.83 mmol, 3.2 equiv) was added in one portion directly into the
center of the vortex through a narrow powder funnel. The initially
light-yellow solution turned to a dark-brown suspension which
changed over 10 minutes to a dark-green suspension. The reaction
was monitored for completion by HPLC-MS and no change to reaction
progress was observed between the samples taken at 30 minutes and 1
h (.about.95% complete). The reaction was allowed to stir overnight
at room temperature, then 2-(2-aminoethylamino)ethanol (0.483 mL,
4.781 mmol, 4 equiv), EtOAc (10 mL) and dH.sub.2O (5 mL) were added
to the stirred suspension, which underwent a colour change to deep
blue. The suspension was stirred vigorously for 4 hr as the
suspended solids gradually dissolved into the biphasic mixture.
This mixture was transferred to a separating funnel and diluted
with EtOAc (100 mL) and brine (10 mL), and the aqueous layer was
extracted 10% IpOH/EtOAc (4.times.50 mL). The organic layers were
pooled and washed with brine (10 mL), dried over Na.sub.2SO.sub.4,
and evaporated to yield a faintly blue crude solid. This crude
solid was dissolved in a mixture of methanol (0.5 mL) and
dichloromethane (6 mL) and purified on a Biotage.RTM. SNAP Ultra
100 g silica gel column (2-20% MeOH in CH.sub.2Cl.sub.2 over 10
column volumes, followed by an 8-column volume plateau at 20%
MeOH). The product eluted as a broad peak after 1-2 column volumes
at .about.20% MeOH in CH.sub.2Cl.sub.2. Fractions containing the
desired material were pooled and concentrated under reduced
pressure to give the title compound as a white solid (1.105 g,
83%). MS m/z obs.=555.9 ((M+2)/2), 1109.8 (M+1).
1.11
(S)-2-((S)-2-amino-3-methylbutanamido)-N-(4-(N-((2R,3R)-3-((S)-1-((3R-
,4S,5R)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbu-
tanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylp-
ropanoyl)sulfamoyl)phenyl)-5-ureidopentanamide (Compound 13)
##STR00061##
[0420] To a solution of Compound 12 (0.926 g, 0.834 mmol) was added
a mixture of dichloromethane (10 mL) and trifluoroacetic acid (2.0
mL). The reaction was monitored by HPLC-MS for consumption of
starting material (.about.45 minutes). The reaction was
co-evaporated with acetonitrile (2.times.10 mL) and dichloromethane
(2.times.10 mL) under reduced pressure to remove excess
trifluoroacetic acid. The resulting residue was dissolved in a
minimal amount of dichloromethane and methanol (3:1, v/v, .about.2
mL), and added to a stirred solution of diethyl ether (200 mL) and
hexanes (100 mL) dropwise via pipette, producing a suspension of
light white solids. The solids were filtered and dried under vacuum
to afford the title compound in the form of a white powder, as the
trifluoroacetate salt (1.04 g, quantitative yield with some
residual solvents). MS m/z obs.=505.8 ((M+2)/2).
1.12
(S)--N-(4-(N-((2R,3R)-3-((S)-1-((3R,4S,5R)-4-((S)-2-((S)-2-(dimethyla-
mino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptan-
oyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoyl)sulfamoyl)phenyl)-2-((S)--
1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-14-isopropyl-12-oxo-3,6,9-trioxa--
13-azapentadecanamido)-5-ureidopentanamide (Linker-Toxin 001)
##STR00062##
[0422] To a stirred solution of Compound 13 (0.722 g, 0.584 mmol)
in N,N-dimethylformamide (4 mL) was added Compound 15 (0.314 g, 1.2
equiv) and diisopropylethylamine (0.305 mL, 3.0 equiv). HPLC-MS
analysis at 2 h indicated no remaining starting material. The
reaction was acidified with TFA (300 .mu.L) and then diluted with
diH.sub.2O+0.1% TFA (9 mL). The resultant solution was loaded onto
a 120 g Biotage.RTM. SNAP Ultra C18 column (Biotage, Uppsala,
Sweden) and purified under an ACN/H.sub.2O+0.1% TFA gradient:
20-60% ACN over 10 column volumes, 60-100% ACN over 5 column
volumes. Product eluted near 40% ACN. Pure fractions as identified
by LCMS were pooled and lyophilized. A white powder solid was
recovered from the lyophilizer. The lyophilization was repeated at
higher concentration (approx. 50 mg/mL in 2:1 H.sub.2O/ACN) into a
vial to produce a denser, less flocculant lyophilized solid (754.2
mg, 91%). MS m/z obs.=647.4 ((M+2)/2), 1292.8 (M+1).
Example 2: Conjugation of Linker-Toxin to Biparatopic Antibody
[0423] Antibody-drug conjugates (ADCs) of the biparatopic anti-HER2
mAb, v10000, and Linker-Toxin 001 were generated by partial
reduction of the antibody interchain disulfide bonds, followed by
capping of the free cysteine residues by reaction with the
maleimide component of the Linker-Toxin. Through variation of the
amount of TCEP used to reduce the antibody, ADCs with average
drug-to-antibody ratios of between 0 and 6 may be obtained. ADCs
were purified to remove contaminant small molecules and
characterized to demonstrate DAR, purity, monomeric content,
endotoxin levels, and binding to antigen positive tumour cells.
[0424] Preparation of v10000 is described in International Patent
Application Publication No. WO 2015/077891. Details of this
antibody are provided in Table 9 below. Sequences are provided in
the Sequence Tables.
TABLE-US-00012 TABLE 9 Variant Chain A Chain B 10000 Domain ECD2
ECD4 containing the epitope Format Fab scFv Antibody name
Pertuzumab - with Y96A in Trastuzumab VL region*, and
T30A/A49G/L69F in VH region CH3 sequence T350V/L351Y/F405A/Y407V
T350V/T366L/K392L/T394W substitutions.sup..sctn. *Fab or variable
domain numbering according to Kabat (Kabat et al., Sequences of
proteins of immunological interest, 5.sup.th Edition, US Department
of Health and Human Services, NIH Publication No. 91-3242, p.647,
1991) .sup..sctn.CH3 numbering according to EU index as in Kabat
(Edelman et al., 1969, PNAS USA, 63: 78-85)
2.1 Conjugation of Anti-HER2 Antibody by Partial Reduction of
Interchain Disulfide Bonds (v17597; DAR 3.9)
[0425] A solution (138.9 mL) of the antibody v10000 (2.0 g) in 10
mM sodium acetate, 9% (w/v) sucrose, pH 4.5 was reduced by addition
of a freshly prepared mixture of 200 mM Na.sub.2HPO.sub.4, pH 8.9
(15.4 mL), 5 mM DTPA solution (39.5 mL in PBS, pH 7.4), and 10 mM
TCEP solution (3.68 mL, 2.3 eq.). After 90 minutes at 37.degree.
C., the reaction was cooled on ice before addition of an excess of
Linker-Toxin 001 (6.41 mL; 8 eq) from a 20 mM DMSO stock solution.
The conjugation reaction was quenched after 90 minutes by addition
of an excess of a 20 mM N-acetyl cysteine solution (4.81 mL; 6
eq.).
2.2 Conjugation of Anti-HER2 Antibody by Partial Reduction of
Interchain Disulfide Bonds (v21252; DAR 2.1)
[0426] A solution (138.9 mL) of the antibody v10000 (2.0 g) in 10
mM sodium acetate, 9% (w/v) sucrose, pH 4.5 was pH-adjusted by
addition of 200 mM Na.sub.2HPO.sub.4, pH 8.9 (15.4 mL). After
addition of a DTPA solution (44 mL in PBS, pH 7.4, final
concentration 1.0 mM), reduction of the interchain disulfides was
initiated by addition of an aqueous 10 mM TCEP solution (1.68 mL,
1.05 eq.). After 90 minutes at 37.degree. C., the reaction was
cooled on ice before addition of an excess of Linker-Toxin 001
(4.81 mL; 6 eq) from a 20 mM DMSO stock solution. The conjugation
reaction was quenched after 90 minutes by addition of an excess of
a 20 mM N-acetyl cysteine solution (4.81 mL; 6 eq.).
2.3 Purification of Antibody Drug Conjugates v17597 and v21252
[0427] Quenched antibody drug conjugate (ADC) solutions were
purified with 9-15 diavolumes of 10 mM sodium acetate, 9% (w/v)
sucrose, pH 4.5 on a Millipore Labscale.TM. Tangential Flow
Filtration instrument using a Pellicon.RTM. XL Ultrafiltration
Module (Ultracel.RTM. 30 kDa 0.005 m.sup.2; Millipore Sigma). The
eluted ADC was sterile filtered (0.22 um). ADCs produced on small
scale were purified over 40 KDa MWCO Zeba.TM. columns (ThermoFisher
Scientific, Waltham, Mass.) preconditioned with either PBS or 10 mM
sodium acetate, 9% (w/v) sucrose, pH 4.5.
[0428] Following purification, the concentration of the ADC was
determined by a BCA assay with reference to a standard curve
generated from v10000. Alternatively, concentrations were estimated
by measurement of absorption at 280 nm (.epsilon.=195065 M.sup.-1
cm.sup.-1).
[0429] Samples of the ADCs were assessed by non-reducing and
reducing SDS-PAGE (see FIG. 1). No extraneous bands were
observed.
2.4 Hydrophobic Interaction Chromatography
[0430] Antibody and ADCs were analyzed by hydrophobic interaction
chromatography (HIC) to estimate the drug-to-antibody ratio (DAR).
Chromatography was on a Proteomix.RTM. HIC Ethyl column
(7.8.times.50 mm, Sm) (Sepax Technologies Inc., Newark, Del.)
employing a gradient of 80% MPA/20% MPB to 35% MPA/65% MPB over a
period of 13.5 minutes at a flow rate of 1 mL/min (MPA=1.5 M
(NH.sub.4).sub.2SO.sub.4, 25 mM Na.sub.xPO.sub.4, and MPB=75% 25 mM
Na.sub.xPO.sub.4, 25% isopropanol).
[0431] The average drug to antibody ratio (DAR) of an ADC can vary
depending on the number of disulphide bonds liberated during the
reduction of the antibody. A single conjugation reaction that
yields an ADC with a particular average DAR comprises a mixture of
species. For v17597 and v21252, a mixture of four species was
generated: unconjugated antibody, ADC with a DAR of 2, ADC with a
DAR of 4 and ADC with a DAR of 6.
[0432] The results of the HIC are shown in FIG. 2 and show that
v17597 has an average DAR of 3.92 (FIG. 2A), and v21252 has an
average DAR of 2.07 (FIG. 2B).
[0433] The individual contributions of the DAR0, DAR2, DAR4 and
DAR6 species to the average DAR of the purified ADCs were assessed
by the integration of the HPLC-HIC chromatogram. Each peak in the
HIC chromatogram was isolated by preparative chromatography and the
identity of the peak was verified by LC-MS. The % content of
individual DAR species for each variant (as determined by HIC) is
shown in Table 10 and in FIG. 2D. As can be seen from Table 10 and
FIG. 2D, v17597 contains significantly more DAR6 species than
v21252, and v21252 contains significantly more DAR0 species than
v17597.
[0434] FIG. 2E illustrates the change in the relative amounts of
DAR 0, 2, 4, and 6 species within v10000-Linker Toxin 001 for a
series of ADC preparations having average DAR values ranging from
0.5 to 6.
TABLE-US-00013 TABLE 10 DAR Distribution for v17597 and v21252 Area
% DAR v17597 v21252 0 2 23 2 35 56 4 26 17 6 36 4
2.5 Size Exclusion Chromatography
[0435] The extent of aggregation of the antibody and ADCs
(.about.15 ug, 5 uL injection volume) was assessed by size
exclusion chromatography (SEC) on an ACQUITY UPLC.RTM. Protein BEH
SEC column (200 angstrom, 1.7 .mu.m, 4.6.times.150 mm) (Waters
Corporation, Milford, Mass.) using a mobile phase consisting of 150
mM phosphate, pH 6.8 and a flow rate of 400 uL/min. Detection was
by absorbance at 280 nm.
[0436] The results are shown in FIG. 3 and summarized in Table 11.
The mAb v10000 is highly monomeric by SEC analysis. No significant
increase in aggregation was observed upon conjugation to
Linker-Toxin 001. A comparison of v21252 and v17597 indicates that
the extent of aggregation is unaffected by increasing the DAR from
2 to 4.
TABLE-US-00014 TABLE 11 Summary of SEC Results Ret Time Width Area
Variant Peak # (min) (min) (mAU*s) Area % v10000 1 2.557 0.1243
86.8 1.16 2 2.938 0.1101 7387.6 98.40 3 3.516 0.1452 3.8 0.44
v17597 1 2.532 0.1343 31.0 0.68 2 2.914 0.1370 4491.3 98.69 3 3.477
0.1370 28.6 0.63 v21252 1 2.549 0.1376 76.4 0.98 2 2.936 0.1212
7685.8 98.47 3 3.477 0.1456 43.4 0.56
2.6 Quantitation of Free Toxin and Linker-Toxin by LC-MS-MS
[0437] The residual concentrations of free toxin (Compound 9),
Linker-Toxin 001, and quenched drug linker N-acetyl
cysteine-Linker-Toxin 001 in the ADC formulations were assessed by
liquid chromatography (LC) separation and mass detection, with
reference to standard curves for each analyte. Separations were
performed on a PolymerX.TM. RP-1 column (3 .mu.m, 100 angstrom,
50.times.4 mm) (Phenomenex Inc., Torrance, Calif.) employing a flow
rate of 0.4 mL/min, column temperature of 30.degree. C., and a
gradient of 75% MPA/25% MPB to 60% MPA/40% MPB over 7.8 minutes
(MPA=0.1% aqueous formic acid, and MPB=0.1% formic acid in
acetonitrile). Positive mode ESI-MRM mass detection was achieved on
an Agilent 6470 Triple Quadrupole mass spectrometer (Agilent
Technologies, Santa Clara, Calif.).
[0438] All samples contained <0.1 mol % analyte relative to
total conjugated payload.
2.7 Flow Cytometry Binding Assay on Antigen-Positive Cells
[0439] The binding of ADCs to antigen-positive tumour cell lines
JIMT-1 (breast carcinoma, Addexbio Technologies, San Diego, Calif.)
and RT-112/84 (bladder carcinoma, Sigma-Aldrich, St. Louis, Mo.)
was compared to parental antibody (v10000) binding by flow
cytometry. Cells were cultured as per vendor instructions. Briefly,
cells (50,000 cells/well) were incubated with antibody or ADC
serial dilutions for 90 minutes on ice. Following this incubation,
cells were washed twice and then incubated with an AlexaFluor.RTM.
647 conjugated anti-hIgG (Jackson ImmunoResearch Inc., Westgrove,
Pa.) secondary reagent for 60 minutes on ice. Cells were then
washed twice and fluorescence was analyzed by flow cytometry
(LSRFortessa.TM. X-20 flow cytometer, BD, San Jose, Calif.).
[0440] The results are shown in FIG. 4 and demonstrate that the
binding of v17597 and v21252 to antigen-positive cells is not
affected by conjugation to toxin, with both ADCs showing similar
binding to the parent antibody v10000.
2.8 Endotoxin Testing
[0441] The endotoxin level of formulated ADCs was assessed using a
Limulus Amebocyte Lysate (LAL) gelation end point assay (Genscript
ToxinSensor.TM. Single Test Kit; GenScript, Piscataway, N.J.) with
a 0.125 EU/mL threshold. All ADCs employed in in vivo experiments
(below) were dosed below 5 endotoxin units per kilogram body
mass.
Example 3: In Vitro Activity of Biparatopic ADCs
[0442] The in vitro potency of v17597 and v21252 was measured by a
cell proliferation assay on antigen-positive tumour cells BT-474
(ductal carcinoma, ATCC, Manassas, Va. (HTB-20)), SK-BR-3 (breast
carcinoma, ATCC, Manassas, Va. (HTB-30)), HCC-1954 (breast
carcinoma, ATCC (CRL-2338)), JIMT-1 (breast carcinoma, Addexbio
Technologies, San Diego, Calif., (C0006005)), ZR-75-1 (breast
carcinoma, ATCC (CRL-1500)) and antigen-negative tumour cells
MDA-MB-468 (breast carcinoma, Addexbio Technologies (C0006003)).
Cells were cultured as per vendor instructions. Briefly, on the day
prior to adding the ADC, cells (50 uL/well, 1000 cells/well) were
added to sterile, tissue culture (TC) treated, 384-well plates
(ThermoFisher Scientific, Waltham, Mass.) and incubated overnight
at 37.degree. C./5% CO.sub.2 to allow the cells to adhere to the
plate surface. In a sterile, U-bottom, 96-well plate, ADCs were
diluted in complete growth medium at 4.3-times the desired final
maximum concentration and were titrated 1:3 in the same medium,
creating a 10-point dose response titration. Control wells with no
ADC (growth medium alone) were included on each microtiter 96-well
plate. 15 uL from the 10-point dose response titration were added
into each well of the 384-well plate containing the seeded cells,
in triplicate, and plates were incubated at 37.degree. C./5%
CO.sub.2 for 5 nights. After 5-night incubation, cell viability was
quantified by the addition of 20 uL/well of CellTiter-Glo.RTM.
(Promega, Madison, Wis.) and incubation at room temperature for 30
min. Luminescence was measured using a microplate luminometer. The
collected relative light units (RLU) were converted to %
cytotoxicity using the growth medium alone control mentioned above
(% Cytotoxicity=1-[Well RLU/average medium alone control RLU]).
Data were fit to curves using non-linear regression methods
available with Prism.RTM. software (GraphPad Software, La Jolla,
Calif.).
[0443] The results are shown FIG. 5 and summarized in Table 12. The
results show that both v17597 and v21252 demonstrate selective cell
killing. HER2 expressing cell lines BT-474, SK-BR-3, HCC1954,
JIMT-1, and ZR-75-1 (FIG. 5A-E) were sensitive to both v17597 and
v21252. Both v17597 and v21252 were ineffective against MDA-MB-468
cells (FIG. 5F), which are from a HER2 negative breast carcinoma
cell line.
TABLE-US-00015 TABLE 12 In Vitro Activity of v17597 and v21252
EC.sub.50 (nM) Variant BT-474 SK-BR-3 HCC1954 JIMT-1 ZR-75-1
MDA-MB-468 v17597 0.04 0.04 0.05 0.19 0.21 NA v21252 0.03 0.04 0.06
0.36 0.47 NA
Example 4: In Vitro Proliferation Assay of v10000-Linker-Toxin 001
at Different Average DARs
[0444] ADCs comprised of v10000 conjugated to Linker-Toxin 001 with
an average DAR ranging from 0.7 to 3.9 were prepared by varying the
amount of TCEP (0.5 to 10 molar equivalents) utilized in the
reduction reaction. The conjugation reaction was conducted in
accordance with the procedures outlined in Example 2 and the
resulting ADCs were purified using a 40 kDa Zeba.TM. column,
pre-equilibrated with PBS pH 7.4.
[0445] The in vitro potency of the ADCs was measured by a cell
proliferation assay on antigen-positive tumour cells SK-OV-3
(ovarian carcinoma, ATCC, Manassas, Va. (HTB-77)), JIMT-1 (breast
carcinoma, DSMZ, Braunschweig, Germany (ACC 589)) and ZR-75-1
(breast carcinoma, ATCC (CRL-1500)). Cells were cultured as per
vendor instructions. Briefly, on the day prior to adding ADC, cells
(100 uL/well, 2500 cells/well) were added to sterile, TC treated,
96-well opaque-walled plates (Corning 3904) and incubated overnight
at 37.degree. C./5% CO.sub.2 to allow the cells to adhere to the
plate surface. On the following day, ADCs were diluted in complete
growth medium (96-well U bottom plate) at 5-times the desired final
maximum concentration and were titrated 1:3 in the same medium,
eight steps (9 compound titration points in total). A control
titration point containing growth medium alone was also included,
creating a 10-point dose response titration in total. 25 uL from
the 10-point dose response titration were added into each well of
the 96-well plate containing the seeded cells, in triplicate, and
plates were incubated at 37.degree. C./5% CO.sub.2 for 5 nights.
Following incubation, cell viability was quantified by the addition
of 25 uL/well of CellTiter-Glo.RTM. (Promega Corporation, Madison,
Wis.) and incubation at room temperature for 30 min. Luminescence
was then measured using a microplate luminometer and the collected
relative light units (RLU) were converted to % cytotoxicity as
described in Example 3.
[0446] The results are shown in FIG. 6. The ADCs having average
DARs between 3.9 and 1.6 showed comparable potency across the three
cell-lines, however, the ADC with average DAR0.7 showed a
significant decrease in potency. The approximate amounts of
individual DAR species making up the DAR0.7, DAR2.2 and DAR3.9 ADCs
are shown in Table 13 and FIG. 6D. It can be seen that the DAR0.7
ADC contains approximately three times as much DAR0 species
(approx. 65% vs. approx. 20%) as the DAR1.9 ADC. The DAR2.2 ADC in
turn contains significantly more DAR0 species than the DAR3.9
species (approx. 20% vs. <3%), however, the DAR2.2 ADC showed
comparable in vitro potency to the DAR3.9 ADC. These results
suggest that there may be a threshold for the proportion of DAR0
species an ADC preparation may contain before the potency of the
ADC is impacted.
TABLE-US-00016 TABLE 13 Approximate DAR Distribution for ADCs
Average DAR of DAR Distribution (%) ADC DAR 0 DAR 2 DAR 4 DAR 6 0.7
65 33 2 0 1.6 33 54 11 2 2.2 20 55 19 5 2.6 13 55 22 10 3.2 7 47 26
21 3.9 3 35 27 35
Example 5: Internalization of Biparatopic ADCs into HER2-Expressing
Cells
[0447] To determine internalization of v21252, pHAb Dye (Promega
Corporation, Madison, Wis.) was coupled to amine residues of
v21252, trastuzumab-Linker-Toxin 001 and a negative control ADC
according to manufacturer's recommended protocols. The negative
control ADC was an anti-RSV Protein F antibody conjugated to
Linker-Toxin 001.
[0448] pHAb-conjugated antibodies can be used to monitor
receptor-mediated antibody internalization. Antibody conjugated
with pHAb Dye bound to antigen on the cell membrane exhibits
minimal fluorescence, but after receptor-mediated internalization
and traffic through the endosome and lysosomal system, the
antibody-pHAb conjugate is exposed to more acidic pH, causing the
antibody-pHAb conjugate to fluoresce.
[0449] pHAb conjugated v21252, pHAb conjugated
trastuzumab-Linker-Toxin 001 and pHAb conjugated control were
incubated with the HER2 expressing cell lines SKBR3 and JIMT-1.
Briefly, SKBR3 and JIMT-1 HER2+ tumour cells were seeded into a
384-well black optical bottom plate (ThermoFisher Scientific,
Waltham, Mass.) at 5,000 cells/well in assay media. The plate was
incubated overnight at 37.degree. C.+5% CO.sub.2. The following
day, pHAb-conjugated antibodies were added to plates at 10 ug/ml
and 1 ug/mL final in assay media. Media containing Vybrant.RTM.
DyeCycle.TM. Violet stain (ThermoFisher Scientific, Waltham, Mass.)
was added at 2 uM final concentration to visualize nuclei. The
plate was incubated at 37.degree. C.+5% CO.sub.2 between time
points. Sample wells were scanned at various time points on the
CellInsight.TM. CX5 High Content Screening (HCS) Platform
(ThermoFisher Scientific, Waltham, Mass.). The plate was scanned
using a 20.times. objective on the SpotAnalysis Bioapplication with
2 channels. Channel 1 (385 nm, Vybrant Dye Cycle Violet) was used
as the focus channel and Channel 2 (560 nm, pHAb) was used to
obtain internalization data. Fluorescence of internalized
pHAb-conjugated antibodies was measured using the parameter "Mean
Total Spot Intensity."
[0450] The results are shown in FIGS. 13 and 14 and show that
v21252 internalizes and traffics to lysosomes in HER2 expressing
cells to a greater level than the monospecific
trastuzumab-Linker-Toxin 001.
Example 6: In Vivo Activity of Biparatopic ADCs
6.1 ADCs v17597 and v21252 Inhibit HBCx-13b Breast Cancer Patient
Derived Xenograft Growth
[0451] Female athymic mice (Envigo, Huntingdon, UK) were
subcutaneously implanted with a 20 mm.sup.3 tumour fragment (n=7
per group). Once tumours reached 75 to 200 mm3 in size, animals
were assigned to treatment groups and v17597, v21252 or vehicle
were dosed by intravenous injection for a total of 2 doses on day 1
and day 15 (q14d x2) as indicated in FIG. 7. Tumour measurements
were performed with a caliper biweekly. Mice were ethically
sacrificed when tumours reached a size of 1764 mm.sup.3. Tumour
volumes are reported as the mean.+-.SEM for each group.
[0452] FIG. 7A provides the results for the tumour response in mice
subcutaneously implanted with HBCx-13b tumour fragments after i.v.
administration of vehicle or v17597. FIG. 7B provides the results
for the tumour response in mice subcutaneously implanted with
HBCx-13b tumour fragments after i.v. administration of vehicle or
v21252. These results show that treatment of HBCx-13b engrafted
mice with either v17597 or v21252 results in a tumour volume
reduction in a dose-dependent manner.
6.2 ADCs v17597 and v21252 Inhibit ST-910 Breast Cancer Patient
Derived Xenograft Growth
[0453] Female athymic nude mice (Charles Rivers Laboratories,
Wilmington, Mass.) were subcutaneously implanted with a .about.70
mg tumour fragment (n=6 per group). Once tumours reached 125 to 250
mm.sup.3 in size, animals were assigned to treatment groups and
v17597, v21252 or vehicle were dosed by intravenous single
injection as indicated in FIG. 8. Tumour measurements were
performed with a digital caliper biweekly. Mice were ethically
sacrificed when tumours reached a size of 2000 mm.sup.3. Tumour
volumes are reported as the mean.+-.SEM for each group.
[0454] FIG. 8A provides the results for the tumour response in mice
subcutaneously implanted with ST-910 tumour fragments after i.v.
administration of vehicle or v17597. FIG. 8B provides the results
for the tumour response in mice subcutaneously implanted with
ST-910 tumour fragments after i.v. administration of vehicle or
v21252. These results show that treatment of ST-910 engrafted mice
with either v17597 or v21252 results in a tumour volume reduction
in a dose-dependent manner.
[0455] ST-910 is a patient derived xenograft (PDX) that represents
HER2 1+ breast cancer while HBCx-13b (used in Example 6.1) is a PDX
that represents HER2 3+ breast cancer. Examples 6.1 and 6.2 thus
demonstrate that both v17597 and v21252 are active in both HER2 3+
and HER2 1+ tumours.
6.3 Pharmacokinetic Analysis
[0456] For the patient derived xenografts, HBCx-13b and ST-910,
pharmacokinetic samples for total antibody (unconjugated and
conjugated antibody) were collected at pre-specified time points
and were evaluated using an ELISA-based assay for total antibody
quantification. Serum concentrations for total antibody for either
v21252 or v17597 were analyzed by first coating 384-well ELISA
plates with goat anti-human IgG Fc antibody (Jackson
ImmunoResearch, West Grove, Pa.) in PBS pH 7.4 and incubating at
4.degree. C. overnight. The following day, plates were washed and
blocked using assay diluent and incubated at RT for 1 hr. After
blocking, standard curve samples, controls, and diluted serum
samples were added to the plates and incubated at RT for 1 hr.
Detection antibody, HRP-goat anti-human IgGF(ab').sub.2 conjugate
(Jackson ImmunoResearch), was then added to the plates and after
1-hr incubation at RT, HRP substrate,
3,3',5,5'-tetramethylbenzidine (TMB), was added to plates. TIB was
quenched using HCl and absorbance was measured at 450 nm using a
plate reader. FIG. 15 shows the total antibody serum
concentration-time profile for HBCx-13b (A) and ST-910 (B).
Example 7: Single-Dose Pharmacokinetics/Tolerability Study of
v17597 and v21252 in Cynomolgus Monkeys
[0457] The objective of this study was to characterize the
pharmacokinetics (PK) and tolerability of v17597 and v21252 in
cynomolgus monkeys following a single intravenous (IV) infusion
administration. The cynomolgus monkey was selected for the
nonclinical safety assessment of both v17597 and v21252 based on
sequence homology and binding affinity. Human and cynomolgus monkey
HER2 share 98% sequence homology, whereas the sequence homology for
dog and mouse/rat HER2 is 93% and 88%, respectively. In addition,
v17597 and v21252 bind to cynomolgus monkey HER2 with similar
affinity to human HER2 (monkey K.sub.D=0.55.times.10.sup.-9; human
K.sub.D=0.83.times.10.sup.-9) and do not bind to dog, mouse or rat
HER2.
[0458] The study demonstrates that a single-dose of v17597 at doses
of 3, 6 or 9 mg/kg was well tolerated, and that a single-dose of
v21252 at doses of 9 or 12 mg/kg was well tolerated.
Materials and Methods
Tolerability
[0459] A single dose of v17597 (3, 6 or 9 mg/kg) or v21252 (9 mg/kg
or 12 mg/kg) was administered by IV infusion over 60 minutes in
female cynomolgus monkeys (N=3). General tolerability was assessed
with clinical observations, body weight, food consumption, and
clinical pathology (hematology and clinical chemistry). Blood was
collected throughout the study for bioanalytical analysis of v17597
or v21252, total antibody, and free toxin (Compound 9). The study
design is summarized in Table 14.
TABLE-US-00017 TABLE 14 Design of Single-Dose Pharmacokinetic and
General Tolerability Study in Cynomolgus Monkeys v17597 Dose v21252
Dose Number of Group (mg/kg) (mg/kg) Females 1 0 0 3 2 3 -- 3 3 6
-- 3 4 9 -- 3 5 -- 9 3 6 -- 12 3
Bioanalytical Methods
[0460] v17597 and v21252: Serum concentrations of v17597 or v21252
(DAR of 1 or greater) were analyzed using an
Electrochemiluminescence assay with Meso Scale Discovery platform
(ECL/MSD) (Meso Scale Diagnostics, LLC, Rockville, Md.) with
anti-toxin mouse IgG as the capture agent and anti-pertuzumab
sulfo-TAG as the detection agent.
[0461] Total Antibody: The total antibody bioanalytical assay
measured the antibody component of v17597 or v21252 regardless of
whether the antibody component was conjugated with toxin (at all
DARs) or not. Serum concentrations of total antibody were analyzed
using an Electrochemiluminescence assay with Meso Scale Discovery
platform (ECL/MSD) with anti-pertuzumab antibody as the capture
agent and anti-trastuzumab sulfo-TAG as the detection agent.
[0462] Toxin (Compound 9): Serum concentrations of toxin were
analyzed using a LC-MS/MS method. Serum samples were precipitated
with acetonitrile/methanol (50:50, v/v) and supernatants were
analyzed. The liquid chromatography system used was a reverse phase
column with a gradient flow consisting of water/acetic acid
(100/0.05, v/v) and acetonitrile. Toxin and the internal standard
(toxin-d4; deuterated Compound 9) were detected using a triple
quadrupole mass spectrometer system equipped with an electrospray
ionization (ESI) source operated in the positive ion mode.
Pharmacokinetic Analysis
[0463] Non-compartmental analysis of the serum sample bioanalytical
results was used to derive PK parameters (maximum serum
concentration [C.sub.max], terminal half-life [T.sub.1/2],
clearance [CL] and apparent volume of distribution [V.sub.ss]).
Results
Pharmacokinetics
[0464] v17597: v17597 exposure was generally dose proportional
between 3 to 9 mg/kg. C.sub.max was achieved at the end of the
60-minute infusion (median Tmax) and increased in a
dose-proportional manner. Systemic exposure (AUC.sub.0-.infin.)
increased in a slightly greater than dose-proportional manner.
Preliminary mean terminal half-life (T.sub.1/2) generally appeared
to increase with increasing dose, clearance (CL) generally appeared
to decease with increasing dose and apparent volume of distribution
(V.sub.ss) generally did not appear to change with dose.
[0465] v21252: v21252 exposure was generally dose proportional
between 9 to 12 mg/kg. C.sub.max was achieved at the end of the
60-minute infusion (median Tmax) and increased in a
dose-proportional manner. The v21252 serum concentration-time
profile is shown in FIG. 9A. Systemic exposure (AUC.sub.0-.infin.)
increased in a slightly greater than dose-proportional manner.
Preliminary mean terminal half-life (T.sub.1/2), clearance (CL) and
apparent volume of distribution (V.sub.ss) generally did not appear
to change with dose.
[0466] Total Antibody (conjugated and non-conjugated): Maximum
serum concentration of total antibody (C.sub.max) was achieved at
the end of the 60-minute infusion (median T.sub.max). The total
antibody serum concentration-time profile of v21252 is shown in
FIG. 9B. A non-compartment model was used to derive PK parameters.
C.sub.max increased in a dose-proportional manner, while
AUC.sub.0-.infin. increased in a slightly greater than
dose-proportional manner for both v17597 and v21252. The mean
terminal half-life of v17597 increased with increasing dose, while
serum clearance (CL) and total apparent volume of distribution
(V.sub.ss) of total antibody decreased with increasing dose. The
mean terminal half-life and total apparent volume of distribution
(V.sub.ss) of v21252 increased with increasing dose, while serum
clearance (CL) of total antibody decreased with increasing
dose.
[0467] Toxin (Compound 9): Following administration of a single
dose of v17597 (3, 6 or 9 mg/kg) or v21252 (9 mg/kg or 12 mg/kg),
all toxin serum concentrations were below the lower limit of
quantitation (LLOQ, <5.00 ng/mL).
Tolerability
[0468] A single-dose of v17597 (3, 6 or 9 mg/kg) or v21252 at doses
of 9 or 12 mg/kg was well tolerated. There was no mortality during
the course of the study. No treatment-related effects were noted in
clinical observations, food consumption, or body weight.
[0469] Minimal to mild changes in clinical pathology parameters
that were considered treatment-related were observed in some
animals. There were no test article-related effects among
hematology endpoints in any treatment group. All fluctuations were
considered within expected ranges for biological and/or
procedure-related fluctuation despite any apparent differences
among individual values.
Example 8: Non-GLP Toxicity Study of v17597 in Cynomolgus
Monkeys
[0470] A non-GLP toxicity study was conducted to investigate the
toxicokinetics and toxicity of v17597 in cynomolgus monkeys. The
study was designed based on results from the single-dose
pharmacokinetic/tolerability study in female cynomolgus monkeys
(Example 6).
[0471] The study demonstrated that administration of v17597 weekly
at doses of 2.25 and 4.5 mg/kg, and bi-weekly at doses of 4.5 and 9
mg/kg was not well tolerated in male and female cynomolgus monkeys.
The no adverse effect level (NOAEL) and the highest non-severely
toxic dose (HNSTD) for v17597 following weekly or bi-weekly
administration for up to 6 weeks was considered to be less than
2.25 mg/kg administered weekly or 4.5 mg/kg administered
bi-weekly.
Materials and Methods
[0472] Vehicle or v17597 was administered by a 1-hr IV infusion
weekly on Days 1, 8, 15, 22, 29 and 36 at doses 0, 2.25 and 4.5
mg/kg, and once every other week on Days 1, 15 and 29 at doses of
4.5 and 9 mg/kg. All animals were evaluated for changes in clinical
signs, food consumption, body weight, blood pressure, ECGs,
respiration rates (visual), clinical pathology (hematology,
clinical chemistry, coagulation, urinalysis), organ weights, and
macroscopic/microscopic examination of tissues. Blood was collected
for toxicokinetic analysis and anti-drug antibody (ADA) analysis.
Animals dosed weekly were terminated on Day 42 and animals dosed
every other week were terminated on Day 36. The study design is
presented in Table 15.
TABLE-US-00018 TABLE 15 Study Design Group Dose (mg/kg) Dose
Regimen No. of Animals 1 0 Weekly 3M/3F 2 2.25 Weekly 3M/3F 3 4.5
Weekly 3M/3F 4 4.5 Every other week 3M/3F 5 9 Every other week
3M/3F
Results
[0473] Based on body weight, clinical observations, and clinical
pathology findings, v17597 was considered to be adverse at all
doses tested in this study. Animals at 9 mg/kg/dose (bi-weekly) and
one female at 4.5 mg/kg/dose (bi-weekly) were terminated early and
only received doses on Days 1 and 15.
[0474] Based on the results of this study, the no adverse effect
level (NOAEL) and the highest non-severely toxic dose (HNSTD) for
v17597 following weekly or bi-weekly administration for up to 6
weeks was considered to be less than 2.25 mg/kg administered weekly
or 4.5 mg/kg administered bi-weekly.
Example 9: Non-GLP Toxicity Study of v21252 in Cynomolgus
Monkeys
[0475] The objective of this study was to further characterize the
toxicokinetics and toxicity of v21252.
[0476] The study demonstrated that administration of v21252 on Days
1, 15 and 29 at doses up to 12 mg/kg was clinically well tolerated
in male and female cynomolgus monkeys. The no observed adverse
event level (NOAEL) was 12 mg/kg and the highest non-severely toxic
dose (HNSTD) was greater than 12 mg/kg.
Materials and Methods
[0477] In this study, vehicle or v21252 was administered to male
and female cynomolgus monkeys by a 1-hr IV infusion once every
other week on Days 1, 15 and 29 at doses of 0, 9 and 12 mg/kg (3
animals per sex at each dose level). All animals were evaluated for
changes in clinical signs, food consumption, body weight, blood
pressure, ECGs, respiration rates (visual), clinical pathology
(hematology, clinical chemistry, coagulation, urinalysis), organ
weights, and macroscopic/microscopic examination of tissues. Blood
was collected for toxicokinetic (TK) analysis (v21252, total
antibody, and free toxin (Compound 9)) and anti-drug antibody (ADA)
analysis, and the animals were terminated on Day 36. Another group
of animals was administered a single dose of 12 mg/kg v21252 on Day
1 and terminated 4, 8 and 15 days post dose (n=2 per timepoint).
The study design is presented in Table 16.
TABLE-US-00019 TABLE 16 Non-GLP Toxicity Study Design v21252 Dose
Day Animals Terminated (Male/Female) Group (mg/kg) 4 8 15 36 1 0 --
-- -- 3/3 2 12 1/1 1/1 1/1 -- 3 9 -- -- -- 3/3 4 12 -- -- --
3/3
Results
Pharmacokinetics
[0478] v21252: Pharmacokinetics were calculated after repeat
administration of v21252. C.sub.max was achieved either at the end
of the 60-minute infusion or 60 minutes after the end of infusion
(median T.sub.max). The v21252 serum concentration-time profile is
shown in FIG. 10. On Day 1, C.sub.max and systemic exposure
(AUC.sub.0-168h) increased in a slightly greater than
dose-proportional manner. On Day 29, C.sub.max and AUC.sub.0-168h
increased in an approximately dose-proportional manner. Systemic
exposure and AUC.sub.0-168h did not appear to change and showed no
accumulation following repeated administration. Mean elimination
half-lives (T.sub.1/2) increased from the 9 mg/kg group to the 12
mg/kg group. A saturable clearance mechanism for v21252 may account
for the difference in T.sub.1/2 and clearance between the low (9
mg/kg) and high (12 mg/kg) dose groups.
[0479] Total Antibody (conjugated and unconjugated): Total antibody
was measured in cynomolgus monkeys after the repeat administrations
of v21252. The C.sub.max for total antibody was achieved at the end
of the 60-minute infusion (median T.sub.max). The total antibody
serum concentration-time profile is shown in FIG. 11. On Day 1,
C.sub.max and systemic exposure (AUC.sub.0-168h) increased in a
slightly greater than dose-proportional manner. On Day 29,
C.sub.max and AUC.sub.0-168h increased in an approximately
dose-proportional manner. Systemic exposure AUC.sub.0-168h was
unchanged and showed no accumulation following repeated
administrations. Similar to v21252, mean elimination half-lives
(T.sub.1/2) for total antibody increased from the 9 mg/kg group to
the 12 mg/kg group.
[0480] The pharmacokinetics of v21252 as indicated by the serum
concentration-time profiles of v21252 and Total Antibody are
indicative of minimal linker-toxin loss from v21252 in vivo (see
FIG. 12).
[0481] Toxin (Compound 9): Free toxin was measured in cynomolgus
monkeys after the repeat administrations of v21252. All payload
(Compound 9) serum concentrations were below the limit of
quantitation (<0.500 ng/mL) with the exception of one female at
12 mg/kg on Day 1, one female at 9 mg/kg on Day 29, and one male at
12 mg/kg on Day 29.
[0482] Anti-drug Antibodies (ADA): Anti-v21252 antibodies were
screened in cynomolgus monkeys following the repeat administrations
of v21252. ADA were detected in serum of a single female in the 9
mg/kg dosing cohort.
Toxicity
[0483] Overall, administration of v21252 was clinically well
tolerated at all doses tested. No treatment related changes in
urinalysis, ECG parameters, or respiratory rates were observed.
[0484] Sporadic, minimal effects on individual body weights were
noted in animals receiving repeat administrations of v21252 at 12
mg/kg/dose. These animals all partially or fully recovered by Day
35. All other animals either maintained or gained weight throughout
the study.
[0485] Minimal to mild changes in clinical signs, clinical
pathology, organ weight or macroscopic/microscopic examination of
tissues were observed in some animals. Macroscopic observations
considered related to v21252 were limited to red discoloration
observed at the infusion site in all animals, including controls.
Test article-related organ weight changes were limited to the
spleen. In animals terminated on Day 36 following 3 bi-weekly
doses, microscopic treatment-related effects included changes in
the gastrointestinal tract, liver, spleen, lymph nodes, pancreas,
skin and the IV infusion sites. All were classified as minimal or
mild. In animals terminated at various times after a single dose of
12 mg/kg, similar minimal to mild test article-related effects were
observed.
[0486] The PK analysis confirmed systemic exposure in the
v21252-treated animals and mean systemic exposure increased with
increasing dose in a dose proportional manner for v21252 and total
antibody, while exposure to free toxin (Compound 9) was only seen
at low levels in a few animals.
[0487] Tables 17-20 show a comparison of the results from the
PK/tolerability studies and the non-GLP repeat dose studies for
v17597 and v21252.
TABLE-US-00020 TABLE 17 Comparison of Mortality Observed in
Single-Dose and Repeat- Dose Studies for v17597 and v21252 in
Cynomolgus Monkeys v17597 Repeat-Dose v21252 PK/ Every PK/ Toler-
Other Toler- Repeat- Dose ability Weekly week ability Dose 12 mg/kg
-- -- -- 0/3 0/6 9 mg/kg 0/3 -- 3/6 0/3 0/6 6 mg/kg 0/3 -- -- -- --
4.5 mg/kg -- 0/6 1/6 -- -- 3 mg/kg 0/3 -- -- -- -- 2.25 mg/kg --
0/6 -- -- --
TABLE-US-00021 TABLE 18 Comparison of NOAEL and HNSTD Determined in
Repeat-Dose Studies for v17597 and v21252 in Cynomolgus Monkeys
v17597 Weekly Every Other week v21252 NOAEL Could not Could not 12
mg/kg be determined be determined (<2.25 mg/kg) (<4.5 mg/kg)
HNSTD Could not Could not >12 mg/kg be determined be determined
(<2.25 mg/kg) (<4.5 mg/kg)
TABLE-US-00022 TABLE 19 ADC Bioanalytical Analysis AUC.sub.0-336 hr
AUC.sub.0-168 hr AUC.sub.0-336 hr First Dose AUC.sub.0-168 hr Last
Dose First Dose Fold Last Dose Fold Drug and Dose (hr*ug/mL)
Difference.sup.# (hr*ug/mL) Difference.sup.# v17597 9,920 1 7,180 1
4.5 mg/kg v17597 24,600 2.2 N/A N/A 9 mg/kg v21252 18,800 1.9
18,700 2.60 9 mg/kg v21252 34,900 3.5 17,700 2.47 12 mg/kg
.sup.#compared to v17597 @ 4.5 mg/kg
TABLE-US-00023 TABLE 20 Total Antibody Bioanalytical Analysis
AUC.sub.0-336 hr AUC.sub.0-168 hr AUC.sub.0-336 First Dose
AUC.sub.0-168 Last Dose First Dose Fold Last Dose Fold Drug and
Dose (hr*ug/mL) Difference (hr*ug/mL) Difference v17597 8,090 1
7,530 1 4.5 mg/kg v17597 18,700 2.3 N/A N/A 9 mg/kg v21252 17,400
2.2 13,900 1.8 9 mg/kg v21252 37,400 4.6 20,600 2.7 12 mg/kg
.sup.#compared to v17597 @ 4.5 mg/kg
Conclusions
[0488] Auristatin analogues of general Formula (I) have been shown
to have good in vivo tolerability when administered to mice.
Conjugation of Compound 9 to the monospecific anti-HER2 antibody
trastuzumab at an average DAR4 produced an ADC that showed
excellent tolerability in cynomolgus monkeys with a highest
non-severely toxic dose (HNSTD) of 18 mg/kg. In contrast, the ADC
comprising Compound 9 conjugated to an anti-HER2 biparatopic
antibody, v10000, at an average DAR4 (v17597) showed greatly
decreased tolerability with a HNSTD of less than 4.5 mg/kg (Example
8). Without being limited to any particular theory, it is proposed
that the decreased tolerability observed for v17597 may be due in
part to the increased on-target binding and internalization of the
biparatopic antibody compared to the monospecific trastuzumab,
leading to increased on-target toxicity, and/or a decreased
proportion of DAR0 or naked species in average DAR4 (v17597)
compared to average DAR2 (v21252) that increases the toxicity
associated with higher DAR species (DAR2, DAR4 and DAR6), and/or
increased proportion of DAR6 species in average DAR4 compared to
average DAR2 increasing the toxicity associated with the highest
DAR species.
[0489] Surprisingly, however, the ADC comprising Compound 9
conjugated to v10000 at an average DAR2 (v21252) showed much
improved tolerability with a HNSTD of 12 mg/kg (Example 9). This
result is unexpected as it has previously been shown that the
toxicity of ADCs comprising either monomethyl auristatin E (MMAE)
or a maytansinoid directly correlates with the total amount of drug
attached to the antibody, i.e. the relationship between DAR and the
maximum tolerated dose is linear for ADCs (Hamblett, et al., Clin.
Cancer Res., 10:7063-7070 (2004); Sun, et al., Bioconj Chem.,
28:1371-81 (2017)). Specifically, the maximum tolerated dose of an
ADC with 8 drug molecules per antibody was 50 mg/kg, and the
maximum tolerated dose of an ADC with 4 drug molecules per antibody
(i.e. half the amount of toxin) was 100 mg/kg (Hamblett, et al.,
ibid.). That is, an ADC with half the amount of toxin of the DAR8
ADC, when administered at the same antibody dose, showed an MTD
that was twice that of the DAR8 ADC.
[0490] v21252 has a DAR of 2 and thus half the amount of toxin as
v17597 when administered at the same antibody dose. Based on
previous studies with v17597, therefore, the amount of v21252 that
would be tolerated was expected to be less than 9 mg/kg (i.e.
2.times. the maximum dose tolerated for v17597). However, as shown
in Example 9, v21252 administered to cynomolgus monkeys at doses of
either 9 or 12 mg/kg every two weeks for three doses was tolerated
and 12 mg/kg was designated as a no observed adverse event level
(NOAEL).
[0491] Importantly, it should be noted that v21252 has less
toxicity and more tolerability compared to v17597 when dosed
bi-weekly, even though it has greater exposure. Based on the
non-GLP toxicology study in the cynomolgus monkeys (Example 8),
v17597 was considered to have adverse findings at both bi-weekly
doses of 4.5 and 9 mg/kg. However, in a similar non-GLP study
(Example 9), v21252 was not considered to have adverse findings at
bi-weekly doses of both 9 mg/kg and 12 mg/kg, despite having
approximately 1.8 to 4.6 fold increases in exposure
(AUC.sub.0-336hr after first dose or AUC.sub.0-168hr last dose)
compared to 4.5 mg/kg of v17597 (summarized in Tables 19 and
20).
[0492] In addition, v21252 demonstrated in vivo efficacy at
exposure levels shown to be tolerated in cynomolgus monkeys.
Specifically, complete responses were achieved in patient derived
xenograft models of both high HER2 and low HER2 tumours at
exposures tolerated in cynomolgus monkeys, as summarized in FIG. 15
(see also, Example 6).
Example 10: GLP Toxicity Study of v21252 in Cynomolgus Monkeys
[0493] In a subsequent GLP toxicity study, v21252 was administered
to cynomolgus monkeys every two weeks at 0, 6, 12 and 18 mg/kg for
4 doses, with a 6 week recovery period. The highest non-severely
toxic dose (HNSTD) was determined to be 18 mg/kg. v21252 was well
tolerated at all doses. No clinical observations were considered
adverse and no mortality was observed in this GLP study. The only
consistent clinical observation was increased diarrhea. No change
in body weight was observed at all doses and no clinical pathology
findings (liver function--aspartate transaminase and alanine
transaminase and hematology--neutrophils, platelets, hemoglobin,
and lymphocytes) were considered adverse. The exposure (C.sub.max
and AUC.sub.0-168hr) of v21252 was virtually identical to that of
v10000 (antibody alone). Details of the study are provided
below.
[0494] The objective of this GLP study was to further characterize
the toxicokinetics and toxicity of v21252 administered 4 times
intravenously to cynomolgus monkeys.
[0495] In the GLP toxicity study, v21252 was administered to male
and female cynomolgus monkeys on Days 1, 15, 29 and 43 at doses of
0, 6, 12 and 18 mg/kg, with a 6 week recovery period. The no
observed adverse event level (NOAEL) was 12 mg/kg and the highest
non-severely toxic dose (HNSTD) was 18 mg/kg.
Materials and Methods
[0496] In this study, vehicle or v21252 was administered to male
and female cynomolgus monkeys by a 1-hr IV infusion once every
other week on Days 1, 15, 29 and 43 at doses of 0, 6, 12 and 18
mg/kg (4 animals per sex at each dose level and an additional 2
animals per sex at 0, 12 and 18 mg/kg for recovery evaluation). All
animals were evaluated for changes in clinical signs, food
consumption, body weight, blood pressure, ECGs, respiration rates
(visual), clinical pathology (hematology, clinical chemistry,
coagulation, urinalysis), organ weights, and
macroscopic/microscopic examination of tissues. Blood was collected
for toxicokinetic (TK) analysis (v21252, total antibody, and free
toxin (Compound 9)) and anti-drug antibody (ADA) analysis, and the
animals were terminated on Day 50 and after 6 weeks recovery at Day
92. The study design is presented in Table 21.
TABLE-US-00024 TABLE 21 GLP Toxicity Study Design v21252 Dose
Animals Terminated on Day (Male/Female) Group (mg/kg) D50 D92 1 0
4/4 2/2 2 6 4/4 -- 3 12 4/4 2/2 4 18 4/4 2/2
Results
Pharmacokinetics
[0497] v21252: Median peak v21252 serum concentrations were
observed by 1 hr following the start of infusion (SOI) on Days 1
and 43. Following bi-weekly administration of v21252, mean
C.sub.max and AUC values for v21252 increased with increasing dose.
Increases in C.sub.max were approximately proportional to dose on
Day 1. On Day 1, a 1:2:3 fold increase in v21252 dose resulted in
an approximate 1:2.3:3.3 fold increase in C.sub.max values, an
approximate 1:2.6:3.8 fold increase in mean AUC.sub.0-168hr values,
and an approximate 1:2.9:4.5 fold increase in AUC.sub.0-336hr
values. On Day 43, C.sub.max and AUC.sub.0-168hr were approximately
dose proportional. On Day 43, a 1:2:3 fold increase in v21252 dose
resulted in an approximate 1:2.5:3.5 fold increase in C.sub.max
values and an approximate 1:3.2:4.7 fold increase in
AUC.sub.0-168hr values. Systemic exposure to v21252 did not appear
to change following repeated bi-weekly IV infusion at 6 mg/kg,
however, the exposure generally appeared to increase following
repeated bi-weekly IV infusion at 12 and 18 mg/kg. The mean
AUC.sub.0-168hr accumulation ratios were 1.20, 1.47 and 1.50 at 6,
12 and 18 mg/kg, respectively. Individual AUC.sub.0-168hr
accumulation ratios ranged from 1.01 to 1.64 at 6 mg/kg, from 1.17
to 1.95 at 12 mg/kg, and from 0.983 to 2.08 at 18 mg/kg.
[0498] Total Antibody (conjugated and unconjugated): Median peak
Total Antibody serum concentrations were observed by 1 hr following
the SOI of v21252 on Days 1 and 43. Following bi-weekly
administration of v21252, mean C.sub.max and AUC.sub.0-168hr values
for Total Antibody increased with increasing dose. On Day 1, a
1:2:3 fold increase in v21252 dose resulted in an approximate
1:2.1:3.3 fold increase in C.sub.max values, an approximate
1:2.4:3.8 fold increase in AUC.sub.0-168hr values, and an
approximate 1:2.8:4.5 fold increase in mean AUC.sub.0-336hr values.
On Day 43, a 1:2:3 fold increase in v21252 dose resulted in an
approximate 1:2.6:3.9 fold increase in C.sub.max values and in an
approximate 1:3.1:4.8 fold increase in AUC.sub.0-168hr values.
Systemic exposure to Total Antibody did not appear to change
following repeated bi-weekly IV infusion of v21252 at 6 mg/kg,
however, but did appear to increase following repeated bi-weekly IV
infusion of v21252 at 12 and 18 mg/kg. The mean AUC.sub.0-168hr
accumulation ratios were 1.20, 1.47 and 1.50 at 6, 12 and 18 mg/kg,
respectively.
[0499] Toxin (Compound 9): Free toxin was measured after the repeat
administrations of v21252. Most toxin (Compound 9) serum
concentrations were below the limit of quantitation (<0.500
ng/mL). The following exceptions were noted: one female at 12 mg/kg
on Day 43 had a single quantifiable toxin (Compound 9)
concentration (0.513 ng/ml at 72 hr post dose); one male at 18
mg/kg on Day 29 had a single quantifiable toxin (Compound 9)
concentration (0.532 ng/mL at 1 hr following the SOI); two males
and two females at 18 mg/kg on Day 43 each had a single
quantifiable toxin (Compound 9) concentration (0.555, 0.505, 0.556
and 0.653 ng/mL, respectively, at 24 hr following the SOI); and one
male at 18 mg/kg on Day 43 had four consecutive quantifiable toxin
(Compound 9) concentrations with an AUC.sub.0-168hr value of 125
hr*ng/mL.
[0500] Anti-drug Antibodies (ADA): A total of 144 samples from all
dosing cohorts were screened for ADA. Seven samples were confirmed
positive in the confirmatory/immunodepletion assay, including one
control animal and a pretest sample from a treated animal. These
latter two samples were deemed to be due to pre-existing reactive
antibodies and not related to v21252 exposure. For the five
remaining positive samples, one female dosed at 18 mg/kg had a
detectable titer on Day 43, and the remaining 4 animals (2 females
dosed at 12 mg/kg and one male and one female dosed at 18 mg/kg)
had detectable titers at the Day 92 recovery point. Although the
actual anti-v21252 antibody results do not suggest a strong
immunogenic response in most animals, circulating v21252 could be
binding with anti-v21252 antibodies, limiting the detection of the
antibodies within this assay format. However, it is unlikely that
ADA significantly impacted the PK of v21252 as no changes in the
serum concentration time data were observed on dosing Day 43 in
comparison with dosing Day 1.
Toxicity
[0501] Repeat-dose administration of v21252 (every other week
.times.4) was generally well tolerated. There were no
v21252-related deaths and no effects noted in ophthalmic and
electrocardiographic evaluations, visual respiration rates,
urinalysis, or troponin I assessments. There were no v21252-related
changes in body weight parameters noted during the treatment or
recovery periods following administration of v21252.
[0502] Increased incidence of soft/watery faeces was noted in
animals administered repeated doses of v21252 at .gtoreq.6 mg/kg.
In addition, sporadic inappetence was noted in male and female
animals at 18 mg/kg and hunched posture was sporadically noted in
female animals at 18 mg/kg. Following the recovery period,
inappetence and hunched posture were absent while the incidence of
soft/watery faeces decreased or resolved, suggesting reversal of
v21252-related effects. During the study, animals were provided
with fluid/nutritional supplementation (frozen Gatorade and
PeptoPro.RTM. diet) due to repeated observations of soft/liquid
faeces. Females receiving repeated administration of v21252
received fluid and/or nutritional supplementation from Day 4 (6 and
18 mg/kg) or Day 8 (12 mg/kg) until the end of the treatment
period. Similarly, males receiving repeated administration of
v21252 received fluid and/or nutritional supplementation from Day 8
(12 mg/kg) or Day 7 (18 mg/kg) until the end of the treatment
period. No fluids or supplementation were provided during the
recovery.
[0503] The clinical pathological findings were not considered to be
adverse because of the limited severity and the reversibility of
the findings. Test article-related hematology changes included:
increases in monocyte counts, morphologic alterations in
neutrophils, decreases in reticulocyte counts and red cell mass
(RBC, hemoglobin and hematocrit) with concomitant increase in red
blood cell distribution width. There were minimal to mild increases
in mean fibrinogen concentrations relative to baseline means at
Days 8 through 50 in males at 18 mg/kg and in females at .gtoreq.12
mg/kg. These changes were test article-related and indicative of an
immune or inflammatory stimulus. These changes had resolved at Day
92. Treatment-related changes were observed in AST, phosphorus,
total protein, albumin, globulin and citrulline.
[0504] Tables 22-25 show a comparison of the results from the
non-GLP repeat dose studies for v17597 and v21252 and the GLP study
for v21252.
TABLE-US-00025 TABLE 22 Comparison of Mortality Observed in Every
Other Week Repeat- Dose Studies for v17597 and v21252 in Cynomolgus
Monkeys v17597 - DAR 4 Cumulative v21252 - DAR 2 Mortality/ Toxin
Dose Mortality/ Cumulative Total Prior to Total Toxin Dose Animals
Mortality animals Dose 18 mg/kg -- -- 0/12 1.44 mg/kg 12 mg/kg --
-- 0/6 0.72 mg/kg 0/12 0.96 mg/kg 9 mg/kg 3/6 0.36 mg/kg 0/6 0.54
mg/kg 6 mg/kg -- -- 0/12 0.48 mg/kg 4.5 mg/kg 1/6 0.36 mg/kg --
--
TABLE-US-00026 TABLE 23 Comparison of NOAEL and HNSTD Determined in
Every Other Week Repeat-Dose Studies for v17597 and v21252 in
Cynomolgus Monkeys v17597 - DAR 4 v21252 - DAR 2 (Cumulative Toxin
Dose) (Cumulative Toxin Dose) NOAEL Could not be determined <4.5
mg/kg 12 mg/kg (<0.54 mg/kg) (0.96 mg/kg) HNSTD Could not be
determined <4.5 mg/kg 18 mg/kg (<0.54 mg/kg) (1.44 mg/kg)
TABLE-US-00027 TABLE 24 Comparison of ADC PK Parameters for v17597
DAR4 and v21252 DAR2 (Toxin Dose Matched) AUC.sub.0-336 hr Half
life First Dose Fold First Dose Fold Toxin Dose Drug (Dose)
(hr*ug/mL) Difference.sup.# (Hours) Difference.sup.# 0.18 mg/kg
v17597 DAR4 9,920 1 39 1 (4.5 mg/kg) v21252 DAR2 18,800 1.9 85.6
2.2 (9 mg/kg) 0.36 mg/kg v17597 DAR4 24,600 1 103 1 (9 mg/kg)
v21252 DAR2 49,800 2.0 179 1.7 (18 mg/kg) .sup.#compared to v17597
DAR4 @ 4.5 and 9 mg/kg
TABLE-US-00028 TABLE 25 Comparison of Total Antibody PK Parameters
for v17597 DAR4 and v21252 DAR2 (Toxin Dose Matched) AUC.sub.0-336
Half life First Dose Dose Fold First Dose Fold Toxin Dose Drug
(Dose) (hr*ug/mL) Difference (Hours) Difference.sup.# 0.18 mg/kg
v17597 DAR 4 8,090 1 37.3 1 (4.5 mg/kg) v21252 DAR 2 17,400 2.2
67.4 1.8 (9 mg/kg) 0.36 mg/kg v17597 DAR 4 18,700 1 81.9 1 (9
mg/kg) v21252 DAR2 50,300 2.7 155 1.9 (18 mg/kg) .sup.#compared to
v17597 @ 4.5 and 9 mg/kg
Conclusions
[0505] The highest non-severely toxic dose (HNSTD) of v21252 was
determined to be 18 mg/kg. v21252 was well tolerated at all doses.
No clinical observations were considered adverse and no mortality
was observed in this GLP study. The only consistent clinical
observation was increased diarrhea. No change in body weight was
observed at all doses and no clinical pathology findings (liver
function--aspartate transaminase and alanine transaminase and
hematology--neutrophils, platelets, hemoglobin, and lymphocytes)
were considered adverse. These GLP toxicology results support
clinical dosing above predicted efficacious doses in humans.
[0506] Surprisingly, the ADC comprising Compound 9 conjugated to
v10000 at an average DAR2 (v21252) showed improved tolerability
compared to an ADC with an average DAR4 (v17597) with a HNSTD of 18
mg/kg. This result is unexpected as it has previously been shown
that toxin Compound 9 conjugated to v10000 at an average DAR4
(v17597) when administered at a toxin dose of 0.36 mg/kg was
associated with mortality either when dosed acutely (with a single
dose of 9 mg/kg) or sub-chronically (with two doses of 4.5 mg/kg
separated by two weeks) (Example 8). In contrast, when v21252
(DAR2) was administered at 0.36 mg/kg dose of toxin (Compound 9)
for four doses (a cumulative toxin dose of 1.44 mg/kg), there was
no mortality and substantially reduced toxicity compared to v17597.
For instance, v21252 administered at a cumulative dose of 0.96
mg/kg of toxin (Compound 9) was associated with no adverse findings
and was designated as a no observed adverse event level (NOAEL).
Furthermore, 1.44 mg/kg cumulative dose of toxin (Compound 9) was
administered with 18 mg/kg of v21252 over 4 doses and was
tolerated. This is a four-fold higher dose than the dose of v17597
that was associated with mortality (0.36 mg/kg).
[0507] Importantly, v21252 has less toxicity and more tolerability
compared to v17597 when dosed every two every weeks, even though it
has approximately two times greater exposure (AUC.sub.0-336hr after
first dose) and two times longer half-life after first dose when
compared at toxin-matched doses (4.5 mg/kg of v17597 v. 9 mg/kg of
v21252 and 9 mg/kg of v17597 v. 18 mg/kg of v21252) (summarized in
Tables 24 and 25).
Example 11: v21252 Inhibits Low HER2 Patient Derived Xenograft
Growth In Vivo
[0508] LTL-654 was derived from an ovarian serous carcinoma patient
metastasis and was scored by immunohistochemistry (HC) as HER2
negative. An earlier biopsy was scored by IHC as HER2
equivocal.
[0509] Female NOD Rag gamma (NRG) mice were subcutaneously
implanted via the renal capsule with two LTL-654 tumour fragments,
approximately 15 mm.sup.3 each. Animals were randomly assigned to
one of two blinded treatment groups of six animals each when mean
tumour volumes reached 70.3-77.8 mm.sup.3.
[0510] Animals were treated with either vehicle or 3 mg/kg of
v21252 administered intravenously once weekly for four total
injections (qwx4) (Table 21). Tumour size was measured using a
Vevo.RTM.3100 imaging system (FUJIFILM VisualSonics, Inc., Toronto,
Canada) using three-dimensional (3D)-mode. Multiple images (70 to
100 per tumour) throughout the whole tumour were recorded and
analyzed using Vevo.RTM. LAB software v2.1.0 (FUJIFILM
VisualSonics, Inc.). Tumour size was measured once weekly after
randomization up to Day 24. Mice were ethically sacrificed when
individual tumours reached a size of 1500 mm.sup.3. Tumour volumes
are reported as the mean.+-.SEM for each group.
[0511] FIG. 16 provides the results for the tumour response in mice
subcutaneously implanted with LTL-654 tumour fragments after i.v.
administration of vehicle or v21252, which demonstrate that
treatment of LTL-654 engrafted mice with v21252 inhibited the
growth rate of the LTL-654 tumour xenografts.
[0512] This example demonstrates that v21252 is effective in a
patient derived xenograft in which HER2 expression is sufficiently
low to be scored by IHC as HER2 negative.
TABLE-US-00029 TABLE 21 LTL-654 Ovarian Cancer PDX Model Study
Design Test Dose Route of Days of Animals per Article (mg/kg)
Administration Administration group Vehicle N/A IV 0, 7, 14, 21 6
v21252 3 IV 0, 7, 14, 21 6 N/A = Not applicable
Example 12: v21252 Prolongs Survival of Mice Bearing Intracranially
Implanted Human Breast Tumours In Vivo
[0513] The constructs used in this example were: control conjugate
(humanized antibody against respiratory syncytial virus conjugated
to Linker-Toxin 001), v21252, v7155 (T-DM1, DAR3.5) and v24029
(trastuzumab conjugated at DAR8 to an exatecan-derivative
topoisomerase I inhibitor (DXd)). The intracranially implanted
BT-474 human breast tumours utilized in this example serve as a
HER2 positive breast cancer brain metastasis model.
[0514] Female Balb/c Nude mice (CByJ.Cg-Foxnlnu/J) mice were
irradiated with a .gamma.-source (2 Gy, .sup.60Co, BioMep,
Bretenieres, France). Anesthetized mice were stereotactically
injected with 1.times.10.sup.5 BT-474 cells in 2 microliters of
RPMI 1640 medium without phenol red. Animals were randomized into
treatment groups and, starting on day 8, were administered
intravenously with vehicle, control conjugate, v21252, v7155 or
v24029 at 6 mg/kg every week for twelve total injections (Table
26). Body weights were recorded twice weekly until day 18 and then
daily thereafter. Mice were ethically sacrificed when bodyweight
loss met or exceeded 20% for 3 consecutive days.
[0515] FIG. 17 provides the survival results for mice
intracranially implanted with BT-474 tumour cells after i.v.
administration of vehicle, control conjugate, v21252, v7155, or
v24029.
[0516] Two additional cohorts of animals intracranially implanted
with BT-474 cells were also randomized into treatment groups and,
starting on day 8, were administered intravenously with either
v21252 or v24029 at 6 mg/kg every two weeks for six total
injections. Body weights were recorded twice weekly until day 18
and then daily thereafter. Mice were ethically sacrificed when
bodyweight loss met or exceeded 20% for 3 consecutive days.
[0517] FIG. 18 provides the survival results for mice
intracranially implanted with BT-474 tumour cells after weekly (qw)
i.v. administration of vehicle, control conjugate or v7155, or i.v.
administration every two weeks (q2w) of either v21252 or
v24029.
[0518] This example demonstrates that v21252 is effective in
prolonging the survival of mice intracranially implanted with
BT-474 breast tumour cells.
TABLE-US-00030 TABLE 26 Intracranially Implanted BT-474 Human
Breast Cancer Model Study Design Test Dose Route of Days of Animals
per Article (mg/kg) Administration Administration group Vehicle N/A
IV 8, 15, 22, 29, 36, 7 43, 50, 57, 64, 71, 78, 85 v21252 6 IV 8,
15, 22, 29, 36, 7 43, 50, 57, 64, 71, 78, 85 v7155 6 IV 8, 15, 22,
29, 36, 7 43, 50, 57, 64, 71, 78, 85 v24029 6 IV 8, 15,22, 29, 36,
7 43, 50, 57, 64, 71, 78, 85 Control 6 IV 8, 15, 22, 29, 36, 7
conjugate 43, 50, 57, 64, 71, 78, 85 N/A = Not applicable
[0519] The disclosures of all patents, patent applications,
publications and database entries referenced in this specification
are hereby specifically incorporated by reference in their entirety
to the same extent as if each such individual patent, patent
application, publication and database entry were specifically and
individually indicated to be incorporated by reference.
[0520] Modifications of the specific embodiments described herein
that would be apparent to those skilled in the art are intended to
be included within the scope of the following claims.
Sequence Tables
TABLE-US-00031 [0521] TABLE A Clone Numbers for Variants v5019,
v5020, v7091, v10000, v6903, v6902 and v6717 Variant H1 clone # H2
clone # L1 clone # L2 clone # 5019 3057 720 1811 -- 5020 719 3041
-- 1811 7091 3057 5244 1811 -- 10000 6586 5244 3382 -- 6903 5065
3468 5037 3904 6902 5065 3468 5034 3904 6717 3317 720 -- --
TABLE-US-00032 TABLE B Sequence for Variants v5019, v5020, v7091,
v10000, v6903, v6902 and v6717 by Clone Number SEQ ID Clone NO. #
Desc Sequence (amino acid or DNA) 3 3468 Full
EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKS
TSGGTAALGCLVKGYFPEPVTVSWNSGALTSGVHTFPAVLKSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP
PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVSLL
CLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 4 3468 Full
GAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGG
AGGGTCCCTGCGCCTGTCTTGCGCCGCTAGTGGCTTCACTTTTAC
CGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCC
TGGAGTGGGTCGCCGATGTGAACCCAAATAGCGGAGGCTCCATC
TACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGACCG
GAGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCG
AAGATACTGCTGTGTACTATTGCGCCCGGAATCTGGGGCCCTCCT
TCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCT
CCGCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTA
GTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTGGTG
AAGGGCTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGG
CGCTCTGACTTCTGGGGTCCACACCTTTCCTGCAGTGCTGAAGTC
AAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTC
AAGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGC
CATCCAATACAAAAGTCGACAAGAAAGTGGAACCCAAGTCTTGT
GATAAAACCCATACATGCCCCCCTTGTCCTGCACCAGAGCTGCTG
GGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATAC
ACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGG
ACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACGTG
GACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGG
AACAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTG
CTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGT
GAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCA
AGGCAAAAGGACAGCCTAGAGAACCACAGGTGTACGTGCTGCCT
CCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGCTGTG
TCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGA
AAGTAATGGCCAGCCTGAGAACAATTACCTGACCTGGCCCCCTG
TGCTGGACTCAGATGGCAGCTTCTTTCTGTATAGCAAGCTGACCG
TCGACAAATCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTCA
GTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCACT GTCACTGTCACCAGGG 5
3468 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSS 6 3468, H1 GFTFTDYT 3057, 3041, 3317
7 3468, H3 ARNLGPSFYFDY 3057, 3041, 3317 8 3468, H2 VNPNSGGS 3057,
3041, 3317 9 1811 Full
DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKL
LIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIY
PYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR
EAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE
KHKVYACEVTHQGLSSPVTKSFNRGEC 10 1811 Full
GATATTCAGATGACCCAGTCCCCAAGCTCCCTGAGTGCCTCAGTG
GGCGACCGAGTCACCATCACATGCAAGGCTTCCCAGGATGTGTC
TATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCA
AGCTGCTGATCTATAGCGCCTCCTACCGGTATACCGGCGTGCCCT
CTAGATTCTCTGGCAGTGGGTCAGGAACAGACTTTACTCTGACCA
TCTCTAGTCTGCAGCCTGAGGATTTCGCTACCTACTATTGCCAGC
AGTACTATATCTACCCATATACCTTTGGCCAGGGGACAAAAGTG
GAGATCAAGAGGACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCC
CCTTCTGACGAACAGCTGAAAAGTGGCACAGCCAGCGTGGTCTG
TCTGCTGAACAATTTCTACCCTCGCGAAGCCAAAGTGCAGTGGA
AGGTCGATAACGCTCTGCAGAGCGGCAACAGCCAGGAGTCTGTG
ACTGAACAGGACAGTAAAGATTCAACCTATAGCCTGTCAAGCAC
ACTGACTCTGAGCAAGGCAGACTACGAGAAGCACAAAGTGTATG
CCTGCGAAGTCACACATCAGGGGCTGTCCTCTCCTGTGACTAAG AGCTTTAACAGAGGAGAGTGT
11 1811 VL DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKL
LIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIY PYTFGQGTKVEIK 12
1811, L1 QDVSIG 3904, 3317 13 1811, L3 QQYYIYPYT 3904, 3317 14
1811, L2 SAS 3904, 3317 15 5034 Full
DYKDDDDKDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQ
QKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATY
YCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDERLKSGTASVV
CLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL
TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 16 5034 Full
GACTACAAAGACGACGATGACAAAGATATCCAGATGACCCAGTC
CCCTAGCTCCCTGTCCGCTTCTGTGGGCGATAGGGTCACTATTAC
CTGCCGCGCATCTCAGGACGTGAACACCGCAGTCGCCTGGTACC
AGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCTACAGTGCA
TCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAG
ATCTGGCACCGATTTCACACTGACTATTTCTAGTCTGCAGCCTGA
GGACTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCC
TACTTTCGGCCAGGGGACCAAAGTGGAGATCAAGCGAACTGTGG
CCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGATGAAAGACTGA
AGTCCGGCACAGCTTCTGTGGTCTGTCTGCTGAACAATTTTTACC
CCAGAGAGGCCAAAGTGCAGTGGAAGGTCGACAACGCTCTGCA
GAGTGGCAACAGCCAGGAGAGCGTGACAGAACAGGATTCCAAA
GACTCTACTTATAGTCTGTCAAGCACCCTGACACTGAGCAAGGC
AGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTCACACATC
AGGGGCTGTCATCACCAGTCACCAAATCATTCAATCGGGGGGAG TGC 17 5034 VL
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL
LIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTP PTFGQGTKVEIK 18
5037 Full DYKDDDDKDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQ
QKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATY
YCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDERLKSGTASVV
CLLNNFYPREAKVQWKVDNALQSGNSKESVTEQDSKDSTYSLSSRL
TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 19 5037 Full
GACTACAAAGACGACGATGACAAAGATATCCAGATGACCCAGTC
CCCTAGCTCCCTGTCCGCTTCTGTGGGCGATAGGGTCACTATTAC
CTGCCGCGCATCTCAGGACGTGAACACCGCAGTCGCCTGGTACC
AGCAGAAGCCTGGGAAAGCTCCAAAGCTGCTGATCTACAGTGCA
TCATTCCTGTATTCAGGAGTGCCCAGCCGGTTTAGCGGCAGCAG
ATCTGGCACCGATTTCACACTGACTATTTCTAGTCTGCAGCCTGA
GGACTTTGCCACATACTATTGCCAGCAGCACTATACCACACCCCC
TACTTTCGGCCAGGGGACCAAAGTGGAGATCAAGCGAACTGTGG
CCGCTCCAAGTGTCTTCATTTTTCCACCCAGCGATGAAAGACTGA
AGTCCGGCACAGCTTCTGTGGTCTGTCTGCTGAACAATTTTTACC
CCAGAGAGGCCAAAGTGCAGTGGAAGGTCGACAACGCTCTGCA
GAGTGGCAACAGCAAGGAGAGCGTGACAGAACAGGATTCCAAA
GACTCTACTTATAGTCTGTCAAGCAGACTGACACTGAGCAAGGC
AGACTACGAAAAGCATAAAGTGTATGCCTGTGAGGTCACACATC
AGGGGCTGTCATCACCAGTCACCAAATCATTCAATCGGGGGGAG TGC 20 5037 VL
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL
LIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTP PTFGQGTKVEIK 21
5037 L1 QDVNTA 22 5037 L3 QQHYTTPPT 23 5037 L2 SAS 24 3382 Full
DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKL
LIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIY
PATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR
EAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE
KHKVYACEVTHQGLSSPVTKSFNRGEC 25 3382 Full
GATATTCAGATGACCCAGTCCCCAAGCTCCCTGAGTGCCTCAGTG
GGCGACCGAGTCACCATCACATGCAAGGCTTCCCAGGATGTGTC
TATTGGAGTCGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCA
AGCTGCTGATCTATAGCGCCTCCTACCGGTATACCGGCGTGCCCT
CTAGATTCTCTGGCAGTGGGTCAGGAACAGACTTTACTCTGACCA
TCTCTAGTCTGCAGCCTGAGGATTTCGCTACCTACTATTGCCAGC
AGTACTATATCTACCCAGCCACCTTTGGCCAGGGGACAAAAGTG
GAGATCAAGAGGACTGTGGCCGCTCCCTCCGTCTTCATTTTTCCC
CCTTCTGACGAACAGCTGAAAAGTGGCACAGCCAGCGTGGTCTG
TCTGCTGAACAATTTCTACCCTCGCGAAGCCAAAGTGCAGTGGA
AGGTCGATAACGCTCTGCAGAGCGGCAACAGCCAGGAGTCTGTG
ACTGAACAGGACAGTAAAGATTCAACCTATAGCCTGTCAAGCAC
ACTGACTCTGAGCAAGGCAGACTACGAGAAGCACAAAGTGTATG
CCTGCGAAGTCACACATCAGGGGCTGTCCTCTCCTGTGACTAAG AGCTTTAACAGAGGAGAGTGT
26 3382 VL DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKL
LIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIY PATFGQGTKVEIK 27
3382 L1 QDVSIG 28 3382 L3 QQYYIYPAT 29 3382 L2 SAS 30 5065 Full
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE
WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDT
AVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSK
STSGGTAALGCEVTDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC
PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
YKCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSL
TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLT
VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 31 5065 Full
GAGGTGCAGCTGGTCGAAAGCGGAGGAGGACTGGTGCAGCCAG
GAGGGTCACTGCGACTGAGCTGCGCAGCTTCCGGCTTCAACATC
AAGGACACCTACATTCACTGGGTCCGCCAGGCTCCTGGAAAAGG
CCTGGAGTGGGTGGCACGAATCTATCCAACTAATGGATACACCC
GGTATGCCGACTCCGTGAAGGGCCGGTTCACCATTTCTGCAGAT
ACAAGTAAAAACACTGCCTACCTGCAGATGAACAGCCTGCGAGC
CGAAGATACAGCCGTGTACTATTGCAGCCGATGGGGAGGCGACG
GCTTCTACGCTATGGATTATTGGGGGCAGGGAACCCTGGTCACA
GTGAGCTCCGCATCAACAAAGGGGCCTAGCGTGTTTCCACTGGC
CCCCTCTAGTAAATCCACCTCTGGGGGAACAGCAGCCCTGGGAT
GTGAGGTGACCGACTACTTCCCAGAGCCCGTCACTGTGAGCTGG
AACTCCGGCGCCCTGACATCTGGGGTCCATACTTTTCCTGCTGTG
CTGCAGTCAAGCGGCCTGTACAGCCTGTCCTCTGTGGTCACTGTG
CCAAGTTCAAGCCTGGGGACTCAGACCTATATCTGCAACGTGAA
TCACAAGCCATCCAATACCAAAGTCGACAAGAAAGTGGAACCCA
AGTCTTGTGATAAAACACATACTTGCCCCCCTTGTCCTGCACCAG
AGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCT
AAAGACACCCTGATGATTAGTAGGACTCCAGAAGTCACCTGCGT
GGTCGTGGACGTGAGCCACGAGGACCCCGAAGTCAAGTTCAACT
GGTACGTGGATGGCGTCGAGGTGCATAATGCCAAGACAAAACCC
AGGGAGGAACAGTACAACTCCACTTATCGCGTCGTGTCTGTCCT
GACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAGTATAAGT
GCAAAGTGAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACA
ATTTCCAAGGCTAAAGGGCAGCCTAGAGAACCACAGGTGTACGT
GTACCCTCCATCTAGGGACGAGCTGACCAAGAACCAGGTCAGTC
TGACATGTCTGGTGAAAGGGTTCTATCCCAGCGATATCGCAGTG
GAGTGGGAATCCAATGGACAGCCTGAGAACAATTACAAGACCAC
ACCCCCTGTGCTGGACTCTGATGGAAGTTTCGCCCTGGTGAGTAA
GCTGACCGTCGATAAATCACGGTGGCAGCAGGGCAACGTGTTCA
GCTGTTCAGTGATGCACGAAGCACTGCACAACCACTACACCCAG
AAAAGCCTGTCCCTGTCCCCCGGC 32 5065 VH
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE
WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDT
AVYYCSRWGGDGFYAMDYWGQGTLVTVSS 33 5065, H1 GFNIKDTY 720,
719 34 5065, H3 SRWGGDGFYAMDY 720, 719 35 5065, H2 IYPTNGYT 720,
719 36 6586 Full EVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGL
EWVGDVNPNSGGSIYNQRFKGRFTFSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKS
TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP
PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 37 6586 Full
GAGGTGCAGCTGGTGGAATCAGGAGGGGGCCTGGTGCAGCCCG
GAGGGTCTCTGCGACTGTCATGTGCCGCTTCTGGGTTCACTTTCG
CAGACTACACAATGGATTGGGTGCGACAGGCCCCCGGAAAGGG
ACTGGAGTGGGTGGGCGATGTCAACCCTAATTCTGGCGGGAGTA
TCTACAACCAGCGGTTCAAGGGGAGATTCACTTTTTCAGTGGAC
AGAAGCAAAAACACCCTGTATCTGCAGATGAACAGCCTGAGGGC
CGAAGATACCGCTGTCTACTATTGCGCTCGCAATCTGGGCCCCAG
TTTCTACTTTGACTATTGGGGGCAGGGAACCCTGGTGACAGTCAG
CTCCGCTAGCACTAAGGGGCCTTCCGTGTTTCCACTGGCTCCCTC
TAGTAAATCCACCTCTGGAGGCACAGCTGCACTGGGATGTCTGG
TGAAGGATTACTTCCCTGAACCAGTCACAGTGAGTTGGAACTCA
GGGGCTCTGACAAGTGGAGTCCATACTTTTCCCGCAGTGCTGCA
GTCAAGCGGACTGTACTCCCTGTCCTCTGTGGTCACCGTGCCTAG
TTCAAGCCTGGGCACCCAGACATATATCTGCAACGTGAATCACA
AGCCATCAAATACAAAAGTCGACAAGAAAGTGGAGCCCAAGAG
CTGTGATAAAACTCATACCTGCCCACCTTGTCCGGCGCCAGAACT
GCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAG
ACACCCTGATGATTTCCCGGACTCCTGAGGTCACCTGCGTGGTCG
TGGACGTGTCTCACGAGGACCCCGAAGTCAAGTTCAACTGGTAC
GTGGATGGCGTCGAAGTGCATAATGCCAAGACCAAACCCCGGGA
GGAACAGTACAACTCTACCTATAGAGTCGTGAGTGTCCTGACAG
TGCTGCACCAGGACTGGCTGAATGGGAAGGAGTATAAGTGTAAA
GTGAGCAACAAAGCCCTGCCCGCCCCAATCGAAAAAACAATCTC
TAAAGCAAAAGGACAGCCTCGCGAACCACAGGTCTACGTCTACC
CCCCATCAAGAGATGAACTGACAAAAAATCAGGTCTCTCTGACA
TGCCTGGTCAAAGGATTCTACCCTTCCGACATCGCCGTGGAGTGG
GAAAGTAACGGCCAGCCCGAGAACAATTACAAGACCACACCCCC
TGTCCTGGACTCTGATGGGAGTTTCGCTCTGGTGTCAAAGCTGAC
CGTCGATAAAAGCCGGTGGCAGCAGGGCAATGTGTTTAGCTGCT
CCGTCATGCACGAAGCCCTGCACAATCACTACACACAGAAGTCC CTGAGCCTGAGCCCTGGC 38
6586 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGL
EWVGDVNPNSGGSIYNQRFKGRFTFSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSS 39 6586 H1 GFTFADYT 40 6586 H3
ARNLGPSFYFDY 41 6586 H2 VNPNSGGS 42 3904 Full
YPYDVPDYATGSDIQMTQSPSSLSASVGDRVTITCKASQDVSIGVA
WYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPE
DFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEELKSGT
ASVVCLLNNFYPREAKVQWKVDNALQSGNSEESVTEQDSKDSTYS
LSSTLELSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 43 3904 Full
TATCCCTACGATGTGCCTGACTACGCTACTGGCTCCGATATCCAG
ATGACCCAGTCTCCAAGCTCCCTGAGTGCATCAGTGGGGGACCG
AGTCACCATCACATGCAAGGCTTCCCAGGATGTGTCTATTGGAGT
CGCATGGTACCAGCAGAAGCCAGGCAAAGCACCCAAGCTGCTGA
TCTACAGCGCCTCCTACCGGTATACTGGGGTGCCTTCCAGATTCT
CTGGCAGTGGGTCAGGAACCGACTTTACTCTGACCATCTCTAGTC
TGCAGCCCGAGGATTTCGCCACCTACTATTGCCAGCAGTACTATA
TCTACCCTTATACCTTTGGCCAGGGGACAAAAGTGGAGATCAAG
AGGACAGTGGCCGCTCCAAGTGTCTTCATTTTTCCCCCTTCCGAC
GAAGAGCTGAAAAGTGGAACTGCTTCAGTGGTCTGTCTGCTGAA
CAATTTCTACCCCCGCGAAGCCAAAGTGCAGTGGAAGGTCGATA
ACGCTCTGCAGAGCGGCAATTCCGAGGAGTCTGTGACAGAACAG
GACAGTAAAGATTCAACTTATAGCCTGTCAAGCACACTGGAGCT
GTCTAAGGCAGACTACGAGAAGCACAAAGTGTATGCCTGCGAAG
TCACCCATCAGGGGCTGTCCTCTCCCGTGACAAAGAGCTTTAACA GAGGAGAGTGT 44 3904
VL DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKL
LIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIY PYTFGQGTKVEIK 45
719 Full DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL
LIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTP
PTFGQGTKVEIKGGSGGGSGGGSGGGSGGGSGEVQLVESGGGLVQP
GGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY
AMDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFP
PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTYPPSRDELTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTPPVLDEDGSFALVSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK
46 719 Full GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTA
GGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACGTTAA
CACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTA
AGCTCCTGATCTATTCTGCATCCTTTTTGTACAGTGGGGTCCCAT
CAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTCACC
ATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAA
CAGCATTACACTACCCCACCCACTTTCGGCCAAGGGACCAAAGT
GGAGATCAAAGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTG
GTGGTGGTTCTGGTGGTGGTTCTGGTGAAGTGCAGCTGGTGGAG
TCTGGGGGAGGCTTGGTACAGCCTGGCGGGTCCCTGAGACTCTC
CTGTGCAGCCTCTGGATTCAACATTAAAGATACTTATATCCACTG
GGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCGCACGTA
TTTATCCCACAAATGGTTACACACGGTATGCGGACTCTGTGAAG
GGCCGATTCACCATCTCCGCAGACACTTCCAAGAACACCGCGTA
TCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCGTTTATT
ACTGTTCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTAC
TGGGGCCAAGGGACCCTGGTCACCGTCTCCTCAGCCGCCGAGCC
CAAGAGCAGCGATAAGACCCACACCTGCCCTCCCTGTCCAGCTC
CAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGC
CAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGC
GTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAA
CTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAAC
CAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTG
CTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAA
GTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAA
CCATCTCTAAGGCCAAAGGCCAGCCAAGGGAGCCCCAGGTGTAC
ACATACCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTC
CCTGACATGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGT
GGAGTGGGAATCAAATGGACAGCCAGAGAACAATTACAAGACC
ACACCTCCAGTGCTGGACGAGGATGGCAGCTTCGCCCTGGTGTC
CAAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGT
TTAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTC
AGAAGAGCCTGTCCCTGTCTCCCGGCAAA 47 719 VL
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL
LIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTP PTFGQGTKVEIK 48
719 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE
WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDT
AVYYCSRWGGDGFYAMDYWGQGTLVTVSS 49 720 Full
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL
LIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTP
PTFGQGTKVEIKGGSGGGSGGGSGGGSGGGSGEVQLVESGGGLVQP
GGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY
AMDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFP
PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPPSRDELTKNQVSLICLVKGFYPSDIAVEW
ESNGQPENRYMTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPGK
50 720 Full GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTA
GGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGGACGTTAA
CACCGCTGTAGCTTGGTATCAGCAGAAACCAGGGAAAGCCCCTA
AGCTCCTGATCTATTCTGCATCCTTTTTGTACAGTGGGGTCCCAT
CAAGGTTCAGTGGCAGTCGATCTGGGACAGATTTCACTCTCACC
ATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAA
CAGCATTACACTACCCCACCCACTTTCGGCCAAGGGACCAAAGT
GGAGATCAAAGGTGGTTCTGGTGGTGGTTCTGGTGGTGGTTCTG
GTGGTGGTTCTGGTGGTGGTTCTGGTGAAGTGCAGCTGGTGGAG
TCTGGGGGAGGCTTGGTACAGCCTGGCGGGTCCCTGAGACTCTC
CTGTGCAGCCTCTGGATTCAACATTAAAGATACTTATATCCACTG
GGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTCGCACGTA
TTTATCCCACAAATGGTTACACACGGTATGCGGACTCTGTGAAG
GGCCGATTCACCATCTCCGCAGACACTTCCAAGAACACCGCGTA
TCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCGTTTATT
ACTGTTCAAGATGGGGCGGAGACGGTTTCTACGCTATGGACTAC
TGGGGCCAAGGGACCCTGGTCACCGTCTCCTCAGCCGCCGAGCC
CAAGAGCAGCGATAAGACCCACACCTGCCCTCCCTGTCCAGCTC
CAGAACTGCTGGGAGGACCTAGCGTGTTCCTGTTTCCCCCTAAGC
CAAAAGACACTCTGATGATTTCCAGGACTCCCGAGGTGACCTGC
GTGGTGGTGGACGTGTCTCACGAGGACCCCGAAGTGAAGTTCAA
CTGGTACGTGGATGGCGTGGAAGTGCATAATGCTAAGACAAAAC
CAAGAGAGGAACAGTACAACTCCACTTATCGCGTCGTGAGCGTG
CTGACCGTGCTGCACCAGGACTGGCTGAACGGGAAGGAGTATAA
GTGCAAAGTCAGTAATAAGGCCCTGCCTGCTCCAATCGAAAAAA
CCATCTCTAAGGCCAAAGGCCAGCCAAGGGAGCCCCAGGTGTAC
ACACTGCCACCCAGCAGAGACGAACTGACCAAGAACCAGGTGTC
CCTGATCTGTCTGGTGAAAGGCTTCTATCCTAGTGATATTGCTGT
GGAGTGGGAATCAAATGGACAGCCAGAGAACAGATACATGACC
TGGCCTCCAGTGCTGGACAGCGATGGCAGCTTCTTCCTGTATTCC
AAGCTGACAGTGGATAAATCTCGATGGCAGCAGGGGAACGTGTT
TAGTTGTTCAGTGATGCATGAAGCCCTGCACAATCATTACACTCA
GAAGAGCCTGTCCCTGTCTCCCGGCAAA 51 720 VL
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL
LIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTP PTFGQGTKVEIK 52
720 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE
WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDT
AVYYCSRWGGDGFYAMDYWGQGTLVTVSS 53 3041 Full
EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKS
TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP
PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYVLPPSRDELTKNQVSLL
CLVKGFYPSDIAVEWESNGQPENNYLTWPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 54 3041 Full
GAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGG
AGGGTCCCTGCGCCTGTCTTGCGCCGCTAGTGGCTTCACTTTTAC
CGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCC
TGGAGTGGGTCGCCGATGTGAACCCAAATAGCGGAGGCTCCATC
TACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGACCG
GAGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCG
AAGATACTGCTGTGTACTATTGCGCCCGGAATCTGGGGCCCTCCT
TCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCT
CCGCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTA
GTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTGGTG
AAGGACTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGG
CGCTCTGACTTCTGGGGTCCACACCTTTCCTGCAGTGCTGCAGTC
AAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTC
AAGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGC
CATCCAATACAAAAGTCGACAAGAAAGTGGAACCCAAGTCTTGT
GATAAAACCCATACATGCCCCCCTTGTCCTGCACCAGAGCTGCTG
GGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATAC
ACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGG
ACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACGTG
GACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGG
AACAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTG
CTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGT
GAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCA
AGGCAAAAGGACAGCCTAGAGAACCACAGGTGTACGTGCTGCCT
CCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGCTGTG
TCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGA
AAGTAATGGCCAGCCTGAGAACAATTACCTGACCTGGCCCCCTG
TGCTGGACTCAGATGGCAGCTTCTTTCTGTATAGCAAGCTGACCG
TCGACAAATCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTCA
GTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCACT GTCACTGTCACCAGGG 55
3041 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSS 56 3057 Full
EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKS
TSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP
PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEY
KCKVSNKALPAPIEKTISKAKGQPREPQVYVYPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALVSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 57 3057 Full
GAAGTGCAGCTGGTCGAATCTGGAGGAGGACTGGTGCAGCCAGG
AGGGTCCCTGCGCCTGTCTTGCGCCGCTAGTGGCTTCACTTTTAC
CGACTACACCATGGATTGGGTGCGACAGGCACCTGGAAAGGGCC
TGGAGTGGGTCGCCGATGTGAACCCAAATAGCGGAGGCTCCATC
TACAACCAGCGGTTCAAGGGCCGGTTCACCCTGTCAGTGGACCG
GAGCAAAAACACCCTGTATCTGCAGATGAATAGCCTGCGAGCCG
AAGATACTGCTGTGTACTATTGCGCCCGGAATCTGGGGCCCTCCT
TCTACTTTGACTATTGGGGGCAGGGAACTCTGGTCACCGTGAGCT
CCGCCTCCACCAAGGGACCTTCTGTGTTCCCACTGGCTCCCTCTA
GTAAATCCACATCTGGGGGAACTGCAGCCCTGGGCTGTCTGGTG
AAGGACTACTTCCCAGAGCCCGTCACAGTGTCTTGGAACAGTGG
CGCTCTGACTTCTGGGGTCCACACCTTTCCTGCAGTGCTGCAGTC
AAGCGGGCTGTACAGCCTGTCCTCTGTGGTCACCGTGCCAAGTTC
AAGCCTGGGAACACAGACTTATATCTGCAACGTGAATCACAAGC
CATCCAATACAAAAGTCGACAAGAAAGTGGAACCCAAGTCTTGT
GATAAAACCCATACATGCCCCCCTTGTCCTGCACCAGAGCTGCTG
GGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCTAAAGATAC
ACTGATGATTAGTAGGACCCCAGAAGTCACATGCGTGGTCGTGG
ACGTGAGCCACGAGGACCCCGAAGTCAAGTTTAACTGGTACGTG
GACGGCGTCGAGGTGCATAATGCCAAGACTAAACCCAGGGAGG
AACAGTACAACAGTACCTATCGCGTCGTGTCAGTCCTGACAGTG
CTGCATCAGGATTGGCTGAACGGGAAAGAGTATAAGTGCAAAGT
GAGCAATAAGGCTCTGCCCGCACCTATCGAGAAAACAATTTCCA
AGGCAAAAGGACAGCCTAGAGAACCACAGGTGTACGTGTATCCT
CCATCAAGGGATGAGCTGACAAAGAACCAGGTCAGCCTGACTTG
TCTGGTGAAAGGATTCTATCCCTCTGACATTGCTGTGGAGTGGGA
AAGTAATGGCCAGCCTGAGAACAATTACAAGACCACACCCCCTG
TGCTGGACTCAGATGGCAGCTTCGCGCTGGTGAGCAAGCTGACC
GTCGACAAATCCCGGTGGCAGCAGGGGAATGTGTTTAGTTGTTC
AGTCATGCACGAGGCACTGCACAACCATTACACCCAGAAGTCAC TGTCACTGTCACCAGGG 58
3057 VH EVQLVESGGGLVQPGGSLRLSCAASGFIFTDYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSS 59 3317 Full
DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKL
LIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIY
PYTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS
LRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQ
RFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDY
WGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVYVYPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLDSDGSFALVSKLTVDKSRWQQGNVFSCSVMHEA LHNHYTQKSLSLSPGK 60
3317 Full GACATTCAGATGACCCAGAGCCCTAGCTCCCTGAGTGCCTCAGT
CGGGGACAGGGTGACTATCACCTGCAAGGCTTCACAGGATGTCA
GCATTGGCGTGGCATGGTACCAGCAGAAGCCAGGGAAAGCACCC
AAGCTGCTGATCTATAGCGCCTCCTACAGGTATACAGGCGTGCC
ATCCCGCTTCTCTGGCAGTGGGTCAGGAACTGACTTTACACTGAC
TATTTCTAGTCTGCAGCCCGAAGATTTCGCCACATACTATTGCCA
GCAGTACTATATCTACCCTTATACTTTTGGCCAGGGGACCAAAGT
GGAGATTAAGGGCGGAGGAGGCTCCGGAGGAGGAGGGTCTGGA
GGAGGAGGAAGTGAGGTCCAGCTGGTGGAATCTGGAGGAGGAC
TGGTGCAGCCAGGAGGGTCCCTGAGGCTGTCTTGTGCCGCTAGT
GGCTTCACCTTTACAGACTACACAATGGATTGGGTGCGCCAGGC
ACCAGGAAAGGGACTGGAATGGGTCGCTGATGTGAACCCTAATA
GCGGAGGCTCCATCTACAACCAGCGGTTCAAAGGACGGTTCACC
CTGTCAGTGGACCGGAGCAAGAACACCCTGTATCTGCAGATGAA
CAGCCTGAGAGCCGAGGATACTGCTGTGTACTATTGCGCCAGGA
ATCTGGGCCCAAGCTTCTACTTTGACTATTGGGGGCAGGGAACA
CTGGTCACTGTGTCAAGCGCAGCCGAACCCAAATCCTCTGATAA
GACTCACACCTGCCCACCTTGTCCAGCTCCAGAGCTGCTGGGAG
GACCTAGCGTGTTCCTGTTTCCACCCAAGCCAAAAGACACTCTGA
TGATTTCTAGAACCCCTGAAGTGACATGTGTGGTCGTGGACGTCA
GTCACGAGGACCCCGAAGTCAAATTCAACTGGTACGTGGATGGC
GTCGAGGTGCATAATGCCAAGACCAAACCCCGAGAGGAACAGT
ACAACTCAACCTATCGGGTCGTGAGCGTCCTGACAGTGCTGCAT
CAGGACTGGCTGAACGGCAAGGAGTATAAGTGCAAAGTGAGCA
ACAAGGCTCTGCCTGCACCAATCGAGAAGACCATTTCCAAGGCT
AAAGGGCAGCCCCGCGAACCTCAGGTCTACGTGTATCCTCCAAG
CCGAGATGAGCTGACAAAAAACCAGGTCTCCCTGACTTGTCTGG
TGAAGGGATTTTACCCAAGTGACATCGCAGTGGAGTGGGAATCA
AATGGCCAGCCCGAAAACAATTATAAGACCACACCCCCTGTGCT
GGACTCTGATGGGAGTTTCGCACTGGTCTCCAAACTGACCGTGG
ACAAGTCTCGGTGGCAGCAGGGAAACGTCTTTAGCTGTTCCGTG
ATGCACGAGGCCCTGCACAATCATTACACACAGAAATCTCTGAG TCTGTCACCTGGCAAG 61
3317 VL DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKL
LIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIY PYTFGQGTKVEIK 62
3317 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSS 63 5244 Full
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL
LIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTP
PTFGQGTKVEIKGGSGGGSGGGSGGGSGGGSGEVQLVESGGGLVQP
GGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFY
AMDYWGQGTLVTVSSAAEPKSSDKTHTCPPCPAPELLGGPSVFLFP
PKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYVLPPSRDELTKNQVSLLCLVKGFYPSDIAVEW
ESNGQPENNYLTWPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPG
64 5244 Full GACATTCAGATGACACAGAGCCCCAGCTCCCTGAGTGCTTCAGT
CGGCGACAGGGTGACTATCACCTGCCGCGCATCCCAGGATGTCA
ACACCGCTGTGGCATGGTACCAGCAGAAGCCTGGAAAAGCCCCA
AAGCTGCTGATCTACAGCGCTTCCTTCCTGTATTCTGGCGTGCCA
AGTCGGTTTTCTGGAAGTAGATCAGGCACTGACTTCACACTGACT
ATCTCTAGTCTGCAGCCCGAAGATTTTGCCACCTACTATTGCCAG
CAGCACTATACCACACCCCCTACATTCGGACAGGGCACTAAAGT
GGAGATTAAGGGCGGGTCAGGCGGAGGGAGCGGAGGAGGGTCC
GGAGGAGGGTCTGGAGGAGGGAGTGGAGAGGTCCAGCTGGTGG
AATCTGGAGGAGGACTGGTGCAGCCTGGAGGCTCACTGCGACTG
AGCTGTGCCGCTTCCGGCTTTAACATCAAAGACACATACATTCAT
TGGGTCAGGCAGGCACCAGGGAAGGGACTGGAATGGGTGGCCC
GCATCTATCCCACAAATGGGTACACTCGATATGCCGACAGCGTG
AAAGGACGGTTTACCATTTCTGCTGATACCAGTAAGAACACAGC
ATACCTGCAGATGAACAGCCTGCGCGCAGAGGATACAGCCGTGT
ACTATTGCAGTCGATGGGGGGGAGACGGCTTCTACGCCATGGAT
TATTGGGGCCAGGGGACTCTGGTCACCGTGTCAAGCGCAGCCGA
ACCTAAATCCTCTGACAAGACCCACACATGCCCACCCTGTCCTGC
TCCAGAGCTGCTGGGAGGACCATCCGTGTTCCTGTTTCCTCCAAA
GCCTAAAGATACACTGATGATTAGCCGCACTCCCGAAGTCACCT
GTGTGGTCGTGGACGTGTCCCACGAGGACCCCGAAGTCAAGTTC
AACTGGTACGTGGACGGCGTCGAGGTGCATAATGCCAAGACTAA
ACCAAGAGAGGAACAGTACAATTCAACCTATAGGGTCGTGAGCG
TCCTGACAGTGCTGCATCAGGATTGGCTGAACGGCAAGGAGTAT
AAGTGCAAAGTGTCTAACAAGGCCCTGCCCGCTCCTATCGAGAA
GACTATTAGCAAGGCAAAAGGGCAGCCACGGGAACCCCAGGTCT
ACGTGCTGCCCCCTAGCAGAGACGAGCTGACCAAAAACCAGGTC
TCCCTGCTGTGTCTGGTGAAGGGCTTTTATCCTAGTGATATCGCT
GTGGAGTGGGAATCAAATGGGCAGCCAGAAAACAATTACCTGAC
ATGGCCACCCGTGCTGGACAGCGATGGGTCCTTCTTTCTGTATTC
CAAACTGACTGTGGACAAGTCTAGATGGCAGCAGGGAAACGTCT
TCAGCTGTTCCGTGATGCACGAGGCCCTGCACAATCATTACACCC
AGAAGTCTCTGAGTCTGTCACCCGGC 65 5244 VL
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKL
LIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTP PTFGQGTKVEIK 66
5244 VH EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLE
WVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDT
AVYYCSRWGGDGFYAMDYWGQGTLVTVSS 67 5244, L1 QDVNTA 5034, 719, 720 68
5244, L2 SAS 5034, 719, 720 69 5244, L3 QQHYTTPPT 5034, 719, 720 70
5244 H1 GFNIKDTY 71 5244 H2 IYPTNGYT 72 5244 H3 SRWGGDGFYAMDY
TABLE-US-00033 TABLE C Sequences for VH and VL Regions of Variants
v7133, v15082, v15085, v15083, v15080, v15079, v15084 and v15081
SEQ ID NO Variant Desc. Sequence 78 7133 VH
EVQLVESGGGLVQPGGSLRLSCAASGFTFADYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSS 79 7133 VL
DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKL
LIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIY PATFGQGTKVEIK 80
15082 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGL
EWVADVNPNSGYSIYNQRFKGRFTLSVDRSWNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSS 81 15082 & VL
DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKL 15085
LIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIY PYTFGQGTKVEIK 82
15085 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFQDYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPWFYFDYWGQGTLVTVSS 83 15083 VH
EVQLVESGGGLVQPGGSLRLSCAASGFTFQDYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSS 84 15083, VL
DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKL 15080,
LIWSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIY 15079 &
PGTFGQGTKVEIK 15081 85 15080 VH
EVQLVESGGGLVQPGGSLRLSCAASGFTFQDYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSWNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSS 86 15079 VH
EVQLVESGGGLVQPGGSLRLSCAASGFTFYDYTMDWVRQAPGKGL
EWVADVNPNSGGSIYNQRFKGRFTLSVDRSWNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSS 87 15084 VH
EVQLVESGGGLVQPGGSLRLSCAASGFTFQDYTMDWVRQAPGKGL
EWVADVNPNSGYSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPWFYFDYWGQGTLVTVSS 88 15084 VL
DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKL
LIWSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIY PYTFGQGTKVEIK 89
15081 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFQDYTMDWVRQAPGKGL
EWVADVNPNSGYSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAED
TAVYYCARNLGPSFYFDYWGQGTLVTVSS
Sequence CWU 1
1
891217PRTArtificial SequenceHuman IgG1 Fc 1Ala Pro Glu Leu Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys1 5 10 15Pro Lys Asp Thr Leu
Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 20 25 30Val Val Asp Val
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 35 40 45Val Asp Gly
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 50 55 60Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His65 70 75
80Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
85 90 95Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
Gln 100 105 110Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
Asp Glu Leu 115 120 125Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr Pro 130 135 140Ser Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn Asn145 150 155 160Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 165 170 175Tyr Ser Lys Leu
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val 180 185 190Phe Ser
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln 195 200
205Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 2152607PRTHomo sapiens
2Thr Gln Val Cys Thr Gly Thr Asp Met Lys Leu Arg Leu Pro Ala Ser1 5
10 15Pro Glu Thr His Leu Asp Met Leu Arg His Leu Tyr Gln Gly Cys
Gln 20 25 30Val Val Gln Gly Asn Leu Glu Leu Thr Tyr Leu Pro Thr Asn
Ala Ser 35 40 45Leu Ser Phe Leu Gln Asp Ile Gln Glu Val Gln Gly Tyr
Val Leu Ile 50 55 60Ala His Asn Gln Val Arg Gln Val Pro Leu Gln Arg
Leu Arg Ile Val65 70 75 80Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
Ala Leu Ala Val Leu Asp 85 90 95Asn Gly Asp Pro Leu Asn Asn Thr Thr
Pro Val Thr Gly Ala Ser Pro 100 105 110Gly Gly Leu Arg Glu Leu Gln
Leu Arg Ser Leu Thr Glu Ile Leu Lys 115 120 125Gly Gly Val Leu Ile
Gln Arg Asn Pro Gln Leu Cys Tyr Gln Asp Thr 130 135 140Ile Leu Trp
Lys Asp Ile Phe His Lys Asn Asn Gln Leu Ala Leu Thr145 150 155
160Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys His Pro Cys Ser Pro Met
165 170 175Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser Ser Glu Asp Cys
Gln Ser 180 185 190Leu Thr Arg Thr Val Cys Ala Gly Gly Cys Ala Arg
Cys Lys Gly Pro 195 200 205Leu Pro Thr Asp Cys Cys His Glu Gln Cys
Ala Ala Gly Cys Thr Gly 210 215 220Pro Lys His Ser Asp Cys Leu Ala
Cys Leu His Phe Asn His Ser Gly225 230 235 240Ile Cys Glu Leu His
Cys Pro Ala Leu Val Thr Tyr Asn Thr Asp Thr 245 250 255Phe Glu Ser
Met Pro Asn Pro Glu Gly Arg Tyr Thr Phe Gly Ala Ser 260 265 270Cys
Val Thr Ala Cys Pro Tyr Asn Tyr Leu Ser Thr Asp Val Gly Ser 275 280
285Cys Thr Leu Val Cys Pro Leu His Asn Gln Glu Val Thr Ala Glu Asp
290 295 300Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys Pro Cys Ala Arg
Val Cys305 310 315 320Tyr Gly Leu Gly Met Glu His Leu Arg Glu Val
Arg Ala Val Thr Ser 325 330 335Ala Asn Ile Gln Glu Phe Ala Gly Cys
Lys Lys Ile Phe Gly Ser Leu 340 345 350Ala Phe Leu Pro Glu Ser Phe
Asp Gly Asp Pro Ala Ser Asn Thr Ala 355 360 365Pro Leu Gln Pro Glu
Gln Leu Gln Val Phe Glu Thr Leu Glu Glu Ile 370 375 380Thr Gly Tyr
Leu Tyr Ile Ser Ala Trp Pro Asp Ser Leu Pro Asp Leu385 390 395
400Ser Val Phe Gln Asn Leu Gln Val Ile Arg Gly Arg Ile Leu His Asn
405 410 415Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu Gly Ile Ser Trp
Leu Gly 420 425 430Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly Leu Ala
Leu Ile His His 435 440 445Asn Thr His Leu Cys Phe Val His Thr Val
Pro Trp Asp Gln Leu Phe 450 455 460Arg Asn Pro His Gln Ala Leu Leu
His Thr Ala Asn Arg Pro Glu Asp465 470 475 480Glu Cys Val Gly Glu
Gly Leu Ala Cys His Gln Leu Cys Ala Arg Gly 485 490 495His Cys Trp
Gly Pro Gly Pro Thr Gln Cys Val Asn Cys Ser Gln Phe 500 505 510Leu
Arg Gly Gln Glu Cys Val Glu Glu Cys Arg Val Leu Gln Gly Leu 515 520
525Pro Arg Glu Tyr Val Asn Ala Arg His Cys Leu Pro Cys His Pro Glu
530 535 540Cys Gln Pro Gln Asn Gly Ser Val Thr Cys Phe Gly Pro Glu
Ala Asp545 550 555 560Gln Cys Val Ala Cys Ala His Tyr Lys Asp Pro
Pro Phe Cys Val Ala 565 570 575Arg Cys Pro Ser Gly Val Lys Pro Asp
Leu Ser Tyr Met Pro Ile Trp 580 585 590Lys Phe Pro Asp Glu Glu Gly
Ala Cys Gln Pro Cys Pro Ile Asn 595 600 6053448PRTArtificial
SequenceH2 clone 3468 Full 3Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Thr Asp Tyr 20 25 30Thr Met Asp Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Asp Val Asn Pro Asn Ser
Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60Lys Gly Arg Phe Thr Leu
Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asn
Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110Thr
Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120
125Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu
130 135 140Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Val
Ser Trp145 150 155 160Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
Phe Pro Ala Val Leu 165 170 175Lys Ser Ser Gly Leu Tyr Ser Leu Ser
Ser Val Val Thr Val Pro Ser 180 185 190Ser Ser Leu Gly Thr Gln Thr
Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205Ser Asn Thr Lys Val
Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220Thr His Thr
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro225 230 235
240Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
245 250 255Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
Glu Asp 260 265 270Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn 275 280 285Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
Asn Ser Thr Tyr Arg Val 290 295 300Val Ser Val Leu Thr Val Leu His
Gln Asp Trp Leu Asn Gly Lys Glu305 310 315 320Tyr Lys Cys Lys Val
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Val 340 345 350Leu
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Leu 355 360
365Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380Ser Asn Gly Gln Pro Glu Asn Asn Tyr Leu Thr Trp Pro Pro
Val Leu385 390 395 400Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
Leu Thr Val Asp Lys 405 410 415Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser Cys Ser Val Met His Glu 420 425 430Ala Leu His Asn His Tyr Thr
Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 44541344DNAArtificial
SequenceH2 clone 3468 Full 4gaagtgcagc tggtcgaatc tggaggagga
ctggtgcagc caggagggtc cctgcgcctg 60tcttgcgccg ctagtggctt cacttttacc
gactacacca tggattgggt gcgacaggca 120cctggaaagg gcctggagtg
ggtcgccgat gtgaacccaa atagcggagg ctccatctac 180aaccagcggt
tcaagggccg gttcaccctg tcagtggacc ggagcaaaaa caccctgtat
240ctgcagatga atagcctgcg agccgaagat actgctgtgt actattgcgc
ccggaatctg 300gggccctcct tctactttga ctattggggg cagggaactc
tggtcaccgt gagctccgcc 360tccaccaagg gaccttctgt gttcccactg
gctccctcta gtaaatccac atctggggga 420actgcagccc tgggctgtct
ggtgaagggc tacttcccag agcccgtcac agtgtcttgg 480aacagtggcg
ctctgacttc tggggtccac acctttcctg cagtgctgaa gtcaagcggg
540ctgtacagcc tgtcctctgt ggtcaccgtg ccaagttcaa gcctgggaac
acagacttat 600atctgcaacg tgaatcacaa gccatccaat acaaaagtcg
acaagaaagt ggaacccaag 660tcttgtgata aaacccatac atgcccccct
tgtcctgcac cagagctgct gggaggacca 720agcgtgttcc tgtttccacc
caagcctaaa gatacactga tgattagtag gaccccagaa 780gtcacatgcg
tggtcgtgga cgtgagccac gaggaccccg aagtcaagtt taactggtac
840gtggacggcg tcgaggtgca taatgccaag actaaaccca gggaggaaca
gtacaacagt 900acctatcgcg tcgtgtcagt cctgacagtg ctgcatcagg
attggctgaa cgggaaagag 960tataagtgca aagtgagcaa taaggctctg
cccgcaccta tcgagaaaac aatttccaag 1020gcaaaaggac agcctagaga
accacaggtg tacgtgctgc ctccatcaag ggatgagctg 1080acaaagaacc
aggtcagcct gctgtgtctg gtgaaaggat tctatccctc tgacattgct
1140gtggagtggg aaagtaatgg ccagcctgag aacaattacc tgacctggcc
ccctgtgctg 1200gactcagatg gcagcttctt tctgtatagc aagctgaccg
tcgacaaatc ccggtggcag 1260caggggaatg tgtttagttg ttcagtcatg
cacgaggcac tgcacaacca ttacacccag 1320aagtcactgt cactgtcacc aggg
13445119PRTArtificial SequenceH2 clone 3468 VH 5Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr 20 25 30Thr Met Asp
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Asp
Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60Lys
Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr65 70 75
80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln
Gly 100 105 110Thr Leu Val Thr Val Ser Ser 11568PRTArtificial
SequenceH1 clone 3057,3317 CDRH1, H2 clone 3468,3041 CDRH1 6Gly Phe
Thr Phe Thr Asp Tyr Thr1 5712PRTArtificial SequenceH1 clone
3057,3317 CDRH3, H2 clone 3468,3041 CDRH3 7Ala Arg Asn Leu Gly Pro
Ser Phe Tyr Phe Asp Tyr1 5 1088PRTArtificial SequenceH1 clone
3057,3317 CDRH2, H2 clone 3468,3041 CDRH2 8Val Asn Pro Asn Ser Gly
Gly Ser1 59214PRTArtificial SequenceL2 clone 1811 Full 9Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg
Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30Val
Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40
45Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile
Tyr Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val Cys Leu Leu
Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln Trp Lys Val
Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155 160Glu Ser Val
Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175Ser
Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185
190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205Phe Asn Arg Gly Glu Cys 21010642DNAArtificial SequenceL2
clone 1811 Full 10gatattcaga tgacccagtc cccaagctcc ctgagtgcct
cagtgggcga ccgagtcacc 60atcacatgca aggcttccca ggatgtgtct attggagtcg
catggtacca gcagaagcca 120ggcaaagcac ccaagctgct gatctatagc
gcctcctacc ggtataccgg cgtgccctct 180agattctctg gcagtgggtc
aggaacagac tttactctga ccatctctag tctgcagcct 240gaggatttcg
ctacctacta ttgccagcag tactatatct acccatatac ctttggccag
300gggacaaaag tggagatcaa gaggactgtg gccgctccct ccgtcttcat
ttttccccct 360tctgacgaac agctgaaaag tggcacagcc agcgtggtct
gtctgctgaa caatttctac 420cctcgcgaag ccaaagtgca gtggaaggtc
gataacgctc tgcagagcgg caacagccag 480gagtctgtga ctgaacagga
cagtaaagat tcaacctata gcctgtcaag cacactgact 540ctgagcaagg
cagactacga gaagcacaaa gtgtatgcct gcgaagtcac acatcagggg
600ctgtcctctc ctgtgactaa gagctttaac agaggagagt gt
64211107PRTArtificial SequenceL2 clone 1811 VL 11Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val
Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30Val Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr
Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55
60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65
70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro
Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
105126PRTArtificial sequenceL2 clones 1811, 3904 CDRL1 and H1 clone
3317 CDRL1 12Gln Asp Val Ser Ile Gly1 5139PRTArtificial SequenceL3
clones 1811, 3904 CDRL3 and H1 clone 3317 CDRL3 13Gln Gln Tyr Tyr
Ile Tyr Pro Tyr Thr1 5143PRTArtificial SequenceL2 clones 1811, 3904
CDRL2 and H1 clone 3317 CDRL2 14Ser Ala Ser115222PRTArtificial
SequenceL1 clone 5034 Full 15Asp Tyr Lys Asp Asp Asp Asp Lys Asp
Ile Gln Met Thr Gln Ser Pro1 5 10 15Ser Ser Leu Ser Ala Ser Val Gly
Asp Arg Val Thr Ile Thr Cys Arg 20 25 30Ala Ser Gln Asp Val Asn Thr
Ala Val Ala Trp Tyr Gln Gln Lys Pro 35 40 45Gly Lys Ala Pro Lys Leu
Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser 50 55 60Gly Val Pro Ser Arg
Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr65 70 75 80Leu Thr Ile
Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys 85 90 95Gln Gln
His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val 100 105
110Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
115 120 125Ser Asp Glu Arg Leu Lys Ser Gly Thr Ala Ser Val Val Cys
Leu Leu 130 135 140Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp
Lys Val Asp Asn145 150 155 160Ala Leu Gln Ser Gly Asn Ser Gln Glu
Ser Val Thr Glu Gln Asp Ser 165 170 175Lys Asp Ser Thr Tyr Ser Leu
Ser Ser Thr Leu Thr Leu Ser Lys Ala 180 185 190Asp Tyr Glu Lys His
Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 195 200 205Leu Ser Ser
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215
22016666DNAArtificial SequenceL1 clone 5034 Full 16gactacaaag
acgacgatga caaagatatc cagatgaccc agtcccctag ctccctgtcc 60gcttctgtgg
gcgatagggt cactattacc tgccgcgcat ctcaggacgt gaacaccgca
120gtcgcctggt accagcagaa gcctgggaaa gctccaaagc tgctgatcta
cagtgcatca 180ttcctgtatt caggagtgcc cagccggttt agcggcagca
gatctggcac cgatttcaca 240ctgactattt ctagtctgca gcctgaggac
tttgccacat actattgcca gcagcactat
300accacacccc ctactttcgg ccaggggacc aaagtggaga tcaagcgaac
tgtggccgct 360ccaagtgtct tcatttttcc acccagcgat gaaagactga
agtccggcac agcttctgtg 420gtctgtctgc tgaacaattt ttaccccaga
gaggccaaag tgcagtggaa ggtcgacaac 480gctctgcaga gtggcaacag
ccaggagagc gtgacagaac aggattccaa agactctact 540tatagtctgt
caagcaccct gacactgagc aaggcagact acgaaaagca taaagtgtat
600gcctgtgagg tcacacatca ggggctgtca tcaccagtca ccaaatcatt
caatcggggg 660gagtgc 66617107PRTArtificial SequenceL1 clone 5034 VL
17Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr
Ala 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
His Tyr Thr Thr Pro Pro 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu
Ile Lys 100 10518222PRTArtificial SequenceL1 cone 5037 Full 18Asp
Tyr Lys Asp Asp Asp Asp Lys Asp Ile Gln Met Thr Gln Ser Pro1 5 10
15Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg
20 25 30Ala Ser Gln Asp Val Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys
Pro 35 40 45Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu
Tyr Ser 50 55 60Gly Val Pro Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr
Asp Phe Thr65 70 75 80Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe
Ala Thr Tyr Tyr Cys 85 90 95Gln Gln His Tyr Thr Thr Pro Pro Thr Phe
Gly Gln Gly Thr Lys Val 100 105 110Glu Ile Lys Arg Thr Val Ala Ala
Pro Ser Val Phe Ile Phe Pro Pro 115 120 125Ser Asp Glu Arg Leu Lys
Ser Gly Thr Ala Ser Val Val Cys Leu Leu 130 135 140Asn Asn Phe Tyr
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn145 150 155 160Ala
Leu Gln Ser Gly Asn Ser Lys Glu Ser Val Thr Glu Gln Asp Ser 165 170
175Lys Asp Ser Thr Tyr Ser Leu Ser Ser Arg Leu Thr Leu Ser Lys Ala
180 185 190Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His
Gln Gly 195 200 205Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly
Glu Cys 210 215 22019666DNAArtificial SequenceL1 clone 5037 Full
19gactacaaag acgacgatga caaagatatc cagatgaccc agtcccctag ctccctgtcc
60gcttctgtgg gcgatagggt cactattacc tgccgcgcat ctcaggacgt gaacaccgca
120gtcgcctggt accagcagaa gcctgggaaa gctccaaagc tgctgatcta
cagtgcatca 180ttcctgtatt caggagtgcc cagccggttt agcggcagca
gatctggcac cgatttcaca 240ctgactattt ctagtctgca gcctgaggac
tttgccacat actattgcca gcagcactat 300accacacccc ctactttcgg
ccaggggacc aaagtggaga tcaagcgaac tgtggccgct 360ccaagtgtct
tcatttttcc acccagcgat gaaagactga agtccggcac agcttctgtg
420gtctgtctgc tgaacaattt ttaccccaga gaggccaaag tgcagtggaa
ggtcgacaac 480gctctgcaga gtggcaacag caaggagagc gtgacagaac
aggattccaa agactctact 540tatagtctgt caagcagact gacactgagc
aaggcagact acgaaaagca taaagtgtat 600gcctgtgagg tcacacatca
ggggctgtca tcaccagtca ccaaatcatt caatcggggg 660gagtgc
66620107PRTArtificial SequenceL1 clone 5037 VL 20Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val
Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30Val Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr
Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55
60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65
70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro
Pro 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
105216PRTArtificial SequenceL1 clone 5037 CDRL1 21Gln Asp Val Asn
Thr Ala1 5229PRTArtificial SequenceL1 clone 5037 CDRL3 22Gln Gln
His Tyr Thr Thr Pro Pro Thr1 5233PRTArtificial SequenceL1 clone
5037 CDRL2 23Ser Ala Ser124214PRTArtificial SequenceL1 clone 3382
Full 24Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser
Ile Gly 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
Gln Tyr Tyr Ile Tyr Pro Ala 85 90 95Thr Phe Gly Gln Gly Thr Lys Val
Glu Ile Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe
Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val
Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val
Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155
160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys
21025642DNAArtificial SequenceL1 clone 3382 Full 25gatattcaga
tgacccagtc cccaagctcc ctgagtgcct cagtgggcga ccgagtcacc 60atcacatgca
aggcttccca ggatgtgtct attggagtcg catggtacca gcagaagcca
120ggcaaagcac ccaagctgct gatctatagc gcctcctacc ggtataccgg
cgtgccctct 180agattctctg gcagtgggtc aggaacagac tttactctga
ccatctctag tctgcagcct 240gaggatttcg ctacctacta ttgccagcag
tactatatct acccagccac ctttggccag 300gggacaaaag tggagatcaa
gaggactgtg gccgctccct ccgtcttcat ttttccccct 360tctgacgaac
agctgaaaag tggcacagcc agcgtggtct gtctgctgaa caatttctac
420cctcgcgaag ccaaagtgca gtggaaggtc gataacgctc tgcagagcgg
caacagccag 480gagtctgtga ctgaacagga cagtaaagat tcaacctata
gcctgtcaag cacactgact 540ctgagcaagg cagactacga gaagcacaaa
gtgtatgcct gcgaagtcac acatcagggg 600ctgtcctctc ctgtgactaa
gagctttaac agaggagagt gt 64226107PRTArtificial SequenceL1 clone
3382 VL 26Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val
Ser Ile Gly 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
Lys Leu Leu Ile 35 40 45Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Tyr Tyr Ile Tyr Pro Ala 85 90 95Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys 100 105276PRTArtificial SequenceL1 clone 3382 CDRL1
27Gln Asp Val Ser Ile Gly1 5289PRTArtificial SequenceL1 clone 3382
CDRL3 28Gln Gln Tyr Tyr Ile Tyr Pro Ala Thr1 5293PRTArtificial
SequenceL1 clone 3382 CDRL2 29Ser Ala Ser130449PRTArtificial
SequenceH1 clone 5065 Full 30Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30Tyr Ile His Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Arg Ile Tyr Pro Thr
Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr
Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65 70 75 80Leu Gln Met
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ser Arg
Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105
110Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
Ala Ala 130 135 140Leu Gly Cys Glu Val Thr Asp Tyr Phe Pro Glu Pro
Val Thr Val Ser145 150 155 160Trp Asn Ser Gly Ala Leu Thr Ser Gly
Val His Thr Phe Pro Ala Val 165 170 175Leu Gln Ser Ser Gly Leu Tyr
Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190Ser Ser Ser Leu Gly
Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205Pro Ser Asn
Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220Lys
Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly225 230
235 240Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
Ile 245 250 255Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
Ser His Glu 260 265 270Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp
Gly Val Glu Val His 275 280 285Asn Ala Lys Thr Lys Pro Arg Glu Glu
Gln Tyr Asn Ser Thr Tyr Arg 290 295 300Val Val Ser Val Leu Thr Val
Leu His Gln Asp Trp Leu Asn Gly Lys305 310 315 320Glu Tyr Lys Cys
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335Lys Thr
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345
350Val Tyr Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
355 360 365Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val
Glu Trp 370 375 380Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
Thr Pro Pro Val385 390 395 400Leu Asp Ser Asp Gly Ser Phe Ala Leu
Val Ser Lys Leu Thr Val Asp 405 410 415Lys Ser Arg Trp Gln Gln Gly
Asn Val Phe Ser Cys Ser Val Met His 420 425 430Glu Ala Leu His Asn
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440
445Gly311347DNAArtificial SequenceH1 clone 5065 Full 31gaggtgcagc
tggtcgaaag cggaggagga ctggtgcagc caggagggtc actgcgactg 60agctgcgcag
cttccggctt caacatcaag gacacctaca ttcactgggt ccgccaggct
120cctggaaaag gcctggagtg ggtggcacga atctatccaa ctaatggata
cacccggtat 180gccgactccg tgaagggccg gttcaccatt tctgcagata
caagtaaaaa cactgcctac 240ctgcagatga acagcctgcg agccgaagat
acagccgtgt actattgcag ccgatgggga 300ggcgacggct tctacgctat
ggattattgg gggcagggaa ccctggtcac agtgagctcc 360gcatcaacaa
aggggcctag cgtgtttcca ctggccccct ctagtaaatc cacctctggg
420ggaacagcag ccctgggatg tgaggtgacc gactacttcc cagagcccgt
cactgtgagc 480tggaactccg gcgccctgac atctggggtc catacttttc
ctgctgtgct gcagtcaagc 540ggcctgtaca gcctgtcctc tgtggtcact
gtgccaagtt caagcctggg gactcagacc 600tatatctgca acgtgaatca
caagccatcc aataccaaag tcgacaagaa agtggaaccc 660aagtcttgtg
ataaaacaca tacttgcccc ccttgtcctg caccagagct gctgggagga
720ccaagcgtgt tcctgtttcc acccaagcct aaagacaccc tgatgattag
taggactcca 780gaagtcacct gcgtggtcgt ggacgtgagc cacgaggacc
ccgaagtcaa gttcaactgg 840tacgtggatg gcgtcgaggt gcataatgcc
aagacaaaac ccagggagga acagtacaac 900tccacttatc gcgtcgtgtc
tgtcctgacc gtgctgcacc aggactggct gaacggcaag 960gagtataagt
gcaaagtgag caataaggct ctgcccgcac ctatcgagaa aacaatttcc
1020aaggctaaag ggcagcctag agaaccacag gtgtacgtgt accctccatc
tagggacgag 1080ctgaccaaga accaggtcag tctgacatgt ctggtgaaag
ggttctatcc cagcgatatc 1140gcagtggagt gggaatccaa tggacagcct
gagaacaatt acaagaccac accccctgtg 1200ctggactctg atggaagttt
cgccctggtg agtaagctga ccgtcgataa atcacggtgg 1260cagcagggca
acgtgttcag ctgttcagtg atgcacgaag cactgcacaa ccactacacc
1320cagaaaagcc tgtccctgtc ccccggc 134732120PRTArtificial SequenceH1
clone 5065 VH 32Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn
Ile Lys Asp Thr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys
Gly Leu Glu Trp Val 35 40 45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr
Arg Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp
Thr Ser Lys Asn Thr Ala Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ser Arg Trp Gly Gly Asp
Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val
Thr Val Ser Ser 115 120338PRTArtificial SequenceH1 clones 5065, 719
CDRH1 and H2 clone 720 CDRH1 33Gly Phe Asn Ile Lys Asp Thr Tyr1
53413PRTArtificial SequenceH1 clones 5065, 719 CDRH3 and H2 clone
720 CDRH3 34Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr1 5
10358PRTArtificial SequenceH1 clones 5065, 719 CDRH2 and H2 clone
720 CDRH2 35Ile Tyr Pro Thr Asn Gly Tyr Thr1 536448PRTArtificial
SequenceH1 clone 6586 Full 36Glu Val Gln Leu Val Glu Ser Gly Gly
Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ala Asp Tyr 20 25 30Thr Met Asp Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Gly Asp Val Asn Pro Asn
Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60Lys Gly Arg Phe Thr
Phe Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg
Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105
110Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe
115 120 125Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
Ala Leu 130 135 140Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
Thr Val Ser Trp145 150 155 160Asn Ser Gly Ala Leu Thr Ser Gly Val
His Thr Phe Pro Ala Val Leu 165 170 175Gln Ser Ser Gly Leu Tyr Ser
Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190Ser Ser Leu Gly Thr
Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205Ser Asn Thr
Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys 210 215 220Thr
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro225 230
235 240Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
Ser 245 250 255Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser
His Glu Asp 260 265 270Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
Val Glu Val His Asn 275 280 285Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr Asn Ser Thr Tyr Arg Val 290 295 300Val Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu305 310 315 320Tyr Lys Cys Lys
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 325 330 335Thr Ile
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Val 340 345
350Tyr Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
355 360 365Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
Trp Glu 370 375 380Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
Pro Pro Val Leu385 390 395 400Asp Ser Asp Gly Ser Phe Ala Leu Val
Ser Lys Leu Thr Val Asp Lys 405 410 415Ser Arg Trp Gln Gln Gly Asn
Val Phe Ser Cys Ser Val Met His Glu 420
425 430Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
Gly 435 440 445371344DNAArtificial SequenceH1 clone 6586 Full
37gaggtgcagc tggtggaatc aggagggggc ctggtgcagc ccggagggtc tctgcgactg
60tcatgtgccg cttctgggtt cactttcgca gactacacaa tggattgggt gcgacaggcc
120cccggaaagg gactggagtg ggtgggcgat gtcaacccta attctggcgg
gagtatctac 180aaccagcggt tcaaggggag attcactttt tcagtggaca
gaagcaaaaa caccctgtat 240ctgcagatga acagcctgag ggccgaagat
accgctgtct actattgcgc tcgcaatctg 300ggccccagtt tctactttga
ctattggggg cagggaaccc tggtgacagt cagctccgct 360agcactaagg
ggccttccgt gtttccactg gctccctcta gtaaatccac ctctggaggc
420acagctgcac tgggatgtct ggtgaaggat tacttccctg aaccagtcac
agtgagttgg 480aactcagggg ctctgacaag tggagtccat acttttcccg
cagtgctgca gtcaagcgga 540ctgtactccc tgtcctctgt ggtcaccgtg
cctagttcaa gcctgggcac ccagacatat 600atctgcaacg tgaatcacaa
gccatcaaat acaaaagtcg acaagaaagt ggagcccaag 660agctgtgata
aaactcatac ctgcccacct tgtccggcgc cagaactgct gggaggacca
720agcgtgttcc tgtttccacc caagcctaaa gacaccctga tgatttcccg
gactcctgag 780gtcacctgcg tggtcgtgga cgtgtctcac gaggaccccg
aagtcaagtt caactggtac 840gtggatggcg tcgaagtgca taatgccaag
accaaacccc gggaggaaca gtacaactct 900acctatagag tcgtgagtgt
cctgacagtg ctgcaccagg actggctgaa tgggaaggag 960tataagtgta
aagtgagcaa caaagccctg cccgccccaa tcgaaaaaac aatctctaaa
1020gcaaaaggac agcctcgcga accacaggtc tacgtctacc ccccatcaag
agatgaactg 1080acaaaaaatc aggtctctct gacatgcctg gtcaaaggat
tctacccttc cgacatcgcc 1140gtggagtggg aaagtaacgg ccagcccgag
aacaattaca agaccacacc ccctgtcctg 1200gactctgatg ggagtttcgc
tctggtgtca aagctgaccg tcgataaaag ccggtggcag 1260cagggcaatg
tgtttagctg ctccgtcatg cacgaagccc tgcacaatca ctacacacag
1320aagtccctga gcctgagccc tggc 134438119PRTArtificial SequenceH1
clone 6586 VH 38Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Ala Asp Tyr 20 25 30Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys
Gly Leu Glu Trp Val 35 40 45Gly Asp Val Asn Pro Asn Ser Gly Gly Ser
Ile Tyr Asn Gln Arg Phe 50 55 60Lys Gly Arg Phe Thr Phe Ser Val Asp
Arg Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asn Leu Gly Pro
Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110Thr Leu Val Thr
Val Ser Ser 115398PRTArtificial SequenceH1 clone 6586 CDRH1 39Gly
Phe Thr Phe Ala Asp Tyr Thr1 54012PRTArtificial SequenceH1 clone
6586 CDRH3 40Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr1 5
10418PRTArtificial SequenceH1 clone 6586 CDRH2 41Val Asn Pro Asn
Ser Gly Gly Ser1 542226PRTArtificial SequenceL2 clone 3904 Full
42Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Thr Gly Ser Asp Ile Gln Met1
5 10 15Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val
Thr 20 25 30Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly Val Ala
Trp Tyr 35 40 45Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
Ser Ala Ser 50 55 60Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly
Ser Gly Ser Gly65 70 75 80Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
Gln Pro Glu Asp Phe Ala 85 90 95Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile
Tyr Pro Tyr Thr Phe Gly Gln 100 105 110Gly Thr Lys Val Glu Ile Lys
Arg Thr Val Ala Ala Pro Ser Val Phe 115 120 125Ile Phe Pro Pro Ser
Asp Glu Glu Leu Lys Ser Gly Thr Ala Ser Val 130 135 140Val Cys Leu
Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp145 150 155
160Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Glu Glu Ser Val Thr
165 170 175Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr
Leu Glu 180 185 190Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
Ala Cys Glu Val 195 200 205Thr His Gln Gly Leu Ser Ser Pro Val Thr
Lys Ser Phe Asn Arg Gly 210 215 220Glu Cys22543678DNAArtificial
SequenceL2 clone 3904 Full 43tatccctacg atgtgcctga ctacgctact
ggctccgata tccagatgac ccagtctcca 60agctccctga gtgcatcagt gggggaccga
gtcaccatca catgcaaggc ttcccaggat 120gtgtctattg gagtcgcatg
gtaccagcag aagccaggca aagcacccaa gctgctgatc 180tacagcgcct
cctaccggta tactggggtg ccttccagat tctctggcag tgggtcagga
240accgacttta ctctgaccat ctctagtctg cagcccgagg atttcgccac
ctactattgc 300cagcagtact atatctaccc ttataccttt ggccagggga
caaaagtgga gatcaagagg 360acagtggccg ctccaagtgt cttcattttt
cccccttccg acgaagagct gaaaagtgga 420actgcttcag tggtctgtct
gctgaacaat ttctaccccc gcgaagccaa agtgcagtgg 480aaggtcgata
acgctctgca gagcggcaat tccgaggagt ctgtgacaga acaggacagt
540aaagattcaa cttatagcct gtcaagcaca ctggagctgt ctaaggcaga
ctacgagaag 600cacaaagtgt atgcctgcga agtcacccat caggggctgt
cctctcccgt gacaaagagc 660tttaacagag gagagtgt 67844107PRTArtificial
SequenceL2 clone 3904 VL 44Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Lys Ala
Ser Gln Asp Val Ser Ile Gly 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ser Ala Ser Tyr Arg Tyr
Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr 85 90 95Thr Phe Gly
Gln Gly Thr Lys Val Glu Ile Lys 100 10545481PRTArtificial
SequenceH1 clone 719 Full 45Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Asp Val Asn Thr Ala 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ser Ala Ser Phe Leu Tyr
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Arg Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95Thr Phe Gly
Gln Gly Thr Lys Val Glu Ile Lys Gly Gly Ser Gly Gly 100 105 110Gly
Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Glu 115 120
125Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser
130 135 140Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp
Thr Tyr145 150 155 160Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val Ala 165 170 175Arg Ile Tyr Pro Thr Asn Gly Tyr Thr
Arg Tyr Ala Asp Ser Val Lys 180 185 190Gly Arg Phe Thr Ile Ser Ala
Asp Thr Ser Lys Asn Thr Ala Tyr Leu 195 200 205Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser 210 215 220Arg Trp Gly
Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly225 230 235
240Thr Leu Val Thr Val Ser Ser Ala Ala Glu Pro Lys Ser Ser Asp Lys
245 250 255Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
Gly Pro 260 265 270Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
Leu Met Ile Ser 275 280 285Arg Thr Pro Glu Val Thr Cys Val Val Val
Asp Val Ser His Glu Asp 290 295 300Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu Val His Asn305 310 315 320Ala Lys Thr Lys Pro
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 325 330 335Val Ser Val
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 340 345 350Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 355 360
365Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
370 375 380Tyr Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
Leu Thr385 390 395 400Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val Glu Trp Glu 405 410 415Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro Pro Val Leu 420 425 430Asp Glu Asp Gly Ser Phe Ala
Leu Val Ser Lys Leu Thr Val Asp Lys 435 440 445Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val Met His Glu 450 455 460Ala Leu His
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly465 470 475
480Lys461443DNAArtificial SequenceH1 clone 719 Full 46gacatccaga
tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc
gggcaagtca ggacgttaac accgctgtag cttggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctattct gcatcctttt tgtacagtgg
ggtcccatca 180aggttcagtg gcagtcgatc tgggacagat ttcactctca
ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcaacag
cattacacta ccccacccac tttcggccaa 300gggaccaaag tggagatcaa
aggtggttct ggtggtggtt ctggtggtgg ttctggtggt 360ggttctggtg
gtggttctgg tgaagtgcag ctggtggagt ctgggggagg cttggtacag
420cctggcgggt ccctgagact ctcctgtgca gcctctggat tcaacattaa
agatacttat 480atccactggg tccggcaagc tccagggaag ggcctggagt
gggtcgcacg tatttatccc 540acaaatggtt acacacggta tgcggactct
gtgaagggcc gattcaccat ctccgcagac 600acttccaaga acaccgcgta
tctgcaaatg aacagtctga gagctgagga cacggccgtt 660tattactgtt
caagatgggg cggagacggt ttctacgcta tggactactg gggccaaggg
720accctggtca ccgtctcctc agccgccgag cccaagagca gcgataagac
ccacacctgc 780cctccctgtc cagctccaga actgctggga ggacctagcg
tgttcctgtt tccccctaag 840ccaaaagaca ctctgatgat ttccaggact
cccgaggtga cctgcgtggt ggtggacgtg 900tctcacgagg accccgaagt
gaagttcaac tggtacgtgg atggcgtgga agtgcataat 960gctaagacaa
aaccaagaga ggaacagtac aactccactt atcgcgtcgt gagcgtgctg
1020accgtgctgc accaggactg gctgaacggg aaggagtata agtgcaaagt
cagtaataag 1080gccctgcctg ctccaatcga aaaaaccatc tctaaggcca
aaggccagcc aagggagccc 1140caggtgtaca catacccacc cagcagagac
gaactgacca agaaccaggt gtccctgaca 1200tgtctggtga aaggcttcta
tcctagtgat attgctgtgg agtgggaatc aaatggacag 1260ccagagaaca
attacaagac cacacctcca gtgctggacg aggatggcag cttcgccctg
1320gtgtccaagc tgacagtgga taaatctcga tggcagcagg ggaacgtgtt
tagttgttca 1380gtgatgcatg aagccctgca caatcattac actcagaaga
gcctgtccct gtctcccggc 1440aaa 144347107PRTArtificial SequenceH1
clone 719 VL 47Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp
Val Asn Thr Ala 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala
Pro Lys Leu Leu Ile 35 40 45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val
Pro Ser Arg Phe Ser Gly 50 55 60Ser Arg Ser Gly Thr Asp Phe Thr Leu
Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr
Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95Thr Phe Gly Gln Gly Thr
Lys Val Glu Ile Lys 100 10548120PRTArtificial SequenceH1 clone 719
VH 48Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys
Asp Thr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr
Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser
Lys Asn Thr Ala Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ser Arg Trp Gly Gly Asp Gly Phe
Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val
Ser Ser 115 12049481PRTArtificial SequenceH2 clone 720 Full 49Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala
20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
Ile 35 40 45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe
Ser Gly 50 55 60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His
Tyr Thr Thr Pro Pro 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
Lys Gly Gly Ser Gly Gly 100 105 110Gly Ser Gly Gly Gly Ser Gly Gly
Gly Ser Gly Gly Gly Ser Gly Glu 115 120 125Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 130 135 140Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr145 150 155 160Ile
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala 165 170
175Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys
180 185 190Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala
Tyr Leu 195 200 205Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys Ser 210 215 220Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met
Asp Tyr Trp Gly Gln Gly225 230 235 240Thr Leu Val Thr Val Ser Ser
Ala Ala Glu Pro Lys Ser Ser Asp Lys 245 250 255Thr His Thr Cys Pro
Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 260 265 270Ser Val Phe
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 275 280 285Arg
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 290 295
300Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
Asn305 310 315 320Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
Thr Tyr Arg Val 325 330 335Val Ser Val Leu Thr Val Leu His Gln Asp
Trp Leu Asn Gly Lys Glu 340 345 350Tyr Lys Cys Lys Val Ser Asn Lys
Ala Leu Pro Ala Pro Ile Glu Lys 355 360 365Thr Ile Ser Lys Ala Lys
Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 370 375 380Leu Pro Pro Ser
Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ile385 390 395 400Cys
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 405 410
415Ser Asn Gly Gln Pro Glu Asn Arg Tyr Met Thr Trp Pro Pro Val Leu
420 425 430Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
Asp Lys 435 440 445Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
Val Met His Glu 450 455 460Ala Leu His Asn His Tyr Thr Gln Lys Ser
Leu Ser Leu Ser Pro Gly465 470 475 480Lys501443DNAArtificial
SequenceH2 clone 720 Full 50gacatccaga tgacccagtc tccatcctcc
ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca ggacgttaac
accgctgtag cttggtatca gcagaaacca 120gggaaagccc ctaagctcct
gatctattct gcatcctttt tgtacagtgg ggtcccatca 180aggttcagtg
gcagtcgatc tgggacagat ttcactctca ccatcagcag tctgcaacct
240gaagattttg caacttacta ctgtcaacag cattacacta ccccacccac
tttcggccaa 300gggaccaaag tggagatcaa aggtggttct ggtggtggtt
ctggtggtgg ttctggtggt 360ggttctggtg gtggttctgg tgaagtgcag
ctggtggagt ctgggggagg cttggtacag 420cctggcgggt ccctgagact
ctcctgtgca gcctctggat tcaacattaa agatacttat 480atccactggg
tccggcaagc tccagggaag ggcctggagt gggtcgcacg tatttatccc
540acaaatggtt acacacggta tgcggactct gtgaagggcc gattcaccat
ctccgcagac 600acttccaaga acaccgcgta tctgcaaatg aacagtctga
gagctgagga cacggccgtt 660tattactgtt
caagatgggg cggagacggt ttctacgcta tggactactg gggccaaggg
720accctggtca ccgtctcctc agccgccgag cccaagagca gcgataagac
ccacacctgc 780cctccctgtc cagctccaga actgctggga ggacctagcg
tgttcctgtt tccccctaag 840ccaaaagaca ctctgatgat ttccaggact
cccgaggtga cctgcgtggt ggtggacgtg 900tctcacgagg accccgaagt
gaagttcaac tggtacgtgg atggcgtgga agtgcataat 960gctaagacaa
aaccaagaga ggaacagtac aactccactt atcgcgtcgt gagcgtgctg
1020accgtgctgc accaggactg gctgaacggg aaggagtata agtgcaaagt
cagtaataag 1080gccctgcctg ctccaatcga aaaaaccatc tctaaggcca
aaggccagcc aagggagccc 1140caggtgtaca cactgccacc cagcagagac
gaactgacca agaaccaggt gtccctgatc 1200tgtctggtga aaggcttcta
tcctagtgat attgctgtgg agtgggaatc aaatggacag 1260ccagagaaca
gatacatgac ctggcctcca gtgctggaca gcgatggcag cttcttcctg
1320tattccaagc tgacagtgga taaatctcga tggcagcagg ggaacgtgtt
tagttgttca 1380gtgatgcatg aagccctgca caatcattac actcagaaga
gcctgtccct gtctcccggc 1440aaa 144351107PRTArtificial SequenceH2
clone 720 VL 51Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp
Val Asn Thr Ala 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala
Pro Lys Leu Leu Ile 35 40 45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val
Pro Ser Arg Phe Ser Gly 50 55 60Ser Arg Ser Gly Thr Asp Phe Thr Leu
Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr
Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95Thr Phe Gly Gln Gly Thr
Lys Val Glu Ile Lys 100 10552120PRTArtificial SequenceH2 clone 720
VH 52Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys
Asp Thr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr
Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser
Lys Asn Thr Ala Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ser Arg Trp Gly Gly Asp Gly Phe
Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110Gly Thr Leu Val Thr Val
Ser Ser 115 12053448PRTArtificial SequenceH2 clone 3041 Full 53Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr
20 25 30Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
Val 35 40 45Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln
Arg Phe 50 55 60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn
Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe
Asp Tyr Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser Ala
Ser Thr Lys Gly Pro Ser Val Phe 115 120 125Pro Leu Ala Pro Ser Ser
Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140Gly Cys Leu Val
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp145 150 155 160Asn
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170
175Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
Lys Pro 195 200 205Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
Ser Cys Asp Lys 210 215 220Thr His Thr Cys Pro Pro Cys Pro Ala Pro
Glu Leu Leu Gly Gly Pro225 230 235 240Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295
300Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
Glu305 310 315 320Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
Pro Ile Glu Lys 325 330 335Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu Pro Gln Val Tyr Val 340 345 350Leu Pro Pro Ser Arg Asp Glu Leu
Thr Lys Asn Gln Val Ser Leu Leu 355 360 365Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Leu Thr Trp Pro Pro Val Leu385 390 395 400Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 405 410
415Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
Pro Gly 435 440 445541344DNAArtificial SequenceH2 clone 3042 Full
54gaagtgcagc tggtcgaatc tggaggagga ctggtgcagc caggagggtc cctgcgcctg
60tcttgcgccg ctagtggctt cacttttacc gactacacca tggattgggt gcgacaggca
120cctggaaagg gcctggagtg ggtcgccgat gtgaacccaa atagcggagg
ctccatctac 180aaccagcggt tcaagggccg gttcaccctg tcagtggacc
ggagcaaaaa caccctgtat 240ctgcagatga atagcctgcg agccgaagat
actgctgtgt actattgcgc ccggaatctg 300gggccctcct tctactttga
ctattggggg cagggaactc tggtcaccgt gagctccgcc 360tccaccaagg
gaccttctgt gttcccactg gctccctcta gtaaatccac atctggggga
420actgcagccc tgggctgtct ggtgaaggac tacttcccag agcccgtcac
agtgtcttgg 480aacagtggcg ctctgacttc tggggtccac acctttcctg
cagtgctgca gtcaagcggg 540ctgtacagcc tgtcctctgt ggtcaccgtg
ccaagttcaa gcctgggaac acagacttat 600atctgcaacg tgaatcacaa
gccatccaat acaaaagtcg acaagaaagt ggaacccaag 660tcttgtgata
aaacccatac atgcccccct tgtcctgcac cagagctgct gggaggacca
720agcgtgttcc tgtttccacc caagcctaaa gatacactga tgattagtag
gaccccagaa 780gtcacatgcg tggtcgtgga cgtgagccac gaggaccccg
aagtcaagtt taactggtac 840gtggacggcg tcgaggtgca taatgccaag
actaaaccca gggaggaaca gtacaacagt 900acctatcgcg tcgtgtcagt
cctgacagtg ctgcatcagg attggctgaa cgggaaagag 960tataagtgca
aagtgagcaa taaggctctg cccgcaccta tcgagaaaac aatttccaag
1020gcaaaaggac agcctagaga accacaggtg tacgtgctgc ctccatcaag
ggatgagctg 1080acaaagaacc aggtcagcct gctgtgtctg gtgaaaggat
tctatccctc tgacattgct 1140gtggagtggg aaagtaatgg ccagcctgag
aacaattacc tgacctggcc ccctgtgctg 1200gactcagatg gcagcttctt
tctgtatagc aagctgaccg tcgacaaatc ccggtggcag 1260caggggaatg
tgtttagttg ttcagtcatg cacgaggcac tgcacaacca ttacacccag
1320aagtcactgt cactgtcacc aggg 134455119PRTArtificial SequenceH2
clone 3041 VH 55Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Thr Asp Tyr 20 25 30Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys
Gly Leu Glu Trp Val 35 40 45Ala Asp Val Asn Pro Asn Ser Gly Gly Ser
Ile Tyr Asn Gln Arg Phe 50 55 60Lys Gly Arg Phe Thr Leu Ser Val Asp
Arg Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asn Leu Gly Pro
Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110Thr Leu Val Thr
Val Ser Ser 11556448PRTArtificial SequenceH1 clone 3057 Full 56Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp Tyr
20 25 30Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
Val 35 40 45Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln
Arg Phe 50 55 60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn
Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe
Asp Tyr Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser Ala
Ser Thr Lys Gly Pro Ser Val Phe 115 120 125Pro Leu Ala Pro Ser Ser
Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140Gly Cys Leu Val
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp145 150 155 160Asn
Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170
175Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser
180 185 190Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
Lys Pro 195 200 205Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys
Ser Cys Asp Lys 210 215 220Thr His Thr Cys Pro Pro Cys Pro Ala Pro
Glu Leu Leu Gly Gly Pro225 230 235 240Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr Leu Met Ile Ser 245 250 255Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val Ser His Glu Asp 260 265 270Pro Glu Val
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 275 280 285Ala
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 290 295
300Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
Glu305 310 315 320Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
Pro Ile Glu Lys 325 330 335Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu Pro Gln Val Tyr Val 340 345 350Tyr Pro Pro Ser Arg Asp Glu Leu
Thr Lys Asn Gln Val Ser Leu Thr 355 360 365Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 370 375 380Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu385 390 395 400Asp
Ser Asp Gly Ser Phe Ala Leu Val Ser Lys Leu Thr Val Asp Lys 405 410
415Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
Pro Gly 435 440 445571344DNAArtificial SequenceH1 clone 3057 Full
57gaagtgcagc tggtcgaatc tggaggagga ctggtgcagc caggagggtc cctgcgcctg
60tcttgcgccg ctagtggctt cacttttacc gactacacca tggattgggt gcgacaggca
120cctggaaagg gcctggagtg ggtcgccgat gtgaacccaa atagcggagg
ctccatctac 180aaccagcggt tcaagggccg gttcaccctg tcagtggacc
ggagcaaaaa caccctgtat 240ctgcagatga atagcctgcg agccgaagat
actgctgtgt actattgcgc ccggaatctg 300gggccctcct tctactttga
ctattggggg cagggaactc tggtcaccgt gagctccgcc 360tccaccaagg
gaccttctgt gttcccactg gctccctcta gtaaatccac atctggggga
420actgcagccc tgggctgtct ggtgaaggac tacttcccag agcccgtcac
agtgtcttgg 480aacagtggcg ctctgacttc tggggtccac acctttcctg
cagtgctgca gtcaagcggg 540ctgtacagcc tgtcctctgt ggtcaccgtg
ccaagttcaa gcctgggaac acagacttat 600atctgcaacg tgaatcacaa
gccatccaat acaaaagtcg acaagaaagt ggaacccaag 660tcttgtgata
aaacccatac atgcccccct tgtcctgcac cagagctgct gggaggacca
720agcgtgttcc tgtttccacc caagcctaaa gatacactga tgattagtag
gaccccagaa 780gtcacatgcg tggtcgtgga cgtgagccac gaggaccccg
aagtcaagtt taactggtac 840gtggacggcg tcgaggtgca taatgccaag
actaaaccca gggaggaaca gtacaacagt 900acctatcgcg tcgtgtcagt
cctgacagtg ctgcatcagg attggctgaa cgggaaagag 960tataagtgca
aagtgagcaa taaggctctg cccgcaccta tcgagaaaac aatttccaag
1020gcaaaaggac agcctagaga accacaggtg tacgtgtatc ctccatcaag
ggatgagctg 1080acaaagaacc aggtcagcct gacttgtctg gtgaaaggat
tctatccctc tgacattgct 1140gtggagtggg aaagtaatgg ccagcctgag
aacaattaca agaccacacc ccctgtgctg 1200gactcagatg gcagcttcgc
gctggtgagc aagctgaccg tcgacaaatc ccggtggcag 1260caggggaatg
tgtttagttg ttcagtcatg cacgaggcac tgcacaacca ttacacccag
1320aagtcactgt cactgtcacc aggg 134458119PRTArtificial SequenceH1
clone 3057 VH 58Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln
Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Thr Asp Tyr 20 25 30Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys
Gly Leu Glu Trp Val 35 40 45Ala Asp Val Asn Pro Asn Ser Gly Gly Ser
Ile Tyr Asn Gln Arg Phe 50 55 60Lys Gly Arg Phe Thr Leu Ser Val Asp
Arg Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asn Leu Gly Pro
Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110Thr Leu Val Thr
Val Ser Ser 11559475PRTArtificial SequenceH1 clone 3317 Full 59Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly
20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
Ile 35 40 45Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe
Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr
Tyr Ile Tyr Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
Lys Gly Gly Gly Gly Ser 100 105 110Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Glu Val Gln Leu Val Glu 115 120 125Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys 130 135 140Ala Ala Ser Gly
Phe Thr Phe Thr Asp Tyr Thr Met Asp Trp Val Arg145 150 155 160Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Asp Val Asn Pro Asn 165 170
175Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe Lys Gly Arg Phe Thr Leu
180 185 190Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn
Ser Leu 195 200 205Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
Asn Leu Gly Pro 210 215 220Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly
Thr Leu Val Thr Val Ser225 230 235 240Ser Ala Ala Glu Pro Lys Ser
Ser Asp Lys Thr His Thr Cys Pro Pro 245 250 255Cys Pro Ala Pro Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 260 265 270Pro Lys Pro
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 275 280 285Cys
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 290 295
300Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
Arg305 310 315 320Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
Val Leu Thr Val 325 330 335Leu His Gln Asp Trp Leu Asn Gly Lys Glu
Tyr Lys Cys Lys Val Ser 340 345 350Asn Lys Ala Leu Pro Ala Pro Ile
Glu Lys Thr Ile Ser Lys Ala Lys 355 360 365Gly Gln Pro Arg Glu Pro
Gln Val Tyr Val Tyr Pro Pro Ser Arg Asp 370 375 380Glu Leu Thr Lys
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe385 390 395 400Tyr
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 405 410
415Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe
420 425 430Ala Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
Gln Gly 435 440 445Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
His Asn His Tyr 450 455 460Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
Lys465 470 475601425DNAArtificial
SequenceH1 clone 3317 Full 60gacattcaga tgacccagag ccctagctcc
ctgagtgcct cagtcgggga cagggtgact 60atcacctgca aggcttcaca ggatgtcagc
attggcgtgg catggtacca gcagaagcca 120gggaaagcac ccaagctgct
gatctatagc gcctcctaca ggtatacagg cgtgccatcc 180cgcttctctg
gcagtgggtc aggaactgac tttacactga ctatttctag tctgcagccc
240gaagatttcg ccacatacta ttgccagcag tactatatct acccttatac
ttttggccag 300gggaccaaag tggagattaa gggcggagga ggctccggag
gaggagggtc tggaggagga 360ggaagtgagg tccagctggt ggaatctgga
ggaggactgg tgcagccagg agggtccctg 420aggctgtctt gtgccgctag
tggcttcacc tttacagact acacaatgga ttgggtgcgc 480caggcaccag
gaaagggact ggaatgggtc gctgatgtga accctaatag cggaggctcc
540atctacaacc agcggttcaa aggacggttc accctgtcag tggaccggag
caagaacacc 600ctgtatctgc agatgaacag cctgagagcc gaggatactg
ctgtgtacta ttgcgccagg 660aatctgggcc caagcttcta ctttgactat
tgggggcagg gaacactggt cactgtgtca 720agcgcagccg aacccaaatc
ctctgataag actcacacct gcccaccttg tccagctcca 780gagctgctgg
gaggacctag cgtgttcctg tttccaccca agccaaaaga cactctgatg
840atttctagaa cccctgaagt gacatgtgtg gtcgtggacg tcagtcacga
ggaccccgaa 900gtcaaattca actggtacgt ggatggcgtc gaggtgcata
atgccaagac caaaccccga 960gaggaacagt acaactcaac ctatcgggtc
gtgagcgtcc tgacagtgct gcatcaggac 1020tggctgaacg gcaaggagta
taagtgcaaa gtgagcaaca aggctctgcc tgcaccaatc 1080gagaagacca
tttccaaggc taaagggcag ccccgcgaac ctcaggtcta cgtgtatcct
1140ccaagccgag atgagctgac aaaaaaccag gtctccctga cttgtctggt
gaagggattt 1200tacccaagtg acatcgcagt ggagtgggaa tcaaatggcc
agcccgaaaa caattataag 1260accacacccc ctgtgctgga ctctgatggg
agtttcgcac tggtctccaa actgaccgtg 1320gacaagtctc ggtggcagca
gggaaacgtc tttagctgtt ccgtgatgca cgaggccctg 1380cacaatcatt
acacacagaa atctctgagt ctgtcacctg gcaag 142561107PRTArtificial
SequenceH1 clone 3317 VL 61Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Lys Ala
Ser Gln Asp Val Ser Ile Gly 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ser Ala Ser Tyr Arg Tyr
Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro Tyr 85 90 95Thr Phe Gly
Gln Gly Thr Lys Val Glu Ile Lys 100 10562119PRTArtificial
SequenceH1 clone 3317 VH 62Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Thr Asp Tyr 20 25 30Thr Met Asp Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Asp Val Asn Pro Asn Ser
Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60Lys Gly Arg Phe Thr Leu
Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asn
Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110Thr
Leu Val Thr Val Ser Ser 11563480PRTArtificial SequenceH2 clone 5244
Full 63Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn
Thr Ala 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
Gln His Tyr Thr Thr Pro Pro 85 90 95Thr Phe Gly Gln Gly Thr Lys Val
Glu Ile Lys Gly Gly Ser Gly Gly 100 105 110Gly Ser Gly Gly Gly Ser
Gly Gly Gly Ser Gly Gly Gly Ser Gly Glu 115 120 125Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 130 135 140Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr145 150 155
160Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala
165 170 175Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser
Val Lys 180 185 190Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn
Thr Ala Tyr Leu 195 200 205Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
Ala Val Tyr Tyr Cys Ser 210 215 220Arg Trp Gly Gly Asp Gly Phe Tyr
Ala Met Asp Tyr Trp Gly Gln Gly225 230 235 240Thr Leu Val Thr Val
Ser Ser Ala Ala Glu Pro Lys Ser Ser Asp Lys 245 250 255Thr His Thr
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro 260 265 270Ser
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 275 280
285Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp
290 295 300Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
His Asn305 310 315 320Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
Ser Thr Tyr Arg Val 325 330 335Val Ser Val Leu Thr Val Leu His Gln
Asp Trp Leu Asn Gly Lys Glu 340 345 350Tyr Lys Cys Lys Val Ser Asn
Lys Ala Leu Pro Ala Pro Ile Glu Lys 355 360 365Thr Ile Ser Lys Ala
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Val 370 375 380Leu Pro Pro
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Leu385 390 395
400Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
405 410 415Ser Asn Gly Gln Pro Glu Asn Asn Tyr Leu Thr Trp Pro Pro
Val Leu 420 425 430Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
Thr Val Asp Lys 435 440 445Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
Cys Ser Val Met His Glu 450 455 460Ala Leu His Asn His Tyr Thr Gln
Lys Ser Leu Ser Leu Ser Pro Gly465 470 475 480641440DNAArtificial
SequenceH2 clone 5244 Full 64gacattcaga tgacacagag ccccagctcc
ctgagtgctt cagtcggcga cagggtgact 60atcacctgcc gcgcatccca ggatgtcaac
accgctgtgg catggtacca gcagaagcct 120ggaaaagccc caaagctgct
gatctacagc gcttccttcc tgtattctgg cgtgccaagt 180cggttttctg
gaagtagatc aggcactgac ttcacactga ctatctctag tctgcagccc
240gaagattttg ccacctacta ttgccagcag cactatacca caccccctac
attcggacag 300ggcactaaag tggagattaa gggcgggtca ggcggaggga
gcggaggagg gtccggagga 360gggtctggag gagggagtgg agaggtccag
ctggtggaat ctggaggagg actggtgcag 420cctggaggct cactgcgact
gagctgtgcc gcttccggct ttaacatcaa agacacatac 480attcattggg
tcaggcaggc accagggaag ggactggaat gggtggcccg catctatccc
540acaaatgggt acactcgata tgccgacagc gtgaaaggac ggtttaccat
ttctgctgat 600accagtaaga acacagcata cctgcagatg aacagcctgc
gcgcagagga tacagccgtg 660tactattgca gtcgatgggg gggagacggc
ttctacgcca tggattattg gggccagggg 720actctggtca ccgtgtcaag
cgcagccgaa cctaaatcct ctgacaagac ccacacatgc 780ccaccctgtc
ctgctccaga gctgctggga ggaccatccg tgttcctgtt tcctccaaag
840cctaaagata cactgatgat tagccgcact cccgaagtca cctgtgtggt
cgtggacgtg 900tcccacgagg accccgaagt caagttcaac tggtacgtgg
acggcgtcga ggtgcataat 960gccaagacta aaccaagaga ggaacagtac
aattcaacct atagggtcgt gagcgtcctg 1020acagtgctgc atcaggattg
gctgaacggc aaggagtata agtgcaaagt gtctaacaag 1080gccctgcccg
ctcctatcga gaagactatt agcaaggcaa aagggcagcc acgggaaccc
1140caggtctacg tgctgccccc tagcagagac gagctgacca aaaaccaggt
ctccctgctg 1200tgtctggtga agggctttta tcctagtgat atcgctgtgg
agtgggaatc aaatgggcag 1260ccagaaaaca attacctgac atggccaccc
gtgctggaca gcgatgggtc cttctttctg 1320tattccaaac tgactgtgga
caagtctaga tggcagcagg gaaacgtctt cagctgttcc 1380gtgatgcacg
aggccctgca caatcattac acccagaagt ctctgagtct gtcacccggc
144065107PRTArtificial SequenceH2 clone 5244 VL 65Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val
Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30Val Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Tyr
Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55
60Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65
70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro
Pro 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
10566120PRTArtificial SequenceH2 clone 5244 VH 66Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30Tyr Ile
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala
Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp
Gly Gln 100 105 110Gly Thr Leu Val Thr Val Ser Ser 115
120676PRTArtificial SequenceH2 clones 5244,720 CDRL1 and L1 clone
5034 CDRL1 and H1 clone 719 CDRL1 67Gln Asp Val Asn Thr Ala1
5683PRTArtificial SequenceH2 clones 5244,720 CDRL2 and L1 clone
5034 CDRL2 and H1 clone 719 CDRL2 68Ser Ala Ser1699PRTArtificial
SequenceH2 clones 5244,720 CDRL3 and L1 clone 5034 CDRL3 and H1
clone 719 CDRL3 69Gln Gln His Tyr Thr Thr Pro Pro Thr1
5708PRTArtificial SequenceH1 clone 5244 CDRH1 70Gly Phe Asn Ile Lys
Asp Thr Tyr1 5718PRTArtificial SequenceH1 clone 5244 CDRH2 71Ile
Tyr Pro Thr Asn Gly Tyr Thr1 57213PRTArtificial SequenceH1 clone
5244 CDRH3 72Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr1 5
10738PRTArtificial SequenceVariant 1582,15084,15081 CDRH2 73Val Asn
Pro Asn Ser Gly Tyr Ser1 5748PRTArtificial SequenceVariant 15085,
15083 and 15080, 15084, 15081 CDRDH1 74Gly Phe Thr Phe Gln Asp Tyr
Thr1 57512PRTArtificial SequenceVariant 15085, 15084 CDRH3 75Ala
Arg Asn Leu Gly Pro Trp Phe Tyr Phe Asp Tyr1 5 10769PRTArtificial
SequenceVariant 15083 and 15080, 15079, 15081 CDRL3 76Gln Gln Tyr
Tyr Ile Tyr Pro Gly Thr1 5778PRTArtificial SequenceVariant 15079
CDRH1 77Gly Phe Thr Phe Tyr Asp Tyr Thr1 578119PRTArtificial
SequenceVariant 7133 VH 78Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ala Asp Tyr 20 25 30Thr Met Asp Trp Val Arg Gln Ala
Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Asp Val Asn Pro Asn Ser
Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55 60Lys Gly Arg Phe Thr Leu
Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asn
Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110Thr
Leu Val Thr Val Ser Ser 11579107PRTArtificial SequenceVariant 7133
VL 79Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser
Ile Gly 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
Gln Tyr Tyr Ile Tyr Pro Ala 85 90 95Thr Phe Gly Gln Gly Thr Lys Val
Glu Ile Lys 100 10580119PRTArtificial SequenceVariant 15082 VH
80Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr Asp
Tyr 20 25 30Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Ala Asp Val Asn Pro Asn Ser Gly Tyr Ser Ile Tyr Asn
Gln Arg Phe 50 55 60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Trp
Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asn Leu Gly Pro Ser Phe Tyr
Phe Asp Tyr Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser
11581107PRTArtificial SequenceVariant 15082 and 15085 VL 81Asp Ile
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp
Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25
30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr
Ile Tyr Pro Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 10582119PRTArtificial SequenceVariant 15085 VH 82Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gln Asp Tyr 20 25 30Thr
Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe
50 55 60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu
Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Asn Leu Gly Pro Trp Phe Tyr Phe Asp Tyr
Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser
11583119PRTArtificial SequenceVariant 15083 VH 83Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gln Asp Tyr 20 25 30Thr Met
Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala
Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe 50 55
60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly
Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser
11584107PRTArtificial SequenceVariant 15083,15080,15079 and 15081
VL 84Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser
Ile Gly 20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45Trp Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
Gln Tyr Tyr Ile Tyr Pro Gly 85 90 95Thr Phe Gly Gln Gly Thr Lys Val
Glu Ile Lys 100 10585119PRTArtificial SequenceVariant 15080
VH 85Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gln
Asp Tyr 20 25 30Thr Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr
Asn Gln Arg Phe 50 55 60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser
Trp Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asn Leu Gly Pro Ser Phe
Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser
Ser 11586119PRTArtificial SequenceVariant 15079 VH 86Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Tyr Asp Tyr 20 25 30Thr
Met Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45Ala Asp Val Asn Pro Asn Ser Gly Gly Ser Ile Tyr Asn Gln Arg Phe
50 55 60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Trp Asn Thr Leu
Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr
Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser
11587119PRTArtificial SequenceVariant 15084 VH 87Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gln Asp Tyr 20 25 30Thr Met
Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala
Asp Val Asn Pro Asn Ser Gly Tyr Ser Ile Tyr Asn Gln Arg Phe 50 55
60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ala Arg Asn Leu Gly Pro Trp Phe Tyr Phe Asp Tyr Trp Gly
Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser
11588107PRTArtificial SequenceVariant 15084 VL 88Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val
Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Ile Gly 20 25 30Val Ala
Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45Trp
Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55
60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65
70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Ile Tyr Pro
Tyr 85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
10589119PRTArtificial SequenceVariant 15081 VH 89Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gln Asp Tyr 20 25 30Thr Met
Asp Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala
Asp Val Asn Pro Asn Ser Gly Tyr Ser Ile Tyr Asn Gln Arg Phe 50 55
60Lys Gly Arg Phe Thr Leu Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ala Arg Asn Leu Gly Pro Ser Phe Tyr Phe Asp Tyr Trp Gly
Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser 115
* * * * *